



Institute of Clinical Medicine, Invärtes Medicin 
University of Helsinki, Finland 
 
Department of Medicine 
Helsinki University Central Hospital, Finland 
 
The National Doctoral Programme of  
Musculoskeletal Disorders and Biomaterials 
 









A CLINICAL AND HEALTH ECONOMICAL 
OBSERVATIONAL STUDY OF ANTI-TUMOR NECROSIS 
FACTOR THERAPY IN THE TREATMENT OF 





















To be presented, with the permission of the Faculty of Medicine of the University 
of Helsinki, for public examination in Lecture Hall 2, Biomedicum Helsinki, 






Supervised by:  
 
Docent Dan C. Nordström, MD, PhD 
Department of Medicine 




Reviewed by:  
 
Dr. Lene Dreyer, MD, PhD 
Department of Rheumatology 
Copenhagen University Hospital  
Hellerup, Denmark 
 
Docent Pekka Lahdenne, MD, PhD 
Hospital for Children and Adolescents 






Docent Heikki Julkunen, MD, PhD 
Division of Rheumatology, Department of Medicine  


















ISBN: 978-951-51-0010-8 (paperback) 
ISBN: 978-951-51-0011-5 (PDF) 
http://ethesis.helsinki.fi 
 





1 LIST OF ORIGINAL PUBLICATIONS ......................................................................... 5 
2 ABBREVIATIONS .......................................................................................................... 6 
3 ABSTRACT ..................................................................................................................... 9 
4 REVIEW OF THE LITERATURE ................................................................................ 11 
4.1 An overview of rheumatoid arthritis (RA) .................................................................. 11 
4.1.1 Implications of RA for the patient and society ..................................................... 11 
4.1.2 Classification criteria ............................................................................................ 12 
4.1.3 Pathogenesis of RA .............................................................................................. 14 
4.2 Evaluating drug effects in RA ..................................................................................... 17 
4.2.1 Randomized controlled trials, clinical trials and observational studies ............... 17 
4.2.2 Assessment of disease status and outcomes of pharmacological therapy ............ 18 
4.3 Treatment of RA, with focus on pharmacotherapy...................................................... 20 
4.3.1 Symptomatic and disease modifying antirheumatic drugs ................................... 20 
4.3.2 Treatment options and strategies .......................................................................... 24 
4.3.3 Treatment aims ..................................................................................................... 25 
4.3.4 Guidelines for the management of RA, with focus on the EULAR 
recommendations ............................................................................................................ 25 
4.4 Tumor necrosis factor (TNF) and its inhibition in RA ................................................ 27 
4.4.1 TNF and its role in RA pathogenesis ................................................................... 27 
4.4.2 Clinical effects of anti-TNF agents in RA, with focus on infliximab, 
etanercept, and adalimumab ........................................................................................... 30 
5 INTRODUCTION AND BACKGROUND OF THE STUDY ...................................... 45 
6 AIMS OF THE STUDY ................................................................................................. 49 
7 PATIENTS AND METHODS ....................................................................................... 50 
7.1 The Finnish register of biological treatment, ROB-FIN .............................................. 50 
7.2 Statistics ....................................................................................................................... 51 
7.3 Additional methods and assessments ........................................................................... 52 
7.3.1 Study I .................................................................................................................. 52 
7.3.2 Study II ................................................................................................................. 52 
7.3.3 Study III ................................................................................................................ 53 
7.3.4 Study IV ............................................................................................................... 54 
7.3.5 Cancer incidence assessments .............................................................................. 54 
8 RESULTS AND DISCUSSION .................................................................................... 55 
8.1 Reporting to the ROB-FIN register and trends in anti-TNF use (V) ........................... 55 
8.2 Effectiveness and safety of infliximab therapy in the treatment of RA (I, V) ............. 58 
8.2.1 Effectiveness of infliximab in RA patients treated with concomitant 
methotrexate and other conventional disease modifying antirheumatic drugs (I) ......... 58 
8.2.2 Adverse events of infliximab in RA patients treated with concomitant 
methotrexate and other conventional disease modifying antirheumatic drugs (I) ......... 61 
8.2.3 Updated analysis of the cohort of RA patients treated with infliximab (V) ......... 61 
8.2.4 Pooled analyses of ROB-FIN data of biological therapies ................................... 64 
8.3 Adverse events of anti-TNF therapy in a routine-care setting (II, V).......................... 64 
8.3.1 Most frequent adverse events (II, V) .................................................................... 66 
8.3.2 Serious adverse events (II, V) .............................................................................. 69 
8.3.3 Cancer (II, V) ....................................................................................................... 70 
8.4 Cost-effectiveness of infliximab therapy (III) ............................................................. 73 
8.5 Outcomes of switching anti-TNF agents (IV) ............................................................. 75 
9 LIMITATIONS AND STRENGTHS OF THE STUDIES ............................................ 83 
 
 
10 MAIN FINDINGS .......................................................................................................... 84 
10.1 Effectiveness of anti-TNF therapy in the treatment of RA (I, V) ............................ 84 
10.2 Adverse events of biological drugs in a routine-care setting (II, V) ........................ 84 
10.3 Cost-effectiveness of infliximab therapy (III).......................................................... 85 
10.4 Outcomes of switching anti-TNF agents (IV) .......................................................... 85 
11 CONCLUSIONS AND FUTURE VISIONS ................................................................. 86 
12 ACKNOWLEDGEMENTS ........................................................................................... 87 






1 LIST OF ORIGINAL PUBLICATIONS 
 
This thesis is based on the following publications: 
 
I. Nordstrom DC, Konttinen L, Korpela M, Tiippana-Kinnunen T, Eklund K, Forsberg 
S, Ilva K, Kaipiainen-Seppanen O, Malmi T, Yla-Kerttula T, Honkanen V. Classic 
disease modifying anti-rheumatic drugs (DMARDs) in combination with 
infliximab. The Finnish experience. Rheumatol Int. 2006;26(8):741-8. 
II. Konttinen L, Honkanen V, Uotila T, Pollanen J, Waahtera M, Romu M, Puolakka 
K, Vasala M, Karjalainen A, Luukkainen R, Nordstrom DC, for the ROB-FIN study 
group. Biological treatment in rheumatic diseases: results from a longitudinal 
surveillance: adverse events. Rheumatol Int. 2006;26(10):916-22. 
III. Virkki LM, Konttinen YT, Peltomaa R, Suontama K, Saario R, Immonen K, Jäntti 
J, Tuomiranta T, Nykänen P, Hämeenkorpi R, Heikkilä S, Isomäki P, Nordström D. 
Cost-effectiveness of infliximab in the treatment of rheumatoid arthritis in clinical 
practice. Clin Exp Rheumatol. 2008;26(6):1059-66. 
IV. Virkki LM, Valleala H, Takakubo Y, Vuotila J, Relas H, Komulainen R, 
Koivuniemi R, Yli-Kerttula U, Mali M, Sihvonen S, Krogerus ML, Jukka E, 
Nyrhinen S, Konttinen YT, Nordström DC. Outcomes of switching anti-TNF drugs 
in rheumatoid arthritis--a study based on observational data from the Finnish 
Register of Biological Treatment (ROB-FIN). Clin Rheumatol. 2011;30(11):1447-
54.  
The studies are referred to in the text by their Roman numerals.  
In addition, some unpublished results are presented (V).  





Ab  antibody 
ACPA  anti-citrullinated protein antibody 
ACR   American College of Rheumatology  
ACR20 American College of Rheumatology 20% improvement criteria 
ACR50 American College of Rheumatology 50% improvement criteria 
ACR70 American College of Rheumatology 70% improvement criteria 
ADA  adalimumab 
ADAb  anti-drug antibody 
ADCC  antibody-dependent cell-mediated cytotoxicity  
AE  adverse event 
anti-CCP anti-cyclic citrullinated peptide 
APC  antigen-presenting cell 
bDMARD biological disease modifying antirheumatic drug  
CD  cluster of differentiation 
CDAI  Clinical Disease Activity Index 
CDC  complement-dependent cytotoxicity  
cDMARD conventional disease modifying antirheumatic drug  
CER  certolizumab pegol 
CI  confidence interval 
CMC  carpometacarpal 
COX  cyclooxygenase 
CQG  cost per QALY gained 
CRP   C-reactive protein  
CUA   cost-utility analysis 
CVD   cardiovascular disease 
DAS   Disease Activity Score 
DAS28  Disease Activity Score using 28 joint counts 
DDD  defined daily dose 
DIP  distal interphalangeal 
DMARD disease modifying antirheumatic drug 
DNA  deoxyribonucleic acid 
ERA  early rheumatoid arthritis 
ESR  erythrocyte sedimentation rate 
ETA  etanercept 
EULAR European League Against Rheumatism 
Fc  fragment crystallizable (of an antibody) 
FcγR   Fc-gamma receptor 
FCR  Finnish Cancer Registry 
FDA   U.S. Food and Drug Administration 
FSM   Finnish Statistics on Medicines 
GAG  glycosaminoglycan 
GC  glucocorticoid 
GOL  golimumab 
HAQ  Health Assessment Questionnaire 
HCQ  hydroxychloroquine 
HLA   human leukocyte antigen 
HR  hazard ratio 
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HRQOL health-related quality of life 
HRT  hormone replacement therapy 
IFN-γ  interferon-gamma  
IFX  infliximab 
IgG   immunoglobulin G 
IL  interleukin 
i.v.  intravenous 
JAK  janus kinase 
JSN  joint-space narrowing 
kDa  kilodalton 
LDAS  low disease activity state 
LEF  leflunomide  
LOE  lack, or loss, of effectiveness 
mAb  monoclonal antibody 
MAPK  mitogen-activated protein kinase 
MCP  metacarpophalangeal 
MDA   minimal disease activity 
MHC  major histocompatibility complex 
MMP  matrix metalloproteinase 
mRNA  messenger RNA 
MTP   metatarsophalangeal 
MTX  methotrexate 
NF-κB  nuclear factor kappa-light-chain-enhancer of activated B cells 
NSAID non-steroidal anti-inflammatory drug 
OC  oral contraceptive 
OR  odds ratio 
PBO  placebo 
PIP   proximal interphalangeal 
PJC  painful joint count 
pLOE  primary lack of effectiveness 
QALY  quality-adjusted life year 
RA  rheumatoid arthritis 
RANKL  receptor activator of nuclear factor kappa-B ligand 
RASF  rheumatoid arthritis synovial fibroblast 
RCT  randomized controlled clinical trial 
RF   rheumatoid factor  
RNA  ribonucleic acid 
ROB-FIN Finnish register of biological treatment 
RR  risk ratio 
SAE  serious adverse event 
s.c.  subcutaneous 
SDAI  Simplified Disease Activity Index 
SF-36  Medical Outcomes Study 36-Item Short Form Health Survey 
SII  Social Insurance Institution of Finland (Kansaneläkelaitos) 
SIR  standardized incidence ratio   
SJC  swollen joint count  
SJC28  swollen joint count, 28 joint index 
SJC54  swollen joint count, 54 joint index 
sLOE  secondary lack (loss) of effectiveness 
SLR  systematic literature review 
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SSZ   sulfasalazine 
TB   tuberculosis 
TJC  tender joint count 
TJC28  tender joint count, 28 joint index 
TJC53  tender joint count, 53 joint index 
TLR  Toll-like receptor   
TNF  tumor necrosis factor 
TNFi  tumor necrosis factor inhibitor 
TNFR  tumor necrosis factor receptor 
TRAF2 TNF receptor-associated factor 2  
ULN  upper limit of normal 
VAS  visual analogue scale 
vdH-S  van der Heijde modification of the Sharp radiographic scoring system 





The advent of biological drugs has significantly, even dramatically, improved the prognosis 
of rheumatoid arthritis (RA) in a substantial proportion of patients with moderate to severe 
active disease refractory to treatment with conventional disease modifying antirheumatic 
drugs. Anti-tumor necrosis factor (anti-TNF) agents were the first biologicals to emerge at 
the turn of the century, and they are still the most widely used among this group of drugs. 
The efficacy and safety of the biological drugs in RA and other rheumatological conditions 
for which they are approved have been evaluated in randomized controlled trials usually of 
three to twelve months duration with strict inclusion and exclusion criteria to define the 
study population.  
 
To enable nationwide prospective, longitudinal follow-up of outcomes in adult patients 
with rheumatologic diseases treated with biological agents, the Finnish Society for 
Rheumatology established the Finnish register of biological treatment, ROB-FIN, in 
accordance with international recommendations. The observational data presented in this 
study indicates the effectiveness of infliximab and other anti-TNF agents in the treatment of 
(long-standing, methotrexate refractory) RA to be similar to the efficacy in randomized 
controlled trials, even though the settings are fundamentally different, e.g., in terms of 
patient selection (eligibility criteria and allocation to treatment), knowledge of the 
intervention (open-label vs. double-blind), and flexibility in the treatment strategy.  
 
Anti-TNF therapy appeared to be well-tolerated in most patients. During a mean follow-up 
time of 2.1 years, adverse events (AEs) were reported in 17%, and led to discontinuation of 
the treatment in 9%, of the registered patients. The most common and treatment-limiting 
AEs comprised of various infections, eczemas and skin reactions, infusion or allergic 
reactions, various general symptoms, and laboratory abnormalities. Patients with RA 
appeared more susceptible to AEs than those with other rheumatological diagnoses (risk 
ratio 1.7, p<0.001). Serious, life-threatening, or fatal adverse events (SAEs, excluding 
cancer) were reported in 3.1% (fatal 0.2%) of the registered patients. The main cluster of 
SAEs comprised of diverse infections (reported in 1.8% of the registered patients). Cancer 
was diagnosed in 3.0% of RA patients during or after biological therapy. Compared with 
the Finnish general population, the overall incidence of cancer did not appear to be 
increased. Cases of skin melanoma and pharyngeal cancer were few, but their incidence 
rates were higher among the ROB-FIN cohort than among the Finnish general population. 
However, the confidence intervals are wide, and further studies would be required in order 
to more reliably assess these risks.  
 
Switching to another biological drug was common and due to lack or loss of response, 
adverse drug reactions, and other reasons. The assessments of the outcomes of anti-TNF 
drug switching gave reason to suspect anti-drug antibodies as a potential contributor to 
reduced drug response. Anti-drug antibodies and serum drug concentrations are not 
routinely monitored currently, but have been increasingly identified as potentially valuable 
assessments in anti-TNF non-responders from both clinical and economical perspectives of 
therapeutic decision making.    
 
An analysis relating the direct medical costs of infliximab to the change in health-related 
quality of life indicated that Finnish RA patients have been cost-effectively treated in terms 
of improvement in functional capacity and patient-reported assessment of disease activity. 
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In absolute terms the direct medical costs of anti-TNF and other biological agents are high, 
but several possibilities exist, or may come to exist, that might lower them and maximize 
the cost-effectiveness; these include the possible advent of biosimilars, the treat-to-target 
approach in the management of RA, and personalized medicine.  
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4 REVIEW OF THE LITERATURE 
4.1 An overview of rheumatoid arthritis (RA) 
4.1.1 Implications of RA for the patient and society 
 
Rheumatoid arthritis (RA) is an autoimmune disease which, in its active form, is 
characterized by chronic polyarticular synovial inflammation and progressive joint damage. 
RA affects approximately 0.5–1% of the adult population worldwide (Firestein, 2003). In 
Finland, the prevalence has been estimated to be 0.8% (ca 40 000 patients); approximately 
two-thirds of the affected patients are women (Kaipiainen-Seppänen, 2004). Approximately 
1600 patients are diagnosed with RA each year; the incidence seems to have declined over 
the past few decades (Kaipiainen-Seppänen, 2004; Kaipiainen-Seppänen and Kautiainen, 
2006). Adult RA may start at any age, but the incidence peaks at the age of 55–65 years. 
Approximately two-thirds of the patients are at working age at the time of diagnosis 
(Puolakka et al., 2010). 
 
Articular symptoms of RA include swelling, tenderness, pain and morning stiffness. The 
most frequently affected joints are the wrists, metacarpophalangeal (MCP) joints, proximal 
interphalangeal (PIP) joints, knees, ankles, elbows, shoulders and metatarsophalangeal 
(MTP) joints, and often the joints (or joint areas) are bilaterally affected (Tanaka et al., 
2005). Tenosynovitis and bursitis also occur. Rheumatoid inflammation is often 
accompanied with elevated C-reactive protein (CRP) and erythrocyte sedimentation rate 
(ESR). The presentation and course of the disease vary greatly between patients (van 
Vollenhoven, 2011). Active, persistent rheumatoid inflammation causes tissue destruction 
in the articular cartilage, subchondral bone and periarticular soft tissues of the affected 
joints, and may ultimately lead to sequelae such as cervical spine disease and joint 
deformities (Rindfleisch and Muller, 2005).  
 
RA is a heterogeneous, systemic disorder, with synovial inflammation being a major 
distinctive feature. Nonarticular manifestations may include fatigue, anemia, Felty’s 
syndrome, pericarditis, pleuritis and certain pulmonary manifestations, subcutaneous 
nodules, cutaneous and other types of vasculitis, neuropathy, amyloidosis, 
glomerulonephritis, and various ocular manifestations (Moreland and Curtis, 2009). RA is 
also associated with comorbid conditions, such as atherosclerosis, cardiomyopathy, heart 
failure, myocardial infarction, stroke, osteopenia and osteoporosis, as well as with an 
increased risk of infections and lymphoproliferative malignancies (Mikuls, 2003; 
Rindfleisch and Muller, 2005; Moreland and Curtis, 2009). RA may also be associated with 
an increased prevalence of certain other autoimmune diseases, such as Hashimoto’s 
thyroiditis (Somers et al., 2006). Both intrinsic effects or features of RA (e.g., inflammatory 
pathways, reduced mobility, smoking) and iatrogenic effects may be involved in the 
development of the comorbid conditions (Mikuls, 2003; Rindfleisch and Muller, 2005). 
Peptic ulcer disease has been predominantly attributed to the usage of non-steroidal anti-
inflammatory drugs (NSAIDs) (Mikuls, 2003).  
 
RA and its comorbid conditions and complications predispose patients to premature or 
accelerated mortality (Mikuls, 2003). Patients are at increased risk of dying of 
cardiovascular diseases (CVDs), infections, cancers, and urogenital, gastrointestinal and 
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respiratory diseases (Sihvonen et al., 2004). Deaths caused by RA declined during a period 
of study from 1971 to 1991 (Koivuniemi et al., 2009).  
 
The public health implications of RA are significant. RA is associated with reduced 
functional and working ability, resulting in a major economic and social burden (Puolakka 
et al., 2004; Rat and Boissier, 2004; Strand and Khanna, 2010). Tight control of the disease 
requires multidisciplinary care and frequent, regular follow-up (Hakala et al., 2009; Smolen 
et al., 2010a). Moreover, 20–30% of patients of working age may become permanently 
work disabled within the first 2–3 years of the disease, and up to 50% within the first 10 
years, despite treatment with disease modifying antirheumatic drugs (DMARDs) (Sokka et 
al., 1999; Barrett et al., 2000; Sokka, 2003; Sokka, 2009). Work capacity and productivity 
may be reduced also in the absence of permanent work disability (Puolakka et al., 2004). 
The indirect costs of RA account for a significant proportion (up to three-fourths) of the 
total costs (Rat and Boissier, 2004). In addition to direct and indirect costs, RA is 
associated with significant “intangible costs” due to reduced quality of life, with, e.g., 
physical, emotional and social well-being being affected by the disease (Kirwan et al., 
2007; Laas et al., 2009; Strand and Khanna, 2010; da Silva et al., 2011). 
 
4.1.2 Classification criteria 
 
The diagnosis of RA is based on symptoms, symptom duration, physical examination, acute 
phase reactants, and serological tests. The American College of Rheumatology (ACR) and 
the European League Against Rheumatism (EULAR) have published classification criteria 
(Aletaha et al., 2010a; Aletaha et al., 2010b), which may be used as a diagnostic aid. 
However, the fundamental purpose of these criteria is to provide a uniform set of standards 
by which to evaluate whether an individual newly presenting with undifferentiated 
inflammatory synovitis is likely to develop persistent and/or erosive RA (for patients with a 
long-standing disease, the classification can be done based on the retrospectively available 
data). The criteria are intended for classification in clinical research and trials, and may 
help to identify those patients who are most likely to benefit from early initiation of 
DMARD therapy. The assessment of criteria fulfillment may be applied only if the patient 
has at least one joint with a definite clinical synovitis (swelling), which is not better 
explained by any other disease. A score-based algorithm is used; the scores from four 
categories (A-D) are added, and a score of ≥6/10 is needed for classification as definite RA. 
The categories and their scorings are as follows (further details are given in the original 
publications):  
 
A) Joint involvement (swelling or tenderness; distal interphalangeal (DIP) joints, first 
carpometacarpal (CMC) joints and first MTP joints are excluded from the assessment) 
 one large joint (shoulder, elbow, hip, knee or ankle): 0  
 2 to 10 large joints: 1 
 1-3 small joints (MCP joints, PIP joints, second to fifth MTP joints, thumb 
interphalangeal joints, wrists; with or without involvement of large joints): 2 
 4-10 small joints (with or without involvement of large joints): 3 
 > 10 joints (at least 1 small joint): 5 
 
B) Serology (international unit values; negative: ≤ upper limit of normal (ULN); low-
positive: >ULN, but ≤ 3×ULN; high-positive: > 3×ULN) 
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 negative rheumatoid factor (RF) and negative anti-citrullinated protein antibody 
(ACPA): 0 
 low-positive RF or low-positive ACPA: 2 
 high-positive RF or high-positive ACPA: 3 
 
C) Acute-phase reactants (normal/abnormal is determined by local laboratory standards)  
 normal CRP and normal ESR: 0 
 abnormal CRP or abnormal ESR: 1 
 
D) Duration of symptoms (patient’s self-report of the maximum duration of signs or 
symptoms of synovitis (pain, swelling, tenderness) of any joint that is clinically 
involved at the time of assessment) 
 <6 weeks: 0 
 ≥6 weeks: 1 
 
These criteria have replaced the 1987 American College of Rheumatology criteria, which 
are as follows (Arnett et al., 1988, traditional format):  
 
For classification as RA, at least four of the following seven criteria have to be fulfilled. 
Criteria 1-4 must have been present for at least six weeks.  
1. Morning stiffness in and around the joints lasting ≥ 1 hour before maximal 
improvement 
2. Arthritis of three or more joint areas simultaneously (soft tissue swelling or fluid 
observed by a physician). The 14 possible joint areas are right or left PIP, MCP, wrist, 
elbow, knee, ankle, and MTP. 
3. Arthritis of hand joints (swelling in a wrist, MCP, and/or PIP joint) 
4. Symmetric arthritis (simultaneous involvement of the same joint areas on both sides 
of the body, possible joint areas being those defined in the second criterion; bilateral 
involvement of PIPs, MCPs or MTPs is acceptable without absolute symmetry) 
5. Rheumatoid nodules (subcutaneous nodules in specific places, observed by a 
physician) 
6. Serum rheumatoid factor, demonstrated by any method which gives a positive result 
for <5% of normal control subjects 
7. Radiographic changes typical of rheumatoid arthritis on posteroanterior hand and 
wrist radiographs (erosions or unequivocal bony decalcification; osteoarthritis 
changes alone do not qualify). 
 
The 1987 criteria replaced the 1956 American Rheumatism Association (ARA) diagnostic 
criteria, and have been used extensively in clinical trials (including those on tumor necrosis 
factor inhibitors (TNFi) and other biological agents) performed over the last couple of 
decades. The need to develop new criteria arose essentially from the changes in the 
management of RA during this period (Cohen and Emery, 2010). It had been recognized 
that early and effective intervention was essential in order to slow down the disease 
progression and prevent functional decline. Furthermore, new treatment options had 
become available by the turn of the century (including TNFi agents), and the diagnostic 
importance of ACPAs had become clear. Because of the recognized importance of early 
diagnosis, the roles of radiographic imaging and rheumatoid nodules have been 
downplayed in the new criteria, although radiographs of the hands and feet are usually 




4.1.3 Pathogenesis of RA 
 
The pathogenesis of RA is complex and not entirely known, especially regarding the 
initiating events which lead to the development of the disease. A genetic predisposal seems 
to be of importance (O’Hanlon et al., 2011). In cross-sectional studies, concordance rates 
for RA have been found to be about 15% in monozygotic twins, compared to about 3.5% in 
dizygotic twins (Aho et al., 1986; Silman et al., 1993). One well-known genetic risk factor 
for disease susceptibility and/or disease severity are the alleles of the human leukocyte 
antigen (HLA) -DRB1 gene that encode for the so called “shared epitope” of the HLA-DRβ 
chain (a part of a major histocompatibility complex (MHC) class II cell surface receptor, 
which is necessary for binding and presentation of antigenic epitopes) (Ling et al., 2007). 
However, in the disease onset the gene environment probably acts together with 
environmental risk factors.  
 
Possible predisposing environmental factors include cigarette smoking and air pollutants, 
viral or bacterial agents, and heavy coffee consumption (Pedersen et al., 2007; Münz et al., 
2009; Hoovestol and Mikuls, 2011). It has been proposed but not proven that protective 
factors include antioxidants, vitamin D and moderate alcohol intake.  
 
It is known that gonadal (estrogens, progesterone, androgens) and adrenal (corticosteroids, 
dehydroepiandrosterone) hormones have immunomodulatory properties (Kanik and Wilder, 
2000; Doran et al., 2004; Nalbandian and Kovats, 2005; Forsblad d’Elia and Carlsten, 
2008). RA is a female predominant disease (female/male incidence ratio being 5:1 in young 
adults, but 1:1 after the age of 60 years), with the highest incidence in females coinciding 
with menopause (Forsblad d’Elia et al., 2003; Doran et al., 2004; Forsblad d’Elia and 
Carlsten, 2008; Islander et al., 2011). Moreover, pregnancy may suppress RA onset or 
activity, while the postpartum period is associated with an increased risk of RA 
development or flare (Kanik and Wilder, 2000; Forsblad d’Elia et al., 2003; Doran et al., 
2004). Results from studies concerning the effects of oral contraceptives (OCs) or hormone 
replacement therapy (HRT) on the risk of RA have been conflicting (Doran et al., 2004; 
Pedersen et al., 2007; Hoovestol and Mikuls, 2011). Some studies indicate that OCs protect 
against the development of RA, while HRT may ameliorate RA inflammation and have 
beneficial effects on disease activity, bone mineral density and radiological disease 
progression (Brennan et al., 1997; Forsblad d’Elia et al., 2003; Doran et al., 2004). 
 
Rheumatoid factor (RF, a group of autoantibodies with anti-IgG specificity) and antibodies 
to citrullinated protein antigens (ACPAs) may be formed already in the subclinical phase of 
RA (Aho et al., 1985; Bridges, 2004; van Vollenhoven, 2011). According to an etiologic 
hypothesis, an environmental agent, e.g. from smoking, may render self-molecules 
immunogenic by causing citrullination of proteins (Klareskog et al., 2006); this 
modification may increase their affinity to the shared epitope, which may elicit CD4+ T cell 
responses (Hill et al., 2003). Although this particular set of events may not explain all the 
pathogenetic cascades of RA, it demonstrates the interplay between genes, environmental 
exposures and autoimmune reactions. Interestingly, immune complexes containing 
citrullinated fibrinogen have been found to effectively act on Toll-like receptor-4 (TLR-4) 
and Fcγ receptor (FcγR) and thereby to stimulate TNF production in macrophages 
(Sokolove et al., 2011). Local inflammation in the synovium could lead to formation of 
citrullinated fibrinogen and consequent generation of ACPA and formation of immune 




In addition to citrullinated protein targets, many other autoantigens have been implied in 
the pathogenesis of RA (Bläß et al., 1999). Initiating antigens may be distinct from 
perpetuating ones (Li et al., 2002; Firestein, 2005). Antigen presentation by professional 
antigen-presenting cells (APCs, i.e. dendritic cells, macrophages and B cells) involves the 
capture, transport, and processing of an antigen and then binding of its antigenic 
determinants (epitopes) to a MHC class II molecule in the endolysosomal compartment, 
and finally expression of the MHC class II – epitope complex on the surface of the APC 
(Firestein, 2005; Panayi, 2005). The MHC-antigen complex may then bind to a 
complementary T cell receptor. This, together with co-stimulatory signals (induced in part 
by danger-associated molecular patterns), e.g., ligation of a CD80/CD86 molecule on the 
APC with a CD28 molecule on the T cell, leads to T cell activation and clonal expansion in 
lymph nodes (Firestein, 2005).  
 
The T cells in RA seem to predominantly differentiate into Type 1 (Th1) or Type 17 (Th17) 
helper T cells which, after migration to the synovium, act in several ways to coordinate the 
synovial inflammation. Th1 cells produce small amounts of the cytokine interferon-γ (IFN-
γ), which, in turn, increases MHC class II expression and primes macrophages to produce 
inflammatory and tissue-damaging mediators, such as TNF-α, proteinases, reactive oxygen 
species and nitric oxide (Ma et al., 2003; Firestein, 2005). Th17 cells and mast cells 
produce the cytokine interleukin-17 (IL-17, in particular IL-17A and also IL-17F), leading 
to increased levels of proinflammatory cytokines (including TNF-α, IL-1β, IL-6, and 
granulocyte macrophage colony-stimulating factor (GM-CSF), e.g., from macrophages and 
various stromal cells), adhesion molecules and matrix metalloproteinases (MMPs), as well 
as stimulation of osteoclastogenesis via induction of receptor activator of nuclear factor 
kappa-B ligand (RANKL) (Jovanovic et al., 1998; Firestein, 2005; Brennan and McInnes, 
2008; Moreland and Curtis, 2009; Hueber et al., 2010; Waite and Skokos, 2012). In 
addition, activated T cells activate or interact with other cells that sustain the inflammation 
and joint destruction: B cells, macrophages, dendritic cells, neutrophils, mast cells, 
fibroblasts, lining cells, mesenchymal stromal cells, endothelial cells, neural cells, 
chondrocytes, osteoblasts, osteocytes and osteoclasts (Firestein, 2005). Some of the main 






Figure 1. Main events and key players in the pathogenesis of RA.  
 
 
B cells activated to plasma cells produce RF and other autoantibodies for export, which 
form immune complexes with the antigens which stimulated their production (Panayi, 
2005). This leads to complement activation and subsequent recruitment of neutrophils and 
macrophages. Macrophages can be activated in several ways: by T cell contact or T cell 
derived cytokines (e.g., IFN-γ, IL-17), by immune complexes which trigger activating FcγR 
signalling, and by innate immune receptors stimulated with danger signals via, e.g., TLRs 
(Bingham, 2002; Sokolove et al., 2011). The accumulation and persistent activation of 
macrophages has been found to correlate with the articular signs and symptoms of RA 
(Tak, 2005).  
 
Oxidative stress can cause mutations in, e.g., the p53 tumor suppressor gene, leading to 
increased synoviocyte proliferation (Tak et al., 2000). Furthermore, activation of RA 
synovial fibroblasts (RASFs) may occur already early in the disease process, e.g. through 
interaction of TLRs of the innate immune system with danger signals (Huber et al., 2006). 
This activation leads to up-regulation of integrins, which enable the fibroblasts to adhere to 
and migrate along the extracellular matrix of the articular cartilage (i.e., collagen type II 
and cartilage glycosaminoglycans, GAGs). Subsequently, the expression of MMPs, 
cathepsins and proto-oncogenes is increased. RASFs also express RANKL which enhances 
the differentiation and fusion of macrophage-lineage osteoclast progenitors into 
multinuclear osteoclasts. In addition, RASFs produce pro-angiogenic factors and a variety 
of chemokines and cytokines. Moreover, apoptosis signalling is impaired in RASFs and 
synovial macrophages. These changes, in concert with other disease processes, lead to 
several interconnected pathophysiological phenomena: synovial hyperplasia, angiogenesis, 
attraction and accumulation of immune cells to the synovium, spreading and invasion of 
inflamed synovial and pannus tissue, and progressive destruction of articular cartilage, bone 




Rheumatoid synovial tissue is characterized by intimal lining hyperplasia, increased 
vascularity and an accumulation of cells in the synovial sublining: dendritic cells, T cells, 
macrophages, B cells, plasma cells, neutrophils, mast cells and natural killer cells (Tak, 
2005; Ahern and Brennan, 2011), even organized into secondary lymphatic follicles, which 
represent the morphological equivalent of the T cell-dependent, B cell-mediated 
immunoglobulin synthesis usually seen in secondary lymphatic tissues (Konttinen et al., 
1981). Pro-inflammatory cytokines, e.g., TNF, IL-1, IL-6 and IL-17, are central mediators 
in processes leading to articular symptoms and damage. They may also be involved in some 
of the systemic manifestations, e.g. anaemia, fatigue, generalized bone loss and 
cardiovascular disease (atherosclerosis, myocardial infarction, coronary artery disease), 
although other causes have been recognized as well (Moreland and Curtis, 2009).  
 
4.2 Evaluating drug effects in RA 
4.2.1 Randomized controlled trials, clinical trials and observational 
studies 
 
A clinical trial is a procedure in medical research with the aim of collecting data on the 
efficacy and safety of health interventions. Clinical trials, e.g. of new treatment modalities, 
may be required prior to gaining marketing authorization. A randomized controlled clinical 
trial (RCT) is a type of clinical trial in which study subjects are allocated to their respective 
intervention in an unpredictable sequence to minimize allocation bias, and the outcomes of 
the study intervention(s) are compared with a control intervention. Well designed and 
properly conducted RCTs provide solid evidence of the study intervention regarding its 
safety and efficacy, i.e., the capacity to produce the intended effect. This may necessitate 
application of strict inclusion and exclusion criteria to define the study sample, which 
narrows down the patient population to a distinctly selected group of patients. For example, 
it has been estimated that less than one-third, even less than one-tenth, of RA patients 
starting TNFi therapy in clinical practice would fulfil the inclusion and exclusion criteria 
which have been used in the clinical trials of TNFi drugs (Kvien et al., 2003; Zink et al., 
2006). Furthermore, patients and investigators participating in RCTs may be particularly 
committed to the trial and trial drug. These, and other factors (such as geographical area in 
which the study is conducted), may lead to a limitation of the external validity, i.e., 
generalizability, of the RCT results. 
 
Observational studies can have a case-control (retrospective) or cohort (prospective) design. 
They can complement RCTs by providing information on effectiveness, i.e., the extent to 
which a treatment modality achieves its intended effect in the usual clinical setting, and 
safety, including long-term and rare events (Marley, 2000; Silverman, 2009). The follow-up 
of patients with chronic conditions may be significantly longer in observational studies, 
compared with the often relatively short duration (e.g. weeks or months) of an RCT. 
Methodological limitations of observational studies include selection bias due to the non-
randomized setting (confounding by indication), and incompleteness of the data due to, e.g., 
the available data being limited to that included in the data source; incomplete or under-




4.2.2 Assessment of disease status and outcomes of pharmacological 
therapy 
 
The individual clinical response to DMARD therapy is variable. Therefore, there is a need 
to quantify the response to treatment, both in clinical trials and routine practice. Various 
measures of disease activity have been published since the 1940s (Ranganath et al., 2006). 
The first approach to classification of the response in clinical trials was based on the 
definition of a complete remission, with the American Rheumatism Association RA 
remission criteria being published in 1981 (Pinals et al., 1981; Hider et al., 2005). 
However, complete remission is seldom achieved (even with contemporary therapies), and 
therefore, criteria to identify patients achieving a sufficient improvement have been 
developed subsequently. The American College of Rheumatology (ACR) improvement 
criteria (Felson et al., 1995) and the European League Against Rheumatism (EULAR) 
response criteria (van Gestel et al., 1996) have gained the most widespread use. However, 
new remission criteria have recently been defined and are recommended for clinical trials 
(Felson et al., 2011a; Felson et al., 2011b). 
 
The ACR criteria were developed based on a relatively widely internationally agreed core 
set of measures recommended for all RA clinical trials (Felson et al., 1993; Felson et al., 
1995). The aim was to develop a single primary efficacy measure. First, baseline and post-
treatment data on the core set of measures obtained from trials was compared with the 
impression of the rheumatologists of the improvement. This was done to reduce the initial 
number of candidate definitions of improvement. The remaining definitions were then 
tested on datasets from placebo-controlled DMARD trials to find those measures that 
maximally distinguished between effective and placebo treatments and minimized placebo 
response rates. In addition, attention was paid to the ease of their practical use. The finally 
selected definition of improvement is known as the ACR20. ACR20 response is achieved 
when the patient has at least 20% improvement in the swollen joint count (SJC) and the 
tender joint count (TJC), and in at least three of the five remaining ACR core set measures, 
i.e. patient and physician global assessments, pain score, physical function and an acute-
phase reactant. In practice, improvement in excess of 20% is usually desired, and therefore 
usually also ACR50 (50% improvement) and ACR70 (70% improvement) response rates 
are reported. The ACR core set of measures can also be used to calculate numeric ACR 
(ACR-N), which is the lowest percentage change in the following three measures: SJC, 
TJC, and the median of the other five measures in the ACR core set (Siegel and Zhen, 
2005). They can also be used to determine the proportion of patients achieving a 
satisfactory state of minimal disease activity (MDA, originally named low disease activity 
state, LDAS) (Wells et al., 2006).  
  
The EULAR response criteria are based on the Disease Activity Score (DAS) (van der 
Heijde et al., 1990; van der Heijde et al., 1993; van Gestel et al., 1996). The DAS is a 
composite measure of disease activity obtained through statistical techniques applied on the 
decisions of rheumatologists to start treatment with DMARDs in patients with early RA. 
The DAS28 modification of the more complex original DAS has gained widespread use, 
and incorporates the 28-joint swollen and tender joint counts, ESR and the patient global 
assessment (Prevoo et al., 1995; van Gestel et al., 1998). Other modifications of the DAS 
and DAS28 provide options for different circumstances and include formulas which 
incorporate CRP instead of ESR and/or which omit the patient global assessment, as well as 
the Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index 
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(CDAI) (Aletaha and Smolen, 2005). Using the EULAR response criteria, patients can be 
classified as good, moderate or non-responders according to the change in the DAS or 
DAS28 and the level of residual disease activity. Using the DAS28, the EULAR response 
criteria are as follows:      
 current DAS28 ≤ 3.2 (indicating low disease activity) and  
 decrease in DAS28 > 1.2: good 
 decrease in DAS28 > 0.6 and ≤ 1.2: moderate 
 decrease in DAS28 ≤ 0.6: none 
 current DAS28 > 3.2 and ≤ 5.1 and 
 decrease in DAS28 > 0.6: moderate 
 decrease in DAS28 ≤ 0.6: none 
 current DAS28 > 5.1 (indicating high disease activity) and 
 decrease in DAS28 > 1.2: moderate 
 decrease in DAS28 ≤ 1.2: none 
 
The question of whether an achieved response is considered “satisfactory” can be examined 
from the viewpoint of the physician’s decision to stop or continue the DMARD, such 
decisions, however, being context and patient specific (e.g., dependent on the available 
treatment options and eventual side effects) (Hider et al., 2005; Ranganath et al., 2006).  
 
RA sequelae and the efficacy or effectiveness of pharmacological therapy can also be 
evaluated radiographically, especially in long-term studies (e.g., beyond six to twelve 
months). Radiographs provide a rather permanent measure of damage that can be evaluated 
serially, and that does not fluctuate with disease activity (Scott et al., 1997; Sokka, 2008). 
In clinical studies, an advantage is also that they can be evaluated in a randomized, blinded 
manner (Boini and Guillemin, 2001). Quantitative methods of assessment include the 
Larsen and Sharp scoring methods and modifications thereof, e.g., the van der Heijde 
modification of the Sharp erosion score. The contemporary scoring methods consider pre-
specified joint areas in the hands, wrists and feet. Sharp methods involve separate scores for 
erosions and joint space narrowing, while Larsen methods give an overall score; the total 
scores have a continuous scale of more than 100 units, and the minimal clinically important 
difference is ca 1% of the maximum score (Sokka, 2008). The Larsen and Sharp scores 
correlate significantly, and the choice of scoring method depends on the required degree of 
reliability and sensitivity to change, and the time available for the assessments (Boini and 
Guillemin, 2001; Sokka, 2008).  
 
Patient-reported outcome measures of health-related quality of life (HRQOL) are further 
recommended efficacy assessments for RA clinical trials (Smolen et al., 2011). The choice 
of instrument depends on the specific purpose of the study. The instrument can be generic, 
such as the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36); EuroQol 
(EQ-5D); and 15D; or disease-specific, such as the Stanford Health Assessment 
Questionnaire (HAQ); Rheumatoid Arthritis Quality of Life Scale (RAQoL); and Arthritis 
Impact Measurement Scales (AIMS) (Carr, 2003; Linde et al., 2008; Smolen et al., 2011) 







Table 1. Health-related quality of life (HRQOL) instruments used in RA outcome studies. 
HRQOL instrument Use  Dimensions of health/functioning 
SF-36 Generic Physical functioning; role limitations due to physical 
problems; bodily pain; social functioning; mental health; 
role limitations due to emotional problems; vitality; 
general health 
EQ-5D Generic*  Mobility; self-care; usual activities; pain/discomfort; 
anxiety/depression 
15D Generic* Mobility; vision; hearing; breathing; sleeping; eating; 
speech/communication; excretion; usual activities; 
mental function; discomfort and symptoms; depression; 
distress; vitality; sexual activity 
HAQ Disease-specific (assessment 
of functional disability) 
Dressing; arising; eating; walking; hygiene; reach; grip; 
usual activities 
RAQoL Disease-specific Physical, emotional, and social limitations 
AIMS Disease-specific Mobility; physical activity; dexterity; household activity; 
social activities; activities of daily living; pain; 
depression; anxiety 
 




Safety monitoring during DMARD therapy is aided by, e.g., Summaries of Product 
Characteristics (SPC), and guidelines issued by local hospitals or national or international 
professional organizations (Saag et al., 2008; Hakala et al., 2009; Pham et al., 2011; Singh 
et al., 2012).  
 
4.3 Treatment of RA, with focus on pharmacotherapy 
4.3.1 Symptomatic and disease modifying antirheumatic drugs 
 
Treatment with NSAIDs is a central component of pain management in RA (Schnitzer and 
Hochberg, 2002). The NSAIDs are a chemically heterogeneous group of drugs, whose 
principal mechanism of action is inhibition of prostanoid synthesis, by inhibition of 
cyclooxygenase (COX) enzymes (COX-1 and COX-2 in the case of nonselective NSAIDs, 
and COX-2 in the case of “coxib NSAIDs”, i.e., COX-2 selective inhibitors) (Pelkonen and 
Ruskoaho, 2003). This results in their antipyretic effect and inhibition of platelet 
aggregation and is, at least partly, responsible for their anti-inflammatory and analgesic 
effects. The therapeutic effects of various NSAIDs are similar, but their pharmacokinetic 
characteristics differ. Long-term usage of nonselective NSAIDs, especially at high doses in 
susceptible patients, may lead to NSAID gastropathy, e.g., to peptic ulceration. 
Susceptibility to peptic ulceration is increased in those of age 65 years or more, who have 
had prior peptic ulcer disease or who use concomitant glucocorticoid (GC) or anticoagulant 
therapy (Schnitzer and Hochberg, 2002). Other serious adverse drug reactions of NSAIDs 
include nephrotoxicity and worsening of asthma (Pelkonen and Ruskoaho, 2003). Weak 
oral opioid analgesics (e.g., codeine, tramadol) are also effective for the treatment of pain in 
RA, at least in the short term (up to six weeks); however, side effects are common, which 




Synthetic GCs are highly effective in quickly reducing inflammation and pain (Pelkonen 
and Ruskoaho, 2003). They affect the inflammatory processes in many ways, primarily by 
regulating the synthesis of proteins through regulation of the gene activity (directly or via 
transcription factors) or the rate of messenger RNA (mRNA) degradation. Importantly, they 
reduce the synthesis of inflammatory mediators and regulate the synthesis of enzymes 
involved in their production, leading to reduced levels of, e.g., prostanoids, cytokines (e.g., 
TNF, IL-1), nitric oxide, free radicals, bradykinin and tachykinins (e.g., substance P). In 
addition, they inhibit many inflammatory cell functions, such as synthesis of adhesion 
molecules in endothelial cells, neutrophil chemotaxis, histamine release from basophils, 
leukocyte movement and lymphocyte proliferation, ultimately leading to a reduction of 
inflammatory cell accumulation to the site of inflammation. GCs may increase the 
susceptibility, and complicate the recognition of, infections, and impede with wound 
healing and metabolic processes. These adverse effects limit long-term systemic usage, 
especially at moderate or high doses. Recently, modified-release GCs have been launched 
to relieve morning stiffness by mimicking the normal circadian rhythm of the 
hypothalamic-pituitary-adrenal axis and of the cortisol production (Buttgereit et al., 2008; 
Buttgereit, 2011).  
 
DMARDs are disease modifying in that they modify the immune system so that 
inflammation is suppressed and disease progression is slowed down. Conventional 
DMARDs (cDMARDs) include methotrexate (MTX), sulfasalazine (SSZ), chloroquine 
derivatives (hydroxychloroquine (HCQ), chroloquine), leflunomide (LEF), gold salts 
(sodium aurothiomalate, auranofin), cyclosporine, penicillamine, and cytostatic drugs 
(azathioprine, chlorambucil, cyclophosphamide) (Pelkonen and Ruskoaho, 2003). The 
exact pharmacodynamic mechanisms of most cDMARDs are not known. However, they 
have various, partially overlapping effects on inflammatory cells or mediators, which may 
explain their anti-inflammatory and antirheumatic effects. In general, it takes several weeks 
for the eventual clinical effect to take place. SSZ and LEF have been developed specifically 
for the treatment of RA, while for most of the other drugs, an antirheumatic effect has been 
found by chance. The main known pharmacodynamic effects of the most common 














Table 2. Features and pharmacodynamic effects of cDMARDs in the treatment of RA. 
Drug name and features Effects (in RA) References 
MTX 
 Antineoplastic agent 
 Inhibits the metabolism of folic acid  
 In RA, low-dose MTX reduces cell-mediated immune 
responses and the production/effects of RF (but not ACPA) 
and various pro-inflammatory cytokines (e.g., IL-1, IL-6, 
TNF) 
 Increases the synthesis of the anti-inflammatory agent 
adenosine 
 May inhibit arachidonic acid metabolism and rapid 
proliferation of cells (lymphocytes) in the synovium. 
Bannwarth et al., 1994 
Pelkonen and 
Ruskoaho, 2003 
Spadaro and Riccieri, 
2005 
SSZ 
 A combination of the 
sulfonamide antibiotic 
sulfapyridine and the 
anti-inflammatory agent 
5-aminosalicylic acid (5-
ASA, i.e. mesalazine) 
 SSZ may inhibit lymphocyte proliferation, the production of 
immunoglobulins (e.g., RF) and various cytokines (e.g., 
TNF), and the actions of neutrophils, and increase the 
release of adenosine  
 Sulfapyridine may affect the angiogenic process of the 
inflamed synovium by reducing endothelial cell proliferation 
Pullar et al., 1985 







 Stabilizes lysosomal membranes (prevents release of 
degradative enzymes) 
 Raises intra-lysosomal pH, which interferes with several 
protein processing events and ultimately, e.g., reduces RF 
levels and lymphocyte proliferation  
 May inhibit antigen presentation, intracellular TLRs, 
prostanoid and leukotriene synthesis and free-radical 
damage    
Meng et al., 2000 
Pelkonen and 
Ruskoaho, 2003 
Smolen et al., 2010a 
Katz and Russell, 
2011 
LEF 
 Active metabolite 
(A771726) 
 Inhibits the enzyme dihydroorotate dehydrogenase 
(DHODH), which leads to reduced proliferation of activated 
lymphocytes 
 Reduces the synthesis of cytokines, free radicals and 
immunoglobulins 




 Injectable sodium 
aurothiomalate 
 Oral auranofin 
 Seem to inhibit the actions of degradative enzymes and 
complement; the synthesis of prostaglandins, leukotrienes 
and IL-1 and the formation of oxygen radicals; and 




Kean and Kean, 2008 
Cyclosporine  Binds to the cytosolic protein cyclophilin, which inhibits 
calcineurin and IL-2 production by activated T lymphocytes  
 Also regulates other cell mediated reactions, e.g., by 
increasing transforming growth factor-beta (TGF-β) and IL-
10 synthesis; decreasing vascular endothelial growth 
factor (VEGF) secretion; decreasing IL-15 and TNF 
production in fibroblasts; and impairing neutrophil 
chemotaxis   
Lorenz, 2003 
Azathioprine 
 Active metabolites (6-
mercaptopurine and 
purine thioanalogues) 
 Purine antimetabolites 
 Inhibit the synthesis of purine nucleotides and interfere 
with deoxyribonucleic acid (DNA) and ribonucleic acid 
(RNA) biosynthesis and function 
 Ultimately inhibit cell (lymphocyte) proliferation   







The biological DMARDs (bDMARDs) are produced with recombinant DNA technology 
and are specifically designed to block key mediators of the RA inflammatory process 
(Hider et al., 2005). The first bDMARDs to emerge were TNFi agents, the first of which 
were licensed and approved for the treatment of RA around the year 2000. TNFi agents for 
human use were actually initially developed for treatment of a septic shock, but proved, in 
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clinical trials, to be ineffective or even detrimental (Abraham et al., 1995; Fisher et al., 
1996; Clark et al., 1998). However, by that time (early 1990s), critical preclinical 
experiments had provided a strong rationale for testing TNFi therapy also in human RA 
(Feldmann and Maini, 2001).  
Currently (2013), five TNFi agents are in clinical use in Finland: infliximab (IFX; licensed 
1999), etanercept (ETA; 2000), adalimumab (ADA; 2003), certolizumab pegol (CER; 
2009) and golimumab (GOL; 2009). Details about their structures and features are 
presented in Table 3.  
 
 
Table 3. Anti-TNF agents and their structures and features.  
Anti-TNF 
agent 
Structure and features References 
IFX  Chimeric anti-TNF-α mAb1, with a human IgG1 constant (Fc) 
region2 and murine variable (Fv) epitope-binding region 
 The presence of the murine component may lead to production of 
HACAs; however, concomitant MTX use reduces the incidence of 
these  
Arend, 2002 
Maini and Feldmann, 2002 
Anderson, 2005 
Horiuchi et al., 2010 
 
ADA  Fully human anti-TNF-α mAb Kempeni, 1999 
GOL  Fully human anti-TNF-α mAb Tak and Kalden, 2011 
ETA  Soluble TNF-α receptor (sTNFR), consisting of two extracellular 
ligand-binding domains of the human 75 kDa TNF type 2 receptor, 
linked to a Fc region of human IgG1 
 The dimeric receptor has a greater affinity for TNF-α than the 
naturally occurring monomeric sTNFR 
 The linkage to the Fc region provides the construct with better 
retention (longer half-life) in the circulation  
 Also binds and neutralizes lymphotoxin-α (TNF-β) 
 Compared to the mAbs, CDC is much weaker with ETA due to the 
structural differences of the respective IgG1 backbones (ETA does 
not contain the CH1 domain nor the hinge region)  
Jarvis and Faulds, 1999 
Moreland et al., 1999 
Arend, 2002 
Buch et al., 2004 
Horiuchi et al., 2010 
 
CER  Human anti-TNF-α mAb Fab region which is conjugated with two 
cross-linked chains of 20 kDa polyethylene glycol (PEG) 
 Pegylation extends the plasma half-life of the construct 
 The construct is unique among the TNFi agents in that it lacks the 
Fc region of IgG1 
Choy et al., 2002 
Horiuchi et al., 2010 
 
Abbreviations: CDC=complement-dependent cytotoxicity; HACAs=human anti-chimeric antibodies; mAb=monoclonal 
antibody.  
1) The mAbs specifically bind to both soluble and membrane-bound human TNF-α with high affinity, forming stable 
immune complexes; this prevents TNF-α from binding to its membrane-bound receptors.  
2) The IgG1 backbone enables induction of complement-dependent cytotoxicity (CDC) or antibody-dependent cell-
mediated cytotoxicity (ADCC). 
 
 
Four other types of biological agents, i.e., not targeting TNF, are available as well for the 
treatment of RA: anakinra (2002), rituximab (1998, approved for RA in 2006), abatacept 
(2007) and tocilizumab (2009) (Curtis and Singh, 2011). Their mechanisms of action are 






Table 4. Mechanisms of action of biological agents not targeting TNF.  
Drug Mechanism of action References 
Anakinra  Competitive IL-1 type I receptor antagonist Cohen et al., 2002 
Rituximab  Anti-CD20 mAb that selectively depletes CD20+ B cells, 
i.e., pre-B cells through mature B cells (but not stem cells or 
plasma cells) 
Cohen et al., 2006 
Abatacept  T cell co-stimulation blocker 
 Structurally a fusion protein consisting of the extracellular 
domain of human cytotoxic T lymphocyte-associated 
antigen 4 (CTLA4) and a part of the Fc region of human 
IgG1 
 By binding to and blocking the CD80/86, it inhibits 
CD80/86-mediated stimulation of T cells via CD28 located 
on the surface of the T cell  
Ruderman and Pope, 2005 
Tocilizumab  Humanized anti-IL-6 receptor alpha (IL-6Rα) mAb 
 Inhibits the binding of IL-6 to membrane-bound and soluble 
IL-6Rα, and thereby blocks IL-6 mediated signal 
transduction  
 By binding to soluble IL-6Rα, it prevents so called 
transsignaling by IL-6/IL-6Rα complexes in target cells that 
lack the ligand-binding IL-6Rα, but contain the ubiquitous 
signal-transducing IL-6Rβ 
Youinou and Jamin, 2009 
Ogata and Tanaka, 2012 
 
 
4.3.2 Treatment options and strategies 
 
The treatment options for RA consist of pharmacological symptom-relieving and/or disease 
modifying therapies, and non-pharmacological measures, which can include physical, 
occupational and psychological approaches (Hakala et al., 2009; Smolen et al., 2010a). 
Pharmacological options include mono- or combination therapy with conventional 
DMARDs (cDMARDs), biological agents, oral or intra-articular glucocorticoids (GCs), 
NSAIDs and/or analgesics. Additional therapies may be needed, e.g., to prevent 
osteoporosis. Non-pharmacological measures include chemosynovectomy or 
radiosynovectomy (low accessability at present), orthopedic surgery (e.g. arthroplasty), 
rehabilitation (e.g. physical therapy, occupational therapy), orthoses and aids and patient 
counseling. Optimal management of RA requires care provided by specialists in 
rheumatology and a multidisciplinary approach, and shared decision-making with the 
patient (Hakala et al., 2009; Smolen et al., 2010a; Smolen et al., 2014).  
 
Disease modification constitutes the fundamental therapeutic intervention in RA (Smolen et 
al., 2010a). During the past couple of decades, DMARD treatment, especially, has 
undergone significant changes. Firstly, treatment strategies have changed, so that treatment 
with a cDMARD is started early (as soon as a diagnosis of RA has been made), DMARDs 
are often used in combinations (combination treatment), appropriate changes to the 
treatment are made as necessary (the sawtooth principle; Fries, 1990; Box 1), and the 
principles of tight control (Treat to Target; Smolen et al., 2010b; Box 1) are applied. 
Secondly, several effective drugs, e.g., biological agents, have become available, and these 
and older ones have been re-evaluated in order to gain better efficacy, e.g., through 
combination therapies. New small molecular signal transduction modifying peroral drugs 





Box 1. The sawtooth strategy and the Treat to Target approach.  
 
Sawtooth 
The sawtooth strategy involves serial use of DMARDs to control disease progression, and 
encompasses the principles of continuous DMARD use started early; setting an individual 
“disability ceiling”; regular quantitative monitoring of disability; and changing the 
DMARD treatment when the disability ceiling is reached.  
 
Treat-to-target 
The treat-to-target approach involves treatment aiming at remission (low disease activity 
being an alternative goal in patients with long-standing disease); regular follow-up 
examinations using composite measures of disease activity (every 1–3 months during active 




4.3.3 Treatment aims 
 
The primary aim of the treatment of RA is clinical remission, defined as the absence of 
signs and symptoms of significant inflammatory disease activity (Hakala et al., 2009; 
Smolen et al., 2010b). For clinical trials, the ACR and EULAR have recently proposed a 
provisional definition of remission (Felson et al., 2011a; Felson et al., 2011b). According to 
this, a patient can be considered to be in remission when swollen joint count (SJC), tender 
joint count (TJC), CRP (in mg/dl), and the patient global assessment (on a scale of 0 to 10) 
are all ≤1, or when the score of the Simplified Disease Activity Index (SDAI) is ≤3.3; the 
SDAI is the simple sum of the SJC (28-joint index), TJC (28-joint index), patient global 
assessment (0-10 scale), physician global assessment (0-10 scale) and CRP (in mg/dl). 
However, low disease activity may be the best achievable state and in this respect an 
acceptable alternative aim, especially in an established, long-standing disease (Smolen et 
al., 2010b). The treatment target should be maintained throughout the course of the disease, 
and until it is reached, it is recommended that drug therapy is adjusted every 3-6 months 
(Smolen et al., 2014). Treatment decisions should be guided by the use of validated 
composite measures of disease activity, which include joint assessments. In addition, 
structural changes and functional impairment should be evaluated. Naturally, comorbidities 
and safety concerns should also be taken into account in all treatment decisions (Smolen et 
al., 2010a; Smolen et al., 2014). Treatment to target and tight control of RA have been 
shown to be highly efficacious, and are aimed at symptom control, prevention of structural 
damage, and normalization of function and social participation (Grigor et al., 2004; 
Schipper et al., 2010; Smolen et al., 2010b).  
 
4.3.4 Guidelines for the management of RA, with focus on the EULAR 
recommendations 
 
Many countries, including Finland, have national guidelines for the management of RA, but 
in this text the EULAR recommendations are described in some detail. The EULAR, ACR 
and Finnish Current Care recommendations for the use of cDMARDs and bDMARDs in 
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the management of RA are largely in accordance (Saag et al., 2008; Hakala et al., 2009; 
Smolen et al., 2010a; Singh et al., 2012; Smolen et al., 2014).  
 
The EULAR recommendations for the management of RA with synthetic (conventional) 
and biological DMARDs and GCs, based on evidence and expert opinion, state that for the 
vast majority of patients with RA, the first treatment approach should include a cDMARD, 
started immediately upon diagnosis (Smolen et al., 2010a; Smolen et al., 2014). A 
suspected diagnosis of RA may be sufficient for cDMARD treatment initiation. Notably, 
early RA may be more amenable to disease modification with cDMARDs, showing a 
greater response rate than is seen in long-standing disease (Anderson et al., 2000). In active 
RA, MTX is usually the initial DMARD used (alone or as part of cDMARD combination 
therapy1), based on its clinical efficacy (unsurpassed by other cDMARDs) and beneficial 
long-term safety profile, with its low price being an additional advantage. For patients with 
contraindications or intolerance to MTX, alternative DMARDs to consider include LEF or 
SSZ (Smolen et al., 2014). Oral low-dose GC provides additional benefit to DMARD 
therapy, but should, due to safety concerns in the intermediate to long term, be tapered as 
soon as clinically feasible.     
 
If the treatment target is not achieved with the first cDMARD strategy, and poor prognosis 
factors are present, addition of a bDMARD should be considered (Smolen et al., 2014). 
Poor prognosis factors include the presence of autoantibodies (RF and/or ACPA), 
especially at high levels; high disease activity, as measured by composite indices, swollen 
joint counts or acute phase reactants (CRP, ESR); and early occurrence of erosions. In the 
absence of poor prognostic factors, changing to another cDMARD strategy (including 
combination therapy) should be considered. If the treatment target is not achieved after 
switching to another cDMARD, or after combination therapy with cDMARDs, addition of 
a bDMARD should be considered; indeed, the bDMARD is recommended to be combined 
with MTX (or other cDMARDs). For patients not achieving the treatment target with a first 
bDMARD, switching to another bDMARD is recommended. Tofacitinib, a new targeted 
synthetic DMARD whose mechanism of action is based on janus kinase (JAK) inhibition, 
may be considered if bDMARD therapy fails; however, tofacitinib is not currently (2013) 
approved for the treatment of RA in Europe.     
 
Currently, it is unclear how to continue or discontinue treatment in patients who have 
achieved remission. However, patients are at higher risk of flaring if treatment with 
cDMARDs is discontinued, and, moreover, remission may be harder to re-achieve upon 
resumption of treatment (ten Wolde et al., 1997). According to expert opinion, after tapered 
GC, tapering of bDMARD while continuing concomitant treatment with cDMARD therapy 
might be considered in cases of persistent remission (e.g. having lasted more than 12 
months) (Smolen et al., 2010a; Smolen et al., 2014). Subsequent tapering of cDMARDs is 
left to the discretion of the patient and doctor.  
 
The FIN-RACo study, pivotal to Finnish rheumatology, compared remission rates and 
various other outcomes during two years in patients with early RA who received an initial 
triple therapy (MTX, SSZ and HCQ) and low-dose oral GC, or SSZ monotherapy with or 
without GC; 63 of 98 patients in this group used GC during the study (Möttönen et al., 
1999). Pre-specified treatment adjustments were allowed in both groups, but those in the 
                                                 
1 cDMARD combination therapies are often specific combinations of two cDMARDs, one of which is usually 
MTX, or triple therapy with MTX, SSZ and HCQ. 
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combination arm had to continue SSZ and HCQ until the end of the study. Those in the 
single-treatment arm were on cDMARD monotherapy (and GC when needed) throughout 
the study, but could, according to the protocol, replace SSZ with MTX, and subsequently 
azathioprine; further replacements were allowed using one of prespecified cDMARDs. Of 
98 patients, 51 switched to MTX during the study. Remission and ACR50 response rates 
were higher in the combination arm than in the single-treatment arm throughout the study. 
The rates tended to improve through the study; at endpoint, the remission rate was 37% in 
the combination arm and 18% in the single-treatment arm. The corresponding ACR50 
response rates were 71% and 58%, respectively. Radiographic outcomes were also better in 
the combination arm. Notably, at endpoint, oral GC was used by more patients in the 
single-treatment arm than in the combination arm (50 vs. 43). Furthermore, more intra-
articular GC injections were given in the single-treatment arm than in the combination arm. 
Adverse event (AE) frequencies were similar in both groups. After the first two years of the 
study, the treatment was unrestricted, but still aimed at remission. However, particularly the 
effectiveness of the initial treatment has been found to be of importance to several long-
term outcomes, such as radiological outcomes and work capacity, with results being 
superior in the initial combination therapy group (Korpela et al., 2004; Puolakka et al., 
2004; Rantalaiho et al., 2010).  
 
4.4 Tumor necrosis factor (TNF) and its inhibition in RA 
 
Human TNF-α (hereafter denoted TNF) is a non-glycosylated protein, which in its 
biologically inactive monomeric form consists of 157 amino acids and has a molecular 
weight of 17 kDa (Callard and Gearing, 1994; Russo and Polosa, 2005). It is formed from a 
trans-membrane precursor through proteolytic cleavage by TNF-α converting enzyme 
(TACE, also known as ADAM17, i.e., a disintegrin and a metallopeptidase 17). Thereafter 
the soluble monomeric TNF aggregates into biologically active 51 kDa homotrimers. Also 
trimeric membrane-bound TNF is biologically active. TNF is produced mainly by 
macrophages, but also e.g. monocytes, T cells, B cells, neutrophils, mast cells and 
endothelial cells (Hopkins and Meager, 1988; Feldmann and Maini, 2001; Panayi, 2005; 
Russo and Polosa, 2005; Wright et al., 2011). Almost all potentially noxious stimuli, 
ranging from physical to chemical and immunological stimuli, have a potential to rapidly 
induce TNF production and/or release; the activation of macrophages and TNF production 
in RA has been discussed in the section reviewing the pathogenesis of RA.    
 
4.4.1 TNF and its role in RA pathogenesis 
 
A study by Tetta et al. (1990), using a biological assay, revealed TNF at detectable 
concentrations in the serum of roughly half of RA patients (treated with NSAID ± low-dose 
GC, but no DMARDs), while not being detected in the serum of healthy control subjects. 
High concentrations (mean ca 6 ng/ml) were found in the serum of patients with severe RA. 
TNF was also found in the synovial fluid of about half of the RA patients; the highest 
synovial fluid TNF concentrations were found in patients with high synovial fluid 
leukocyte counts (mean TNF concentration ca 5 ng/ml in patients with leukocyte counts of 
> 10×109/l). TNF was not detected in the synovial fluid of osteoarthritis patients. Hopkins 
and Meager (1988) used an immune-assay and found higher TNF levels in the synovial 
fluids of patients with seropositive RA than in patients with other arthritides (including 
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osteoarthritis). In this study, TNF levels did not seem to be associated with synovial fluid 
cell counts. 
 
The biological responses to TNF are elicited by its binding to TNF receptors, of which two 
types exist: the 55 kDa Type I receptor (TNFR1, p55 or CD120a), which is constitutively 
expressed by most cell types and is the main receptor for soluble TNF, and the 75 kDa 
Type II (TNFR2, p75 or CD120b), the expression of which is highly regulated and which is 
typically expressed by cells of the immune system, and is the main receptor for membrane-
associated TNF (Callard and Gearing, 1994; Varfolomeev and Ashkenazi, 2004; Russo and 
Polosa, 2005; Parameswaran and Patial, 2010). Deleuran et al. (1992), using 
immunohistochemical staining, found both TNFR types in the rheumatoid synovial 
membrane and at the cartilage-pannus junction. Since TNFR expressing cells were in the 
vicinity of TNF producing cells or stained also for TNF, it was reasoned that they are 
subjected to paracrine and autocrine stimulation. While TNFR expressing cells were also 
found in osteoarthritic and normal synovial tissue, their numbers were lower and the 
staining intensity was weaker. Indeed, TNF activates a variety of cell types found in the 
rheumatoid joint, including macrophages, fibroblast-like synoviocytes, chondrocytes and 
osteoclasts (Bingham, 2002). Interestingly, also nociceptors have been found to express 
TNFRs (Schaible, 2010).  
 
The TNFRs trigger several intracellular signaling pathways, and the cellular responses to 
TNF are remarkably diverse. In the regulation of synovial inflammation, signal transduction 
through MAP kinase (mitogen-activated protein kinase) and NF-κB (nuclear factor kappa-
light-chain-enhancer of activated B cells) pathways are of central importance (Sweeney and 
Firestein, 2004; Varfolomeev and Ashkenazi, 2004) (Figure 2). Binding of TNF to TNFR1 
leads first to the binding of TRADD, i.e., TNFR-associated death domain protein, to the 
cytoplasmic phase of the TNFR1. This triggers recruitment of the additional adaptor 
proteins TNFR-associated factor 2, i.e., TRAF2, and receptor interacting protein-1, i.e., 
RIP-1 (Devin et al., 2000; Sweeney and Firestein, 2004; Russo and Polosa, 2005); TNFR2 
recruits TRAF2 directly. The combination of TRAF2 and RIP results in the activation of 
the IKK (inhibitor of kappa B kinase, i.e., IκB kinase) enzyme complex, which catalyzes 
phosphorylation and degradation of the NF-κB inhibitor IκB. Subsequently the 
transcription factor NF-κB is released, whereby it may translocate into the nucleus and 
activate its target genes, including those of the cytokines TNF, IL-1, IL-2, IL-3, IL-6 and 
IL-8 (among others); the inflammatory mediators COX-2 and iNOS (inducible nitric oxide 
synthase); the cell adhesion molecules E-selectin, ICAM-1 (intercellular adhesion 
molecule-1) and VCAM-1 (vascular cell adhesion molecule-1); the growth factors G-CSF 
(granulocyte colony-stimulating factor), M-CSF (macrophage colony-stimulating factor) 
and GM-CSF (granulocyte macrophage colony-stimulating factor); the cytokine receptor 
IL-2R; as well as immunoregulatory molecules (including T cell receptors and MHC) and 
the acute phase protein SAA (serum amyloid A protein) and complement factors (Bingham, 
2002; Sweeney and Firestein, 2004). TNF also induces antiapoptotic genes through NF-κB 
(Varfolomeev and Ashkenazi, 2004). This promotes, e.g., macrophage survival (Lo et al., 






Figure 2. Simplified overview of signal transduction events elicited by TNF (in RA).  
 
 
Notably, TNF activates NF-κB, and NF-κB targets the TNF gene, whereby a positive 
feedback loop may be established and results in a persistent inflammation (Wright et al., 
2011). Moreover, TNF is one of the most prominent elements in the cytokine network 
regulating synovial inflammation in RA, since it induces the expression of, and has 
synergistic interactions with, several other proinflammatory cytokines; one such cytokine is 
IL-1, with which TNF shares many complementary and overlapping activities (Bingham, 
2002; Romas et al., 2002).     
 
In addition to activating the NF-κB signal transduction pathway, TNF (via TRAF2) also 
activates the p38 mitogen-activated protein kinases (MAPKs) and c-Jun N-terminal kinases 
(JNK), which, in turn, activate various transcription factors, such as activator protein 1 (AP-
1) from the JNK pathway, leading to increased production of TNF and other cytokines and 
various metalloproteinases (Kumar et al., 2003; Sweeney and Firestein, 2004; Varfolomeev 
and Ashkenazi, 2004; Russo and Polosa, 2005). TNF (and certain other cytokines, 
including IL-1 and IL-6) also stimulates the production of VEGF, the transcription of which 
is regulated by the transcription factor family known as hypoxia-inducible factor (HIF) 




Consequently, TNF is involved in several reciprocally connected pathophysiological 
phenomena in RA: it triggers local expression of chemokines and cytokines; it promotes 
adhesion, extravasation, recruitment and activation of inflammatory cells (neutrophils, 
lymphocytes, monocytes) and the accumulation of synovial fluid; it facilitates the transition 
from innate to acquired immunity; it stimulates the proliferation of synovial cells; it 
contributes to the processes of angiogenesis, pannus formation, and cartilage and bone 
destruction; and it participates in nociception (Bingham, 2002; Nagase and Kashiwagi, 
2003; Sweeney and Firestein, 2004; Varfolomeev and Ashkenazi, 2004; Schaible, 2010; 
Calmon-Hamaty et al., 2011).  
 
4.4.2 Clinical effects of anti-TNF agents in RA, with focus on 
infliximab, etanercept, and adalimumab 
Efficacy based on randomized, double-blind, placebo or active-comparator 
controlled clinical trials  
 
The basis for this section of the literature review is a systematic literature review (SLR) of 
the efficacy and safety of TNFi agents in the treatment of RA, performed and published by 
our research group (Aaltonen et al., 2012). To be included in the SLR, patients had to be 
adults ≥ 16 years of age fulfilling the ACR 1987 revised criteria for the classification of 
RA, and be randomized either to an intervention or control group. The intervention was 
required to comprise one of the commercially available biological TNFi agents (IFX, ETA, 
ADA, CER or GOL), and the control was required to comprise either placebo (PBO) or a 
combination of PBO and MTX. The TNFi agents had to have the same route of 
administration as the commercially available products, and be within the same dose range 
as that recommended for these. Efficacy was to be measured as ACR response rates 
(ACR20, ACR50 and/or ACR70) at any time point during the study. Additionally, 
information regarding safety had to be reported. These predefined inclusion criteria were 
defined so as to encompass the major RCTs performed with TNFi agents in the treatment of 
RA in an extensive and representative manner.  
 
Most of the resultant RCTs were phase III trials, and most of them were conducted in North 
America, Europe or Australia. Some eligibility criteria are uniform between the studies. For 
instance, steady, pre-enrolment doses of oral GC (≤10 mg prednisone equivalent daily 
dose) and NSAID were allowed, and a washout of DMARDs (other than MTX) was 
required before commencing the study. However, definitions of active disease varied, and 
details on these are reviewed for each study separately below. Here, the review of efficacy 
will focus on ACR response rates, and, where available, remission rates, changes in HAQ 
score, and radiographic outcomes, although various other efficacy measures may have been 
reported as well in the individual studies. The focus of the current review will be on IFX, 
ETA and ADA, as these are the agents included in the experimental section of this thesis; 
and on efficacy outcomes up to 12 months, in accordance with the published SLR, although 






Synopsis of the efficacy 
 
The efficacy in terms of ACR20, ACR50 and ACR70 of TNFi agents appears comparable 
across many trials, and is sometimes summarized as a “60-40-20” rule, i.e., approximately 
60%, 40% and 20% of the treated patients reach ACR20, ACR50 and ACR70, respectively 
(McInnes and O’Dell, 2010). MTX naïve patients with early RA (ERA) consistently show 
high comparator response rates that are frequently comparable to the rates of TNFi 
monotherapy after a few weeks or months after commencement; however, a significantly 
more rapid response is achieved with TNFi therapy (Bathon et al., 2000). A combination 
therapy with a TNFi agent and concomitant MTX is more effective than TNFi or MTX 
single therapy in most studies of early or established RA, in terms of both clinical and 
radiographic outcomes. Some studies indicate that radiographic responses can differ 




The ATTRACT study compared the combination of IFX and MTX (IFX+MTX) with PBO 
and MTX (PBO+MTX) in patients with active disease despite treatment with MTX (Maini 
et al., 1999; Lipsky et al., 2000). The ACR response rates at 30 weeks are presented in 
Table 5; the rates were similar at 54 weeks. In addition, IFX halted the progression of joint 
damage. The mean change in the radiographic total score at 54 weeks was 1.3 (from a 
baseline mean value of 79) in the intervention group, compared with 7.0 (from a baseline 
mean value of 82) in the control group (p<0.001; van der Heijde modification of the Sharp 
scoring system (vdH-S) was used, with a scale of 0 to 440). Interestingly, joint damage was 
halted in IFX treated patients regardless of their clinical response. IFX had a beneficial 
effect both on erosions and joint-space narrowing (JSN), and both on hands and feet. 
Improvements were also seen in physical functioning, as assessed by HAQ, and some other 
health-related quality of life measures (SF-36 physical component, vitality and social 




Table 5. Summary of ACR response rates in RCTs performed with IFX in the treatment of 
RA. IFX was used at standard dosage (3 mg/kg intravenously at 0, 2 and 6 weeks, and 







Inclusion criteria / definition 














IFX+MTX vs. PBO+MTX 
ATTRACT; Maini 
et al., 1999; 
Lipsky et al., 
2000 
SJC ≥ 6, TJC ≥ 6, and two of 
the following: morning 
stiffness ≥ 45 minutes, ESR > 
28 mm/h, and CRP > 2 mg/dl 
50 vs. 20 
 
27 vs. 5 8 vs. 0 30 weeks 
Abe et al., 2006 Same as in the ATTRACT 
study 
61 vs. 23 31 vs. 9 10 vs. 0 14 weeks 
ATTEST; Schiff 
et al., 2008 
SJC ≥ 10, TJC ≥ 12, and CRP 
≥ 1 mg/dl 
59 vs. 42 
 
37 vs. 20 24 vs. 9 28 weeks 
St. Clair et al., 
2004 
ERA, MTX naïve; SJC ≥ 10, 
TJC ≥ 12, and at least one of 
the following: RF positivity, 
radiographic erosions of the 
hands or feet, or CRP ≥ 2 
mg/dl 
62 vs. 54  46 vs. 32 33 vs. 21 54 weeks 
 
ERA=early rheumatoid arthritis 
 
 
A Japanese RCT of IFX+MTX vs. PBO+MTX gave ACR response rates similar to those 
seen in the ATTRACT study (Abe et al., 2006) (Table 5). The dose of MTX was 
significantly lower in the Japanese study (with patients of somewhat lower average body 
weight than that of patients in the U.S. or Europe, and treated according to the Japanese 
practice which prohibits MTX doses higher than 8 mg/week) than in the ATTRACT study 
(mean 7.1 mg/week and 7.4 mg/week in the intervention and control group, respectively, 
vs. 16 mg/week). 
 
IFX+MTX and PBO+MTX in the treatment of RA patients with inadequate response to 
MTX were also compared in the ATTEST trial (Schiff et al., 2008). The ACR response 
rates at day 197 (approximately 28 weeks) are presented in Table 5. Remission rates 
(defined as DAS28 score < 2.6) were 13% and 3% for the intervention and control group, 
respectively.  
 
The ACR response rates of both IFX+MTX and PBO+MTX were comparatively high in 
MTX naïve patients with active early RA of ≤ 3 years duration (compared to established, 
long-standing disease) (Clair et al., 2004) (Table 5). Remission rates (defined as DAS28 
score < 2.6) were 21% and 15% for the intervention and control group, respectively 
(p=0.07). The mean change in the vdH-S total score was 0.4 (from a baseline mean value of 
11.6) in the intervention group, compared with 3.7 (from a baseline mean value of 11.3) in 
the control group (p<0.001). The favorable effect of IFX pertained to both erosion and JSN 
scores. HAQ scores (scale 0 to 3) improved with a mean ± standard deviation (SD) of 0.80 
± 0.65 in the intervention group, and 0.68 ± 0.63 in the control group (p<0.05).  
 
A magnetic resonance imaging (MRI) study, involving a small number of patients with RA 
symptom duration < 12 months, rendered significantly higher ACR response rates at 14 and 
54 weeks in the IFX+MTX group, compared with the PBO+MTX group (Quinn et al., 
2005). IFX+MTX treatment led to a significant reduction in the MRI detected synovitis 






ETA monotherapy vs. PBO 
 
Moreland et al. (1999) compared ETA 25 mg subcutaneously (s.c.) twice weekly (standard 
dosage) as monotherapy (i.e., no concomitant DMARDs were permitted during the study), 
with PBO, in RA patients with active disease, who had discontinued one to four DMARDs 
due to lack of effect. The ACR response rates at three months are presented in Table 6; the 
rates were similar at six months. HRQOL, as measured by HAQ, also improved 
significantly in the intervention group. Treatment benefits were uniform irrespective of 
NSAID or GC usage or body weight. In a study by Keystone et al. (2004a), ETA 
monotherapy at 25 mg twice weekly or 50 mg once weekly rendered ACR20 response rates 
at 8 weeks of 47% and 51%, respectively, compared to 21% for PBO.  
 
 
Table 6. Summary of ACR response rates in RCTs performed with ETA in the treatment of 
RA. ETA was used at standard dosage (25 mg subcutaneously twice weekly, or 50 mg once 





Inclusion criteria / definition 














ETA (mono) vs. PBO 
Moreland et al., 
1999 
SJC ≥ 10, TJC ≥ 12 and at 
least one of the following: 
morning stiffness ≥ 45 
minutes, ESR ≥ 28 mm/h, and 
CRP > 2 mg/dl 
62 vs. 23 
 
41 vs. 8 15 vs. 4 12 weeks  
ETA (mono) vs. MTX 
TEMPO; 
Klareskog et al., 
2004 
SJC ≥ 10, painful joint count 
(PJC) ≥ 12, and at least one 
of the following: morning 
stiffness ≥ 45 minutes, ESR ≥ 
28 mm/h, and CRP ≥ 2 mg/dl 
76 vs. 75 
 
48 vs. 43 24 vs. 19 52 weeks 
Bathon et al., 
2000 
ERA, MTX naïve; SJC ≥ 10, 
TJC or PJC ≥ 12, and at least 
one of the following: morning 
stiffness ≥ 45 minutes, ESR ≥ 
28 mm/h, and CRP ≥ 2 mg/dl; 
RF positive or at least 3 
radiographic bone erosions in 
the hands, wrists or feet.  
72 vs. 65   52 weeks 
ETA+MTX vs. PBO+MTX 
Weinblatt et al., 
1999 
SJC ≥ 6 and TJC ≥ 6 66 vs. 33 42 vs. 0 15 vs. 0 12 weeks 
TEMPO; 
Klareskog et al., 
2004 
See earlier 85 vs. 75 69 vs. 43 43 vs. 19 52 weeks 
COMET; Emery 
et al., 2008 
ERA, MTX naïve; DAS28 ≥ 
3.2, and ESR ≥ 28 mm/h or 
CRP ≥ 2 mg/dl 





ETA monotherapy vs. MTX 
 
ETA 25 mg s.c. twice a week monotherapy was compared with MTX in the treatment of 
active RA in the TEMPO trial (Klareskog et al., 2004). Eligible patients had to have an 
insufficient response, at the discretion of the investigator, to at least one DMARD other 
than MTX. ACR response rates at 52 weeks were similar for ETA monotherapy and MTX 
(Table 6). Remission rates (defined as DAS < 1.6) were also similar in the ETA 
monotherapy and MTX groups (16% and 13%, respectively), as were also the mean HAQ 
improvements (1.7 to 1.0 and 1.7 to 1.1, respectively). However, radiographic outcomes 
were superior in the ETA monotherapy group. In this group, the mean change in the total 
Sharp score was 0.52 (from 21.8 at baseline), compared with 2.80 (from 26.8 at baseline) in 
the MTX group (p<0.05). The mean change in erosion score was 0.21 and 1.68, 
respectively (p<0.01), and the mean change in JSN score was 0.32 and 1.12 (not 
statistically significantly different). The proportion of patients without radiographic 
progression (change in total score ≤ 0.5) was 68% and 57%, respectively (p<0.05).   
 
A study by Bathon et al. (2000) compared ETA (25 mg s.c. twice a week) monotherapy 
with MTX in MTX naïve patients with active early RA of ≤ 3 years duration. ACR 
response rates were significantly higher (p<0.05) in the ETA monotherapy group than in 
the MTX group at most evaluations during the first six months, but were approximately the 
same thereafter (up to 12 months) (Table 6). Also radiographic assessments indicated that 
ETA monotherapy had a more rapid effect. At six months, the mean total Sharp score had 
increased by 0.57 (from a mean of 2.4 at baseline) in the ETA monotherapy group, 
compared with 1.06 (from a mean of 12.9 at baseline) in the MTX group (p=0.001); at 12 
months the corresponding increases were 1.00 and 1.59 (p=0.11). At the end of the study, 
the erosion score had not increased in 72% of the patients receiving ETA monotherapy, 
compared with 60% of those receiving MTX (p<0.01). The mean increase in the modified 
Sharp erosion score was 0.30 and 0.68 (p=0.001) at six months for the two groups, 
respectively; at 12 months the corresponding figures were 0.47 and 1.03, respectively 
(p=0.002). No significant differences between the treatment groups were found for the 
changes in JSN. In this study, the patients with the best clinical improvement (especially in 
CRP) had the least evidence of radiographic progression.  
 
Combination of ETA and MTX 
 
ETA+MTX and PBO+MTX were compared in RA patients with active disease despite 
treatment with MTX (Weinblatt et al., 1999). ACR response rates at 12 weeks were similar 
to those seen in the study by Moreland et al. (1999) (Table 6), with similar responses at 24 
weeks. The median HAQ score improved from 1.5 at baseline to 0.8 at 24 weeks in the 
intervention group, while it did not change significantly in the control group. The efficacy 
of ETA+MTX was superior to that of the PBO+MTX regardless of NSAID or GC usage or 
the MTX dose. Compared to this study, a Taiwanese RCT rendered similar or somewhat 
higher ACR response rates at 12 weeks: in the ETA+MTX group the ACR20, ACR50 and 
ACR70 response rates were 90%, 66% and 24%, respectively, and in the PBO+MTX group 




The TEMPO trial compared ETA+MTX with ETA and MTX as single therapies 
(Klareskog et al., 2004). Efficacy outcomes of the single therapies are reviewed above; 
here, the outcomes of the combination treatment are reviewed. ACR response rates at 52 
weeks were superior in the combination therapy group compared to the single therapies 
(Table 6). The remission rate was 35% (p<0.0001 for the combination therapy vs. single 
therapies), and the mean HAQ score improved from 1.8 to 0.8 (p<0.0001 for the 
combination therapy vs. single therapies). Mean negative radiographic progression scores 
were seen in the combination group, indicating repair of joint damage. The mean change in 
the total Sharp score, the erosion score and the JSN score were -0.54 (p<0.001 for the 
combination therapy vs. single therapies), -0.30 (p<0.0001 for the combination therapy vs. 
MTX), and -0.23 (p<0.001 or less for the combination therapy vs. single therapies). The 
proportion of patients without radiographic progression was 80% (p<0.005 or less for the 
combination therapy vs. single therapies).  
 
In the study by Keystone et al. (2004a), ETA 25 mg twice weekly, ETA 50 mg once 
weekly, or PBO with or without concomitant MTX rendered ACR20 response rates at 8 
weeks (the primary efficacy end point) of 51%, 49% and 17%, respectively. In this study, 
MTX usage did not have a significant impact on the achievement of the response. 
Additionally, sex, race, body weight, age, and individual ACR core set measures at baseline 
did not significantly affect the achievement of the primary efficacy end point.  
 
The COMET trial compared the combination of ETA 50 mg once weekly and MTX to 
PBO+MTX in the treatment of MTX naïve patients with active early RA of ≤ 2 years 
duration (Emery et al., 2008). ACR response rates at 52 weeks of both combination and 
control treatments were similar or somewhat higher compared to those seen in other trials 
performed on patients long-standing disease (Table 6). Remission (defined as DAS28 < 
2.6) was achieved by 50% and 28% of the respective groups (p<0.0001). The HAQ score 
improved from 1.7 to 0.7 in the combination group, and from 1.6 to 0.9 in the MTX group 
(p<0.0001). Radiographic non-progression (change in vdH-S total score ≤ 0.5) was seen in 
80% and 59% of the respective groups (p<0.0001). The change in the radiographic total 
score, from baseline to 52 weeks, was 0.27 and 2.44 in the two groups, respectively; the 
change in the total score seemed to be driven by joint erosion, rather than by JSN. Fewer 




ADA monotherapy vs. PBO 
 
van de Putte et al. (2003) compared ADA (20 mg s.c. once weekly, phase II study) 
monotherapy with PBO in the treatment of patients for whom treatment with at least one 
DMARD had failed. The ACR response rates at 12 weeks are presented in Table 7. HAQ 
improved from 1.8 to 1.3 in the intervention group, but stayed at 1.6 in the control group 
(p≤0.001). Similar results were seen in a phase III study, where ADA was used at a 
standard dosage (40 mg every other week) (van de Putte et al., 2004; Table 7). Concomitant 
GC treatment did not seem to affect the response (ACR20, the primary efficacy end point) 






Table 7. Summary of ACR response rates in RCTs performed with ADA in the treatment 
of RA. ADA was used at standard dosage (40 mg subcutaneously every other week), except 
in van de Putte et al. (2003) where the dosage was 20 mg once weekly. Bolded values 





Inclusion criteria / definition 














ADA (mono) vs. PBO 
van de Putte et 
al., 2003 
SJC ≥ 10 and TJC ≥ 12, and 
either ESR ≥ 28 mm/h or CRP 
≥ 2 mg/dl 
51 vs. 10 
 
24 vs. 1 11 vs. 0 12 weeks 
van de Putte et 
al., 2004 
Same as van de Putte et al., 
2003 
46 vs. 19 22 vs. 8 12 vs. 2 26 weeks 
CHANGE; 
Miyasaka, 2008 
SJC ≥ 10 and TJC ≥ 12, and 
CRP ≥ 2 mg/dl 
43 vs. 13 21 vs. 3 17 vs. 1 12 weeks 
ADA (mono) vs. MTX 
PREMIER; 
Breedveld et al., 
2006 
SJC ≥ 8, TJC ≥ 10, and either 
ESR ≥ 28 mm/h or CRP ≥ 1.5 
mg/dl; RF positive or at least 
one joint erosion. 
54 vs. 63  41 vs. 46 26 vs. 28 52 weeks 
ADA+MTX vs. PBO+MTX 
ARMADA; 
Weinblatt et al., 
2003 
SJC ≥ 6 and TJC ≥ 9 67 vs. 15  55 vs. 8 27 vs. 5 24 weeks 
Keystone et al., 
2004b 
SJC ≥ 6, TJC ≥ 9 and CRP > 
1 mg/dl; RF positive or at least 
one radiographic joint erosion 
in the hands or feet. 
63 vs. 30  
 
39 vs. 10 21 vs. 3 24 weeks 
Chen et al., 2009 SJC > 6 and TJC > 9 for at 
least 3 months 
54 vs. 33  34 vs. 17 14 vs. 0 12 weeks 
PREMIER; 
Breedveld et al., 
2006 
See earlier 73 vs. 63 62 vs. 46 46 vs. 28 52 weeks 
 
 
The Japanese CHANGE trial used a similar study design as that of van de Putte et al. to 
compare ADA monotherapy (20 mg, 40 mg or 80 mg every other week) with PBO 
(Miyasaka, 2008). The ACR response rates at 12 weeks are presented in Table 7. The rates 
were similar at 24 weeks, despite a larger proportion of patients having developed anti-
ADA antibodies (Abs) (44% in the CHANGE trial vs. 12% in the study by van de Putte et 
al., 2004). Anti-ADA Ab concentrations were relatively low in most cases though. The 
ACR20 response rate at 24 weeks (the primary efficacy end point) was lower among the 
anti-ADA Ab positive patients than among the anti-ADA Ab negative patients (28% vs. 
57%). This was in contrast to the study by van de Putte et al. (2004), where the ACR20 
response rate after 26 weeks of ADA monotherapy at standard dosage did not differ 






ADA monotherapy vs. MTX 
 
Breedveld et al. (2006) compared single therapies of ADA (the standard dosage 40 mg s.c. 
every other week) or MTX in the treatment MTX naïve patients with active early RA of < 3 
years duration in the PREMIER study. ACR response rates at one year in patients treated 
with ADA monotherapy were not superior to those seen in the MTX group (Table 7). 
Remission (defined as DAS28 < 2.6) was achieved by 23% and 21% of the respective 
groups. The mean HAQ score improved from 1.6 to 0.8 in the ADA group, and from 1.5 to 
0.7 in the MTX group. The ACR response and remission rates and the HAQ improvements 
were similar after two years. Interestingly, despite the comparable clinical efficacy of ADA 
and MTX monotherapies, there was significantly less radiographic progression in the ADA 
group. In this group, the mean change in the modified total Sharp score was 3.0 at one year 
and 5.5 at two years (from 18.8 at the baseline), compared with 5.7 at one year and 10.4 at 
two years in the MTX group (from 21.9 at the baseline) (p<0.001). In the ADA group, the 
mean change in the erosion score was 1.7 at one year and 3.0 at two years, compared with 
3.7 at one year and 6.4 at two years in the MTX group. The mean changes in the JSN score 
at one and two years were 1.3 and 2.6, respectively, in the ADA group, and 2.0 and 4.0, 
respectively, in the MTX group. A larger proportion of patients in the ADA group had no 
radiographic progression (change in the total score ≤ 0.5), compared with the MTX group 
(at one year, 51% and 37% for the two groups, respectively, and at two years, 45% and 
34%, respectively; p<0.01).  
  
Combination of ADA and MTX 
 
The ARMADA trial compared ADA 40 mg s.c. every other week (standard dosage) and 
concomitant MTX with PBO+MTX in the treatment of patients with active RA despite 
treatment with MTX (Weinblatt et al., 2003). The ACR response rates at 24 weeks are 
presented in Table 7. A Korean study (Kim et al., 2007) rendered ACR response rates of a 
similar range as those seen in the ARMADA trial, although with a comparatively higher 
ACR20 rate in the control group; at 24 weeks, the ACR20, ACR50 and ACR70 response 
rates in the intervention group were 62%, 43% and 22%, respectively, and in the control 
group, 37%, 14% and 8%, respectively. 
  
Also a study by Keystone et al. (2004b) assessed outcomes of ADA at a standard dosage 
with concomitant MTX (dosage similar to that used in the ARMADA trial), and compared 
them with PBO+MTX in patients with active RA despite treatment with MTX. The ACR 
response rates at 24 weeks are presented in Table 7. HAQ improved from 1.5 to 0.9 in the 
intervention group, compared to a change from 1.5 to 1.2 in the control group (p≤0.001). 
The ACR response rates and HAQ improvements were similar at 52 weeks. Compared with 
PBO, treatment with ADA also led to significantly better outcomes in all SF-36 domains, 
except the emotional role domain. Radiographic outcomes were also superior in the 
intervention group. At the 52 week assessment, the mean change in the modified total 
Sharp score was 0.1 and 2.7 for the two groups, respectively (p≤0.001). The mean change 
in erosion score was 0.0 and 1.6, respectively (p≤0.001). No new erosions were seen in 
62% and 46%, respectively (p≤0.01), and improved erosion scores were seen in 38% and 





Chen et al. (2009) compared the efficacy of treatment with ADA+MTX to that of treatment 
with PBO+MTX in Taiwanese patients with an active RA. The ACR response rates at 12 
weeks are presented in Table 7. Despite the trend for higher response rates in the 
combination group, they were not statistically significantly better than the corresponding 
rates in the MTX group, perhaps due to the relatively small number of patients in the 
groups (35 and 12, respectively). However, a statistically significant difference in HAQ 
improvement was found; the HAQ score improved from 1.7 at the baseline to 1.1 at 12 
weeks in the combination arm, compared with a change from 1.8 to 1.6 in the control arm 
(p<0.05). 
 
The PREMIER trial compared ADA+MTX with ADA and MTX as single therapies in the 
treatment of early RA (Breedveld et al., 2006). Efficacy outcomes of the single therapies 
are reviewed above; here, the outcomes of the combination treatment are reviewed. The 
ACR response rates at one year are presented in Table 7; the rates were similar at two 
years. Remission was achieved by 43% and 49% at one and two years, respectively. The 
mean HAQ score improved from 1.5 at the baseline to 0.4 at one year, with a similar 
improvement at two years. The ACR response and remission rates and HAQ improvements 
were better in the combination arm than in the single treatment arms (p<0.05 or less), 
except for the HAQ score of the ADA+MTX combination vs. ADA monotherapy at two 
years (p=0.06). The radiographic outcomes were better in the combination arm than in the 
single treatment arms. At one and two years, the total Sharp score increased by a mean of 
1.3 and 1.9 (from 18.1 at the baseline), the erosion score by a mean of 0.8 and 1.0, 
respectively, and the JSN score by a mean of 0.5 and 0.9, respectively (p<0.005 compared 
with the single therapies). The proportion of ADA+MTX treated patients with no 
radiographic progression was 64% at one year and 61% at two years (p<0.01 compared 
with the single therapies).    
 
Safety based on systematic literature review and meta-analysis of RCTs 
 
The safety assessments in our SLR and meta-analysis were based on the same RCTs that 
were selected for the efficacy assessments, and focused on discontinuations due to AEs and 
occurrences of any AE, serious adverse events (SAEs), any infection, serious infections and 
infusion or injection-site reactions (Aaltonen et al., 2012). These will be the focus in the 
present RCT review as well. The assessments include all dosages studied in the trials. 
However, higher doses of IFX or ADA were not associated with higher rates of AEs or 
discontinuation due to AEs. In contrast, infusion reactions were less likely to occur in 
patients on high doses of IFX, compared to those on standard dosage (RR 0.7, p<0.05). 





IFX+MTX treated patients had a 2-fold risk of treatment discontinuation due to an AE, 
compared to those treated with PBO+MTX (p<0.05) (Aaltonen et al., 2012). The 
occurrences of AEs, SAEs, infections, and serious infections were comparable between the 
two groups. However, the risk of infusion reaction was somewhat increased in the 






Intervention was not associated with a higher discontinuation rate due to AE in any of the 
comparisons, i.e., ETA vs. PBO, ETA vs. MTX, ETA+MTX vs. MTX, and ETA+MTX vs. 
ETA (Aaltonen et al., 2012). In fact, RRs for the interventions were < 1, indicating a lower 
risk of discontinuation due to AE. However, only the pooled analysis (ETA vs. any control) 
showed a statistically significant result, with a RR of 0.7 (p<0.05). The interventions were 
not associated with higher rates of AEs, SAEs, infections, and serious infections (ETA vs. 
PBO was not numerically assessable). However, ETA with or without concomitant MTX 
was associated with a higher risk of injection-site reactions, compared to the control arms 
that did not include ETA (ETA vs. PBO, RR 3.9; ETA vs. MTX, RR 6.9; ETA+MTX vs. 
MTX, RR 4.4; all p<0.05); the RR for ETA+MTX vs. ETA was 0.5 (p<0.05). The pooled 




Treatment with ADA+MTX was associated with a higher discontinuation rate due to AE 
than the treatment with PBO+MTX (RR 1.6, p<0.05) (Aaltonen et al., 2012). The relative 
risks were not statistically significantly higher in the other comparisons, i.e., ADA vs. PBO, 
ADA vs. MTX, and ADA+MTX vs. ADA; the pooled RR was 1.6 (p<0.05). Intervention 
was not associated with higher rates of AEs overall. Moreover, intervention was not 
associated with higher rates of SAEs or infections in the two numerically assessable 
comparisons, i.e., ADA vs. PBO and ADA+MTX vs. MTX. Although the relative risks for 
serious infections seemed higher for most of the interventions, they were not statistically 
significantly different from the control treatments (ADA vs. PBO, RR 4.2; ADA+MTX vs. 
MTX RR 2.4; ADA+MTX vs. ADA, RR 3.1); the RR for ADA vs. MTX was 0.4. ADA 
was associated with a higher rate of injection-site reactions compared to PBO (RR 7.7, 
p<0.05). However, ADA+MTX was not associated with a higher risk compared with 
PBO+MTX. The pooled estimate was 3.1 (not statistically significant). 
 
Comparison to other RCT-based systematic literature reviews and meta-analyses of 
safety 
 
To confirm the results of the RCT-based SLR and meta-analysis of safety data performed 
by Aaltonen et al., (2012), comparisons were made to earlier published data on the same 
topic where similar methodology was used (Table 8).   
 
 
Table 8. Comparison of RCT-based SLR and meta-analysis of safety. Where not otherwise 
specified, the TNFi agents were used at standard dosages. Risk ratios and odds ratios refer 
to intervention vs. control, unless otherwise stated.   
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Reference  Bongartz et al., 2006 Alonso-Ruiz et al., 
2008 
 
Leombruno et al., 
2009 
Result compared to 
Aaltonen et al., 2012 
Trial durations 



















due to AE 
n.a. IFX, RR 2.0; p<0.05 
ADA, RR 1.4; p<0.05 
ETA, RR 0.7; p<0.05 
Pooled, p=ns 
n.a. Similar  
AE rate n.a. IFX, p=ns 
ADA, p=ns 
ETA, p=ns 
Pooled, RR 1.02; 
p<0.05 
n.a. Similar 








IFX was not associated 
with a higher SAE rate 




n.a. IFX was not associated 
with a higher infection 
rate 
Serious infection Low-dose IFX or 
ADA2, OR 1.8; 
p<0.05 
High-dose IFX or 
ADA3, OR 2.3; 
p<0.05   











High-dose IFX or 
ADA5, RR 1.8; p<0.05 
 
Differences between 
intervention and control 
were not statistically 
significant. 
High dose IFX vs. 
standard dose, RR 1.5, 
p=ns  
Infusion reaction n.a. IFX, RR 2.7; p<0.05 n.a. Similar 
Injection-site 
reaction 
n.a. ADA, RR 1.7; p<0.05 
ETA, RR 5.1; p<0.05 
n.a. Similar. However, the 
pooled estimate for ADA 
(RR 3.1) was not 
statistically significant. 
Malignancy4 Low-dose IFX or 
ADA2, OR 1.4; p=ns 
High-dose IFX or 
ADA3, OR 4.3; 
p<0.05   






















n.a., not assessed in the study; ns, not significant. 
1) IFX dose up to 10 mg/kg every 4 weeks; assessments of high-dose ADA and ETA were not possible to perform. 
2) Low dose defined as IFX ≤ 3 mg/kg every 4 weeks or ADA 20 mg weekly 
3) High dose defined as IFX ≥ 6 mg/kg every 8 weeks or ADA 40 mg every other week 
4) Malignancies assessed in Leombruno et al. (2009) were lymphomas, non-melanoma skin cancers, and the 
composite endpoint of non-cutaneous cancer or melanoma 
5) IFX doses were up to 10 mg/kg every 4 weeks and ADA doses up to 80 mg weekly; on average, high doses were 





The results regarding treatment discontinuations due to AE, AE rates, and infusion or 
injection-site reactions were largely similar when comparing earlier studies with that of 
Aaltonen et al., (2012). The main discrepancies among the studies relate to the occurrence 
of SAEs and infections in IFX treated patients, and the occurrence of serious infections in 
anti-TNF mAb treated patients. In the study by Leombruno et al. (2009), the risk of serious 
infection (all dosages of all three TNFi agents analyzed) decreased significantly with an 
increasing trial duration (p<0.05). Other dose- or time-dependencies were not found in their 
study (i.e., when assessing risk of death, SAEs and malignancies).  
 
Safety based on observational studies, with focus on infections and cancer 
 
Observational data indicates that mortality due to cardiovascular disease (CVD), infection 
or cancer is lower in TNFi treated patients, compared with RA patients not treated with 
these agents (Dixon et al., 2006; Carmona et al., 2007; Galloway et al., 2011). One study 
found an association between TNFi therapy and a reduced mortality in women, but not in 
men, with RA (Jacobsson et al., 2007).  
 
Observational data regarding the risk of infections in TNFi treated RA patients (vs. 
cDMARD treated patients) have yielded mixed results. Dixon et al. (2006) did not find 
evidence of an increased overall risk of serious infections, after adjustment for the baseline 
risk (age, sex, disease severity, comorbidity, extra-articular manifestations, GC use, and 
smoking). However, the rate of serious skin and soft tissue infections was increased in the 
TNFi treated patients (ca 4-fold). In addition, serious intracellular bacterial infections 
occurred exclusively in the TNFi treated cohort (19 of 7,664 vs. 0 of 1,354). Galloway et al. 
(2011) observed a small but significant overall risk of serious infection in TNFi treated 
patients (hazard ratio (HR) 1.2, adjusted for age, sex, disease activity, disease duration, 
smoking, GC use, and comorbidities). Notably, the risk of infections was highest during the 
first six months of therapy (HR 1.8). Wolfe et al. (2006) observed a dose-related 
association between GC use and hospitalization due to pneumonia, but no increased risk 
due to TNFi therapy. In a study by Listing et al. (2005), the RR for infections overall was 
4.1 for IFX and 3.3 for ETA; the RR of serious infection was 2.7 and 2.8, respectively. RRs 
adjusted for age, number of DMARD failures, DAS28, CRP level, RF positivity, and 
disability were 3.0 and 2.3, respectively, for infections overall, and 2.1 and 2.2, 
respectively, for serious infections. The adjusted RRs for serious infections were not 
statistically significant. Among the infections found more frequently in TNFi treated 
patients were serious and non-serious respiratory tract infections, bacterial skin and 
subcutaneous tissue infections, and bone and joint infections. In a series of 60 consecutive 
IFX or ETA treated patients, prospectively followed up for up to 33 months at a Swiss 
university hospital department of rheumatology, 11 contracted a serious infection (Kroesen 
et al., 2003). The incidence of serious infections was 0.181 per year of TNFi treatment, vs. 
0.008 in the two preceding years.  
 
The risk of solid cancer does not appear to be increased among TNFi treated RA patients 
during the first five years of therapy (Askling et al., 2005; Setoguchi et al., 2006; Furst et 
al., 2012). Results concerning risk of hematologic (lymphoproliferative) malignancies 
remain inconclusive (Setoguchi et al., 2006). Some studies have found an increased risk 
among RA patients treated with TNFi agents, with an up to 5-fold hazard rate for 
lymphoma (Wolfe and Michaud, 2004; Geborek et al., 2005; Setoguchi et al., 2006). 




Scientific evidence gives reason to consider infections and malignancies as possible adverse 
effects of TNFi therapy. The effects of TNF and, by extension, TNFi therapy, on cancer are 
complex (Balkwill, 2006). Paradoxically, TNF seems to have tumor suppressing and tumor 
promoting effects, depending on the context; many of them are yet to be further elucidated 
(Balkwill, 2002). TNF may act to suppress tumors by acting as an important effector 
molecule in CD8+ T-cell and natural killer (NK)-cell mediated killing of immunogenic 
tumor cells. In addition, high doses of therapeutically administered TNF can induce 
apoptosis and necrosis of tumor cells and destroy tumor vasculature. However, chronic 
production of TNF in the tumor microenvironment may enhance tumor development and 
spread via mechanisms often shared with inflammatory processes. For example, TNF can 
contribute to tissue remodeling and stromal development necessary for tumor growth and 
spread; induce other effector molecules, such as chemokines, cytokines, angiogenic factors, 
MMPs, and adhesion molecules; contribute to DNA damage via oxidative stress; and 
enhance the growth and survival of tumor cells.  
 
TNF is involved in the host defense against infectious agents in that it induces chemokines, 
cytokines, and endothelial adhesion molecules and leads to proliferation, activation, and 
directed migration of leukocytes (Ehlers, 2003; Furst et al., 2006). In addition, TNF is vital 
to the formation and maintenance of granulomas, i.e., cell collections consisting of 
macrophages, T cells and various other host cells (Ehlers, 2003; Tufariello et al., 2003; 
Furst et al., 2006). Granulomas are formed when acute inflammatory processes are unable 
to destroy an invading agent, such as Mycobacterium tuberculosis, which then resides 
within the macrophages. The granuloma functions as an immune microenvironment to 
facilitate interactions between the cells contained therein, a continuous and dynamic 
process. The granuloma essentially contains the infectious agent in a latent form, confining 
it to the granulomas.  
 
Neutralization of TNF can interfere with these host defense mechanisms and increase the 
susceptibility to infections. Furthermore, TNFi therapy may inhibit phagosome maturation 
in macrophages and increase regulatory T cell (Treg) function, which may increase the 
susceptibility to tuberculosis (TB) (Harris et al., 2008; Harris and Keane, 2010). Early on 
(during phase III RCTs and early post-marketing surveillance), it became apparent that 
TNFi therapy indeed increases the risk of TB and other granulomatous infections (Wallis et 
al., 2004). This has mandated TB screening and treatment of individuals at risk of 
developing TB due to, e.g., a latent infection or with an active infection, prior to starting 
TNFi therapy (Tufariello et al., 2003; Singh et al., 2012).  
 
Although these precautionary measures have significantly decreased the risk, a continuous 
vigilance is needed as the risk is not completely eliminated (e.g., due to anergy and false-
negative skin test result), as activation of latent TB may be difficult to identify in patients 
treated with systemic GCs and TNFi, as the presentation of TB associated with TNFi 
therapy is frequently atypical (extrapulmonary or disseminated TB), and as screening tests 
are not routinely available for other latent granulomatous infections (Tufariello et al., 2003; 
Furst et al., 2006; Gómez-Reino et al., 2007). Interestingly, the incidence of TB and other 
granulomatous infections appears to be higher in IFX than ETA treated patients (Wallis et 
al., 2004; Furst et al., 2006). This may be due to differences between the TNF binding 
avidity of the agents, their pharmacokinetics (e.g., half-life, peak concentration), antibody-
mediated cell lysis (which, e.g., can lead to monocytopenia), their ability to induce 
apoptosis of monocytes and T cells, or to inhibit IFN-γ production. Ehlers (2003) points out 
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that a complete neutralization of TNF must be avoided; TNFi therapy of RA should inhibit 
TNF activity significantly to reduce the disease activity, but still only partially to allow 
sufficient TNF activity to resist infections.  
 
Other clinical effects and special considerations 
Autoimmunity and immunogenicity 
 
In RCTs, the proportion of patients who have newly become positive for anti-nuclear Abs 
(ANA) has ranged from 11% to 12% in ADA treated patients, and up to 40% in IFX treated 
patients; the percentages in the control groups have ranged from 6% to 11% (Weinblatt et 
al., 2003; Keystone et al., 2004b; St. Clair et al., 2004; van de Putte et al., 2004). 
Antibodies (Abs) to double-stranded DNA (dsDNA) have been reported usually in <10% of 
IFX, ADA or ETA treated patients; in one study on IFX, the percentage was 24% (Maini et 
al., 1999; Moreland et al., 1999; Weinblatt et al., 1999; Weinblatt et al., 2003; Keystone et 
al., 2004b; St. Clair et al., 2004). The percentages in the control groups have ranged from 
0% to 3%. However, lupus-like reactions or other connective tissue disorders developed 
infrequently during the TNFi trials.     
 
The reported frequencies of anti-drug Abs (ADAbs) against the anti-TNF mAbs (IFX and 
ADA) vary between the studies where this has been assessed. Up to nearly half of IFX 
treated patients may develop such Abs during the first year of therapy (Haraoui et al., 2004; 
Abe et al., 2006; Wolbink et al., 2006). Development of anti-ADA Abs has been reported 
in 12% during six months in one study, and 44% in another (van de Putte et al., 2004; 
Miyasaka et al., 2008). ADAbs may be associated with lower response rates and somewhat 
higher frequencies of infusion reactions or injection-site reactions. No other clinically 
important differences between AEs were apparent in the RCTs. Anti-ETA Abs develop in 





So far, clinical trials of TNFi agents (and other bDMARDs) have not principally focused on 
nonarticular manifestations of RA. However, the role of TNF and the effects of TNFi 
therapy on CVDs has been a matter of considerable interest owing to the predisposition of 
RA patients to morbidity and premature or accelerated mortality due to CVD, and 
recognition of the involvement of inflammatory processes and TNF in atherosclerosis and 
heart failure (Mikuls, 2003; Anker and von Haehling, 2004; Sihvonen et al., 2004; Sarzi-
Puttini et al., 2005; Dixon and Symmons, 2007; Popa et al., 2007). TNF is an important 
contributor to the development of atherosclerotic lesions in that it induces proatherogenic 
changes in lipid metabolism and upregulates adhesion molecules, leading to the migration 
of monocytes into the vessel wall intima where they can become foam cells and form fatty 
streaks (Sarzi-Puttini et al., 2005; Dixon and Symmons, 2007; Popa et al., 2007). TNF may 
also increase collagen breakdown in the fibrous cap (via MMPs), which may lead to a 
plaque rupture. In addition, TNF has prothrombotic effects. Although TNFi therapy has 
been associated with an increase in high-density lipoprotein (HDL)-cholesterol in the short-
term (weeks), this was not consistently accompanied by a favorable effect on the 
atherogenic index (Vis et al., 2005; Popa et al., 2007). It is currently unclear whether the 
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effects on the lipid profile persist and reduce atherogenesis in the long-term. RCTs of IFX 
and ETA in moderate to severe congestive heart failure (CHF) revealed that TNFi therapy 
did not improve the outcomes (clinical status, hospitalization, death), or was even 
detrimental (Chung et al., 2003; Mann et al., 2004). 
 
Other special considerations 
 
Due to possible infectious complications, TNFi and other biological agents are not 
recommended during the perioperative period of joint replacement and other (major) 
elective surgery (Saag et al., 2008). It is, as yet, unclear whether TNFi treated RA patients 
are at increased risk of surgical site infections (da Cunha et al., 2012). Live vaccines are 
contraindicated during biological therapy (Saag et al., 2008; Repo and Peltomaa, 2012). In 
cases where such vaccines are needed, the biological agent should be suspended during the 
peri-vaccination period.  
 
The approved TNFi agents are classified by the U.S. Food and Drug Administration (FDA) 
to the pregnancy risk category B, which means that 1) animal reproduction studies have 
failed to demonstrate a risk to the fetus, but there are no adequate and well-controlled 
studies of pregnant women; or 2) animal studies demonstrate a risk, and adequate and well-
controlled studies in pregnant women have not been done during the first trimester (Law et 
al., 2010). A recent SLR suggests that the overall risk of TNFi agents is relatively low; 
however, the data is insufficient to draw any firm conclusions (Bogas et al., 2011). 
According to the current guidelines of the Finnish Society for Rheumatology, biological 
agents should be discontinued before planned pregnancy and are not recommended during 




5 INTRODUCTION AND BACKGROUND OF THE STUDY 
 
The advent of biological drugs has significantly, even dramatically, improved the prognosis 
of rheumatoid arthritis (RA) in a substantial proportion of patients with moderate to severe 
active disease refractory to treatment with conventional disease modifying antirheumatic 
drugs (cDMARDs). Tumor necrosis factor inhibitors (TNFi) agents were the first 
biologicals to emerge at the turn of the century, and they are still the most widely used 
among this group of drugs. During the first decade of clinical use, almost 2 million patients 
with various immune-mediated inflammatory disorders were treated with these agents 
worldwide (Kerbleski and Gottlieb, 2009). Jönsson et al. (2008) estimated, based on data 
from 2006, that ca 9% of Finnish RA patients (ca 3200 patients) use TNFi agents; this 
point-estimate seems to have stayed nearly the same, around 10%, in more recent years. A 























Table 9. Timeline and statistics relating to the use of anti-TNF agents in Finland, with 
focus on the years 2001, 2004, 2007 and 2010. 
Year Marketing authorizations1 
(MA), launches and 
reimbursability 




No. of recipients of 
reimbursement3,4 
1999 IFX MA 13.8.1999     
2000 ETA MA 3.2.2000  
Initial problems with production 
capacity   
   
2001 
 
 IFX: RA, CD 




2002 ETA reimbursable 1.12.2002    
2003 Re-launch of ETA5  
ADA MA 8.9.2003 
   
2004 
 
ADA reimbursable 1.3.2004 IFX: RA, CD, AS 









 IFX: RA, CD, AS, UC, PsA, 
plaque psoriasis 
ETA: RA, JIA, PsA, AS, plaque 
psoriasis 





2009 CER and GOL MA 1.10.2009    
2010 
 
CER reimbursable 1.5.2010 
GOL reimbursable 1.10.2010 
IFX: RA, CD, AS, UC, PsA, 
plaque psoriasis, PCD 
ETA: RA, JIA, PsA, AS, plaque 
psoriasis, plaque psoriasis in 
children 
ADA: RA, PsA, AS, JIA, plaque 
psoriasis, CD 
CER: RA 








Abbreviations: ADA=adalimumab (Humira); AS=ankylosing spondylitis; CD=Crohn’s disease; CER=certolizumab pegol 
(Cimzia); DDD=defined daily dose; ETA=etanercept (Enbrel); GOL=golimumab (Simponi); IFX=infliximab (Remicade); 
JIA=juvenile idiopathic arthritis; MA=marketing authorization; NA=not applicable/available; No.=number; PCD=pediatric 
Crohn’s disease; PsA=psoriatic arthritis; RA=rheumatoid arthritis; UC=ulcerative colitis.  
1) Data from the Fimea web database; 2) Data from Pharmaca Fennica (printed version); 3) Data from the Finnish Statistics 
on Medicines; 4) Based on reimbursement code 313 of the Social Insurance Institution of Finland (SII). The code pertains 
to medicinal products eligible for restricted basic refund, and is defined as: “etanercept, infliximab and other significant and 
expensive drugs used in the treatment of rheumatoid diseases” (2004); “adalimumab, anakinra and etanercept (rheumatoid 
diseases)” (2007); “adalimumab, anakinra, etanercept, golimumab (from 1.10.2010) and certolizumab pegol (from 1.5.2010) 
(rheumatoid diseases)” (2010). 5) Jönsson et al., 2008. 
 
 
The efficacy and safety of the biological drugs in RA and other rheumatological indications 
for which they are approved have been evaluated in randomized controlled trials (RCTs) 
usually of 3 to 12 months duration with strict inclusion and exclusion criteria to define the 
study population. In order to acquire information on the safety and effectiveness in “real-
life” clinical settings, international recommendations have encouraged data collection into 
national long-term registers (Furst et al., 2002; Braun et al., 2003; Braun et al., 2006; Furst 
et al., 2007; Furst et al., 2010). In 1999, with the first biological drug being launched in 
Finland, the Finnish Society for Rheumatology set up a national register of biological 




National Current Care guidelines for RA were first published in 1999; recommendations for 
the use of biological drugs (TNFi and anakinra) were included in the 2003 update. These 
stated that biological therapy is warranted if the patient suffers from severe and 
continuously active disease (swollen joint count (SJC) ≥ 6, tender joint count (TJC) ≥ 6, 
morning stiffness ≥ 45 min and/or erythrocyte sedimentation rate (ESR) ≥30 mm/h and/or 
C-reactive protein (CRP) ≥2.8 mg/dl) despite combination therapy with cDMARDs 
(including methotrexate (MTX) ≥ 15 mg/week) and low-dose oral glucocorticoid (GC) 
(e.g., FIN-RACo combination; Möttönen et al., 1999). Treatment response according to 
ACR50 criteria was recommended to be assessed three months after the commencement of 
the biological drug. The newest update of the guidelines (2009) does not include such 
specific recommendations, but clearly emphasizes the importance of early, effective 
treatment with the aim of reaching clinical remission within the first year. Patients who 
continue to have active disease despite treatment with MTX and combination therapy with 
cDMARDs are eligible for biological drug therapy, primarily with a TNFi agent.    
 
The use of TNFi and other biological drugs has led to significant increases in the direct 
costs of treatment of RA and other inflammatory arthritides. According to the Finnish 
Statistics on Medicines (FSM), the average cost per patient receiving reimbursement based 
on reimbursement code 313 of the Social Insurance Institution of Finland (SII) (see Table 
9) in the years 2004, 2007, and 2010 were 12 803 €, 13 075 €, and 12 327 €, respectively, 
the total costs being 19 231 000 €, 44 074 000 €, and 61 365 000 €, respectively; the cost of 
infliximab (IFX) is not included in these figures. For a person weighing 70 kg and receiving 
IFX 3 mg/kg (i.e., 210 mg) every eight weeks, the annual drug cost would be 8 652 € 
(according to calculations based on the wholesale price; Finnish Statistics on Medicines, 
2010), except for the first year when the cost would be 10 649 € due to the loading dose. In 
addition, there is the cost of intravenous (i.v.) infusion, which in 2007 was estimated to be 
212 € per administration (Virkki et al., 2008). In comparison, the annual cost of low-dose 
(≤ 25 mg/week) MTX or hydroxychloroquine (HCQ) 300 mg daily is < 100 €, while that 
of, e.g., sulfasalazine (SSZ) 2 g daily is < 300 €, and that of leflunomide (LEF) 20 mg daily 
is < 1000 € (retail prices according to Pharmaca Fennica 2011). Rheumatology has become 
one of the most costly specialties in Finland with regard to pharmacological therapy. 
Already in 2005 rheumatologists prescribed drugs for an average of 220 000 € per 
prescriber, while the corresponding figure for all physicians was 75 000 € (Timo Klaukka, 
personal communication). In fact, TNFi agents bring about one of the highest medicinal 
expenditures in many (Western) coutries; in Finland for example, the top three medicinal 
expenditures in 2011 were due to ADA, IFX and ETA (Jönsson et al., 2008; Bendtzen, 
2012; Kurki and Heinonen, 2012). However, TNFi and other biological drugs have a 
potential to prevent negative long-term outcomes, such as disability and work incapacity 
(Sokka, 2009), whereby their direct costs may be offset by savings in indirect costs.      
 
While the efficacy of the TNFi agents seems comparable on a patient-population level, it is 
currently not possible to predict the extent to which an individual patient will respond to 
TNFi treatment or specific agents (Buch et al., 2004; Klaasen et al., 2009). The TNFi 
agents are structurally different, and although they share the same target molecule, they 
seem to have different actions clinically, e.g., having a differential effect in certain other 
inflammatory conditions (e.g., Crohn’s disease) and somewhat differing safety profiles 
(Tracey et al., 2008). Some studies have indicated differences in their TNF binding 
characteristics; ability to bind lymphotoxin-α; and ability to induce complement-dependent 
cytotoxicity (Scallon et al., 2002; Mpofu et al., 2005; Mitoma et al., 2008; Kaymakcalan et 
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al., 2009). Other factors which may lead to variability in clinical responses include genetic 
differences in the treated patients; antibody-mediated clearance of the TNFi agents; and 
different pharmacokinetic profiles (Lutt and Deodhar, 2008). In view of the differing 
characteristics, switching a TNFi agent to another may be efficacious in case of treatment 
failure with the initial one. On the other hand, several biological drugs not targeting TNF 
are now available. The updated consensus statement on biological agents for the treatment 
of rheumatic diseases states that the optimal treatment of TNFi refractory RA remains to be 




6 AIMS OF THE STUDY 
 
 To assess the medium- to long-term (2 to 5 years) effectiveness of TNFi therapy in 
RA (Study I) 
 To assess the safety and tolerability of TNFi and anti-IL-1 therapy in the medium- to 
long-term (up to 5 years) in a routine-care setting (Study II) 
 To assess the cost-effectiveness of IFX therapy in RA and factors affecting it (Study 
III) 
 To assess the extent to which RA patients benefit from switching a first TNFi agent to 




7 PATIENTS AND METHODS 
 
7.1 The Finnish register of biological treatment, ROB-FIN 
 
Patient data for the studies was obtained from the Finnish register of biological treatment 
(ROB-FIN). The ROB-FIN register was established by the Finnish Society for 
Rheumatology, with the aim of nationwide longitudinal follow-up of outcomes in adult 
patients with rheumatologic diseases treated with biological agents. The national guidelines 
for patient selection for biological treatment are presented in the Introduction and 
background of the study – section. ROB-FIN register data collection started in 1999 and is 
ongoing. The register is maintained with the approval from the Internal Medicine Ethics 
Committee of the Hospital District of Helsinki and Uusimaa, and the Office of the Data 
Protection Ombudsman (Tietosuojavaltuutetun toimisto). For patient enrollment into the 
register, informed consent is required. The refusal rate is estimated to be <5% of the 
patients (Heikki Valleala, personal communication). 
 
Reporting to the register is voluntary and not restricted to specific medical specialties or 
care centers. The register data are provided on a prospective, regular basis using structured 
forms available via the web site of the Society. Reporting occurs at baseline before starting 
biological therapy, and at pre-specified intervals during therapy (at 3 and 6 months, and 
semiannually thereafter, coinciding with routine rheumatologic care) and on 
discontinuation of therapy. The centralized database input is funded by the pharmaceutical 
companies with biological drugs on the market in Finland (in alphabetical order, Abbott, 
Biovitrum, Bristol-Myers Squibb, Janssen, MSD, Pfizer, Roche, Schering-Plough, UCB, 
Wyeth). The research for the studies included in this thesis have been funded by 
unrestricted grants from foundations and pharmaceutical companies, and salary from the 
Ministry of Education and Culture via the National Doctoral Programme of 
Musculoskeletal Disorders and Biomaterials (TBDP) and the Ministry of Social Affairs and 
Health via the special state subsidy (EVO) for health science research (see 
Acknowledgements). 
 
The data collected includes: 
 patient demographics and background information (e.g., date of birth, sex, 
diagnosis, year of diagnosis, weight, height, and the presence/absence of RF, anti-
cyclic citrullinated peptide (anti-CCP) positivity, HLA-B27 positivity, radiographic 
erosions, and sacroiliitis)  
 the medications prescribed to the patient for the treatment of the rheumatologic 
disease (biological agent, NSAID, analgesic, GC, cDMARD), and the reason for 
eventual changes in the biological treatment 
 the parameters needed for assessment of disease activity and response to treatment 
according to internationally adopted criteria (e.g., the ACR core set measures, 
DAS28 and EULAR response criteria)  
 work capacity and resource utilization (patient-reported; added to the register in 
2007)  
 adverse events occurring during the treatment (description of the event, assessments 




The general inclusion criteria and numbers of patients of studies I to IV are presented in 
Table 10. Further details are given in the Results and discussion – section.  
 
 
Table 10. Inclusion criteria and numbers of patients of studies I to IV. 








Reference Nordström et al., 
2006 
Konttinen et al., 2006 Virkki et al., 2008 Virkki et al., 2011 
Rheumatologic 
diagnosis 
RA Any RA RA 
First TNFi agent IFX Any* IFX Any 
Baseline report 
required 
Yes No Yes No 
Follow-up report 
required 
No Yes (AE) Yes Yes 
Additional 
requirements 
None None Baseline HAQ and 
patient’s global 
assessment 
Switch to a second 
TNFi agent; data on 
both treatments 
No. of patients 
registered in ROB-FIN 











No. of patients fulfilling 
the inclusion criteria of 
the study 
364 248 297 479 
Updated analyses Yes (Study V),  
February 2012 









Data were analyzed with SPSS statistical software (versions 12 to 15; SPSS, Chicago, IL). 
The significance level was set at p<0.05 in all statistical testing. Two-tailed levels of 
significance were used throughout. Analyses were per protocol. Variable descriptives were 
checked for possible extreme values or errors in data input. Baseline demographics and 
disease characteristics were assessed using frequency calculations and descriptive statistics. 
Distributions of continuous variables were analyzed graphically and using statistical tests of 
normality (Kolmogorov-Smirnov or Shapiro-Wilk, as appropriate). Most of the continuous 
variables had skewed distributions and required nonparametric tests. In the case of ≥3 
groups being compared, an overall test was performed prior to pairwise testing, which 
required a statistically significant overall result. Study I (effectiveness) contained many 
pairwise comparisons, and corrections for the multiple testing were made using the 
Bonferroni method. The following statistical methods were used, as appropriate:  
 For group comparisons of categorical data: Chi-square, Cochran’s Q, or McNemar’s 
tests 




 For independent samples with a continuous scale were compared using Kruskal–
Wallis or Mann–Whitney tests, as appropriate. 
In addition, odds ratios were obtained from logistic regression, and survival analysis was 
performed using Kaplan–Meier plots and log-rank tests.   
 
7.3 Additional methods and assessments 
 
7.3.1 Study I 
 
Response assessment considered changes in ACR core set measures and ACR response 
rates during IFX therapy. ACR response rate assessments focused on the ACR50 response 
after three months of IFX therapy, according to the 2003 National Current Care guidelines 
for RA (presented in the Introduction and background of the study – section), and on the 
ACR20 response after six months, which was compared to the primary endpoint of the 
ATTRACT study, i.e., the ACR20 response rate after 30 weeks of IFX with concomitant 
MTX (Maini et al., 1999; the study is presented in the Review of the literature – section). 
Effectiveness of combination therapies of IFX and cDMARDs was assessed based on 
presence or absence of MTX, and presence or absence of other cDMARDs in addition to 
MTX. Medication assessments also considered changes in the use, and dose, of oral GC. 
Discontinuation rates of IFX were evaluated, and updated analyses also evaluated time-to-
event by means of survival analyses of IFX and biological DMARD (bDMARD) treatment. 
Survival analyses were performed according to a scenario in which patients lost to follow-
up were assumed to have continued therapy, and another in which they were assumed to 
have discontinued therapy. AEs occurring during IFX treatment were also assessed.  
 
7.3.2 Study II 
 
For the AE analyses, the reported AEs were classified into groups of similar events. The 
basis for the classification was the grouping used in the AE report form2. If several signs 
and symptoms of an AE were reported, only the overruling main event was used for the 
statistical analyses. The classification of the AE seriousness was done at the discretion of 
the physician reporting the event. The predefined classes correspond to those used in 
reporting AEs to the Finnish Medicines Agency (Fimea), and are specified as mild, 
moderate, serious, life-threatening, fatal; anomaly; disablement; malignancy; and prolonged 
hospitalization. Serious AEs (SAEs) include those that require hospitalization or 
intervention to prevent life-threatening illness or injury or permanent impairment, but can 
also comprise other important medical events (web sites of the European Medicines 
Agency3 and FDA4). Therefore, in the present study, all cases of tuberculosis (TB), 
septicaemia and AEs leading to hospitalization were classified as serious irrespective of the 
classification in the report (missing or not classified as a SAE); such AEs included cerebral 
infarction, cerebral hemorrhage, pulmonary embolism, myocardial infarction, heart failure 





4http://www.fda.gov/safety/medwatch/howtoreport/ucm053087.htm, accessed 30.12.2013 
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(in a patient who required an artificial pacemaker), and hemiplegia. In the present study, 
cancers are classified separately from these SAEs. Incidence rates of cancers among the 
ROB-FIN cohort were compared with those of the Finnish general population (men and 
women over the age of 15 years) using data from the Finnish Cancer Registry and by 
calculating standardized incidence ratios (SIR).   
 
7.3.3 Study III 
 
Functional disability has been found to be the strongest predictor of cost in RA 
(Kavanaugh, 2005). Treatments that improve functional status therefore have the potential 
to lower the costs of the disease. Moreover, improvement in functional status correlates 
with improvement in quality of life, which is also affected by the level of disease activity 
(Kavanaugh, 2005; Kobelt et al., 2005). Health-related quality of life can be quantified 
using health state classification instruments, which have been presented in the literature 
review section. These yield values of utility, usually ranging from 0 to 1, which correspond 
to the weight associated with a particular health state. These weights can be used to 
calculate quality-adjusted life years (QALYs); this is done by multiplying the utility score 
associated with a particular health state by the duration of time spent in that health state. In 
the present study, a cost-utility analysis (CUA) was performed in which utility scores were 
appointed according to Kobelt et al. (2005). The scores were derived from the EQ-5D 
health state classification instrument and related to HAQ score and patient’s global 
assessment of disease activity using multiple regression. They are based on a survey of 616 
RA patients, carried out in 2002 by the department of rheumatology at Malmö University 
Hospital in Sweden. In the present study, QALYs were calculated based on these utilities 
(Table 11), using patient-level data up to the last visit registered in ROB-FIN. 
 
 
Table 11. Utilities by functional state and disease activity, ascribed by Kobelt et al. (2005). 
HAQ score Utility when global VAS <40 
mm 
Utility when global VAS ≥40 
mm 
<0.6 0.780 0.709 
0.6 to <1.1 0.704 0.568 
1.1 to <1.6 0.676 0.441 
1.6 to <2.1 0.562 0.446 
≥2.1 0.408 0.213 
 
VAS=visual analogue scale 
 
 
The following assumptions were made prior to calculation of changes in QALYs resulting 
from IFX therapy: IFX therapy was added to an ongoing cDMARD therapy, which had 
been optimized for the individual patient, but which had not led to a satisfactory response; 
the effect onset of IFX was assumed to occur two weeks after the commencement (Maini et 
al., 1999); and, had the patient not started IFX, he/she would have continued cDMARD 
therapy with the patient’s global assessment remaining at the baseline level and the HAQ 
score progressing 0.031 units/year (Scott et al., 2000). The costs considered were direct 
medical costs as follows: cost of IFX 622.22 €/100 mg, and cost of i.v. infusion 211.73 
€/administration (used in the correspondence with national drug pricing and reimbursement 
authorities; Schering-Plough, personal communication, 2007). Patient-level costs were 
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calculated based on dose and dosage frequency, and they were related to the change in 
QALYs resulting from IFX therapy. Discounting was not performed. A cost of ≤40,000 € 
per QALY gained was considered cost effective (Rawlins and Culyer, 2004; Maetzel, 
2005). Patient characteristics, baseline disease status, IFX dose, use of concomitant MTX, 
and the magnitude of response, in terms of HAQ, global VAS, DAS28 and ACR50, were 
compared among the subgroups with a cost per QALY gained of ≤40,000 € or >40,000 €, 
or with no QALY benefit.     
 
7.3.4 Study IV 
 
Reasons for switching were classified as follows: (1) lack of effectiveness (LOE), (2) AE, 
and (3) other reasons (known or unknown reasons, which may include nonmedical ones 
such as reimbursement or patient preference). In practice, switching due to LOE occurs at 
the discretion of the attending rheumatologist, i.e., taking into account the effect of the drug 
and the needs of the patient. According to the 2003 National Current Care guidelines for 
RA, ACR50 response at three months of TNFi therapy warrants treatment continuation. 
Therefore, switching due to LOE was assumed in the following cases: (1) if LOE was 
reported by the attending rheumatologist as the reason for the switch, or (2) if the reason for 
switching was not reported, but ACR50 response was not achieved (primary LOE) or had 
been lost (secondary LOE). The effectiveness of switching was assessed based on SJC, 
CRP, DAS28, and ACR50 response. The studied time points were, for the first TNFi agent, 
the baseline and 3 months, best and last observations during treatment; and for the second 
TNFi agent, the 3 months, best and last observations. Survival analysis was performed on 
the treatment duration of the second TNFi agent, with the end points being discontinuation 
due to LOE or AE. 
 
7.3.5 Cancer incidence assessments 
 
Data concerning cancers diagnosed in ROB-FIN registered RA patients was obtained from 
the Finnish Cancer Registry (FCR), with permission from the National Institute for Health 
and Welfare. The FCR was founded in 1952, and has since maintained a nationwide 
database covering > 99% of all cancers diagnosed in Finland (Teppo et al., 1994; Pukkala 
et al., 2011). In the present study, standardized incidence ratios (SIR) were calculated in 
order to compare cancer incidences from 2002 through 2008 in RA patients during or 
within one year after anti-TNF therapy, with those in the Finnish adult population (age ≥ 15 
years). The RA patients were followed up from 1.1.2002 or from a later baseline visit. The 
follow-up ended at the date of cancer diagnosis or, in patients not diagnosed with cancer, 
one year after the last registered visit or 31.12.2008 (whichever occurred first); eventual 
deaths occurring during the extension period were not accounted for. SIR calculations were 
performed for cancer overall and site-specifically for cancers that were diagnosed in >1 RA 
patient. Patients diagnosed with cancer before starting TNFi treatment were not excluded 
from the analyses. Cancer rates in the Finnish adult population were obtained from the 
statistical yearbooks published by the FCR; rates in the years 2002, 2005, and 2008 were 




8 RESULTS AND DISCUSSION 
8.1 Reporting to the ROB-FIN register and trends in anti-TNF 
use (V) 
 
By February 2012, roughly 25 500 ROB-FIN register reports had been filed concerning 
4 834 patients, 54% of whom had RA. The number of registered patients has grown steadily 




Figure 3. Numbers of cumulative, registered, and new patients, respectively, in the ROB-




Overall, reports were sent from 16 of 21 hospital district areas covering roughly 80% of the 
Finnish population; annually, reports came from ca two-thirds of the districts. Reports 
mostly came from central and regional hospitals, but also other units, such as city hospitals. 
In addition, reports were sent from the Rheumatism Foundation Hospital in Heinola, where 
patients from various parts of the country were treated. Overall, nearly 300 physicians 
reported to the register, indicating that, in addition to rheumatologists, also other specialists 
or specialists in training were involved in the management and documentation of 
rheumatology patients using biologicals (the number of rheumatologists in Finland is ca 
140, roughly half of whom work as attending rheumatologists; Luosujärvi, 2006).   
 
Figure 4 shows the numbers and proportions of patients starting treatment with various 
TNFi agents in the years 2001 to 2010. The notable increase by the year 2004 was, 
presumably, due to the availability of guidelines for their use and the increased experience 
with this type of drugs, as well as the availability of self-injectable, reimbursed drug 






Figure 4. Numbers and proportions of ROB-FIN registered patients starting various TNFi 
agents in the years 2001, 2004, 2007 and 2010 (all diagnoses included). Of all registered 
patients, 1392 had been treated with IFX, 2344 with ETA, 2117 with ADA, 90 with CER, 
and 111 with GOL. GOL=golimumab; CER=certolizumab pegol; ADA=adalimumab; 
ETA=etanercept; IFX=infliximab.  
 
 
Table 12 shows the numbers of TNFi treated, ROB-FIN registered patients and the 
coverage of the SII code 313 reimbursed patients and of the defined daily doses (DDDs) of 
TNFi agents consumed in Finland in the years 2001 to 2010. The DDDs encompass all 
indications of use, including rheumatological disorders in adults, juvenile idiopathic 
arthritis (JIA), Crohn’s disease (CD), ulcerative colitis (UC), and plaque psoriasis.  
 
 
Table 12. The number of TNFi treated, ROB-FIN registered patients (all diagnoses 
included); proportion of SII code 313 reimbursed patients who were registered in ROB-
FIN; and proportion of the defined daily doses (DDDs) of IFX, etanercept (ETA), and 
adalimumab (ADA) consumed in Finland covered in the ROB-FIN register, in the years 
2001, 2004, 2007, and 2010.  








DDDs of IFX 
Proportion of 
DDDs of ETA 
Proportion of 
DDDs of ADA 
2001 247 NA 23% NA NA 
2004 1239 62% 32%  50%  NA 
2007 2129 51% 21%  48%  39%  







The DDD coverage is lower for IFX than for ETA and ADA, which may be due to the 
higher recommended dose of IFX in the treatment of CD and psoriasis (5 mg/kg, as 
opposed to 3 mg/kg in the treatment of RA). The number of patients with pediatric or non-
rheumatological indications could be estimated to have been in the order of 1000 in the year 
2010 (FSM; Tynjälä et al., 2009; Jussila et al., 2011). ROB-FIN may be estimated to have 
encompassed ca 60% of all Finnish adult patients with rheumatological indications using 
biological drugs in the mid-2000s, and around one-third in the later part of the decade. The 
coverage in the reporting hospital distric areas is higher compared with the nationwide 
estimate (ca 94% in 2004, and 44% in 2010, assuming two-thirds of the patients were from 
such areas). The follow-up is prospective, and no apparent documentation bias is evident. 
Taken together, it would seem that the patients registered in ROB-FIN make up a 
representative sample of the Finnish RA patients who use biological drugs.  
 
The smaller coverage of register data from 2010 (compared with, e.g., 2004 and 2007) may, 
to some extent, be explained by the lag-time in the register data obtainability. However, it is 
also supposedly due to the considerable increase in the number of patients being treated 
with biological agents, whereby more effective means of data collection is called for. While 
the ROB-FIN paper forms can be used in the patient monitoring in the clinics, the 
electronic data acquisition provides even better tools through graphs and other data 
summaries; this type of monitoring of treatment response in individual patients may 
reinforce voluntary reporting to registers (Hetland, 2005). Clinical information software 
(GoTreatIT) is currently being implemented in several Finnish rheumatology units, and 
data obtained in this way may be incorporated to the ROB-FIN register in the near future.  
 
In accordance with earlier observations (Kvien et al., 2001; Kvien et al., 2003; Sokka and 
Pincus, 2003; Zink et al., 2006), it appeared that even less than one-tenth of ROB-FIN 
patients starting TNFi therapy would fulfil the selection criteria of RCTs. The general 
criteria of the ATTRACT trial (i.e., SJC ≥ 6, TJC ≥ 6, and two of the following: morning 
stiffness ≥ 45 minutes, ESR > 28 mm/h, and CRP > 2 mg/dl; concomitant MTX required 
but no other cDMARDs allowed; prednisone-equivalent daily dose of oral GC not 
exceeding 10 mg) (Maini et al., 1999) were fulfilled by only 9% of the RA patients (Table 
13; the figures are crude estimates as 1) duration of morning stiffness is not assessed in 
ROB-FIN and was assumed to be a fulfilled criterion in the analysis, and 2) ATTRACT and 
most other RCTs have used a 66 SJC and 68 TJC index, while ROB-FIN uses a 54 SJC and 
53 TJC index). Application of more stringent criteria of other RCTs (e.g., higher required 











Table 13. Proportion of ROB-FIN registered RA patients fulfilling the general selection 
criteria of the ATTRACT trial (see text) during various time periods and overall, and 
period-wise comparisons of disease activity, disease duration, and age of RA patients 





























with early RA 











8% 38% 19% 5.1  
(4.2 to 5.7) 




5% 25% 19% 4.8  
(3.7 to 5.6) 
9 28% 55 
Overall 
(n=1614) 
9% 37% 22% NA NA NA NA 
 
IQR=interquartile range; NA=not assessed 
 
 
The disease activity of RA patients starting TNFi therapy has decreased through the years 
(p<0.001), but remains on a high or moderate level (Table 13). The disease duration 
(assessed as time since diagnosis) has decreased (p<0.001). However, the age at 
commencement has increased somewhat (p<0.001). Similar trends have been observed in 
other European countries, i.e., the baseline disease activity has decreased and age increased, 
and an increasing proportion of the patients is treated with TNFi agents relatively early 
(within a few years) in the disease course (Hetland et al., 2008; Söderlin and Geborek, 
2008; Hyrich et al., 2011; Gómez-Reino et al., 2012). Despite the finding of older age at 
baseline, there has not been evidence of increased comorbidity (Hyrich et al., 2011; 
Gómez-Reino et al., 2012). 
 
8.2 Effectiveness and safety of infliximab therapy in the 
treatment of RA (I, V)  
 
8.2.1 Effectiveness of infliximab in RA patients treated with 
concomitant methotrexate and other conventional disease 
modifying antirheumatic drugs (I) 
 
At the time of the analyses performed for Study I (Nordström et al., 2006), ROB-FIN 
encompassed 436 patients with RA who had received IFX at least once in the time period 
between May 1999 and September 2004, and who had not used bDMARDs earlier. The 
requirement of a filed baseline report was fulfilled in 364 cases, and these patients made up 
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the study cohort. The mean age of the patients was 49 years (range 18 to 77 years), and 253 
(70%) were women. Two-thirds had a seropositive disease. The patients had moderate to 
severe disease at baseline (Table 14). Most patients had long-standing disease; the median 
time since diagnosis was 11 years (range 0 to 47 years). 28 of 254 patients with reported 
disease duration had been diagnosed ≤ 3 years earlier.  
 
 
Table 14. ACR core set measures in the cohort of IFX treated RA patients (n=364) at 
baseline, after three months on IFX, and at the last observation of biological therapy (IFX 
or other) (3 months IFX vs. baseline, p<0.001; last observation vs. baseline, p<0.001).   
 Baseline 3 months IFXb,c Last observation (IFX or other 
bDMARD) 
 Median  IQR n Median IQR n Median IQR n 
SJC 10 6 to 17 353 2 1 to 6 258 1 0 to 4 352 
TJC  11 6 to 19 337 3 1 to 8 248 2 0 to 5 351 
CRP (mg/dl)  3.2 1.3 to 
6.2 
352 1.0 0.5 to 
2.7 
260 0.6 0.4 to 
1.6 
349 
ESR (mm/h) 35 19 to 58 349 18 9 to 36 258 16 7 to 30 348 
Patient’s global 
(mm VAS)  
65 48 to 78 318 25 12 to 50 240 29 13 to 55 349 
Pain (mm VAS)  65 44 to 80 322 26 11 to 53 245 30 14 to 55 348 
Doctor’s global 
(mm VASa) 
75 50 to 75 304 25 25 to 50 227 18 7 to 34 326 
HAQ score  1.3 0.8 to 
1.9 
322 0.9 0.3 to 
1.4 




IQR=interquartile range, n=number of patients. a) Up to year 2004, register forms had a 5-grade Likert scale, which has 
been converted to 100 mm VAS as follows: grade 1, 0 mm; grade 2, 25 mm; grade 3, 50 mm; grade 4, 75 mm; grade 5, 
100 mm. b) At the time of analysis, 323 patients had used IFX for at least three months. Included in this assessment are 
the patients with reported data from the 3 months visit. c) These values persisted throughout the follow-up in the patients 
who remained on IFX. 
 
 
At baseline, 95% used a concomitant cDMARD and 86% used oral GC; combination 
therapy with two or more concomitant cDMARDs was common, used in 44%. Only 68% 
used MTX; of the MTX users, 30% used HCQ and 21% used SSZ, which suggests that the 
FIN-RACo combination was not very widely used in this setting. Patients who did not use 
MTX most frequently used leflunomide (31%) or azathioprine (22%). cDMARD usage 
remained stable during the 24 month follow-up (no statistically significant changes), while 
oral GC usage decreased. At 12 and 24 months after commencement of IFX, 79% and 67% 
used oral GC, respectively. In GC users, GC doses were reduced within the first months of 
IFX therapy, from a median prednisone-equivalent daily dose of 7.5 mg at baseline to 5.0 
mg at three months and thereafter (p<0.001). By three months, 41% of the patients had 
discontinued usage of NSAIDs, while only 4% had started usage. 
 
The ACR20 and ACR50 response rates at three months after commencement of IFX were 
64% (144/225) and 41% (92/225), respectively. Sub-analyses of ACR response rates in 
groups of patients who used concomitant MTX, but no other cDMARDs (IFX+MTX 
group), MTX and SSZ (± other cDMARDs) (IFX+MTX+SSZ group), and cDMARDs 
other than MTX (IFX+non-MTX group), were performed. Oral GC use among these groups 
was similar (p=0.33 at baseline, p=0.22 after three months). The IFX+MTX+SSZ group 
tended to have smaller values of baseline ACR core set measures; the differences in TJC 
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and HAQ score were statistically significant between the IFX+MTX+SSZ group and the 
IFX+non-MTX group (TJC median 6 vs. 14, HAQ score median 1.0 vs. 1.6; both p<0.05). 
The ACR20 and ACR50 response rates at three months in the subgroups are presented in 
Table 15. The differences between the groups were not statistically significant.  
 
 
Table 15. ACR20 and ACR50 response rates at three months after commencement of IFX. 
At the time of analysis, 314 of the 364 patients in the cohort had used IFX for at least three 
months; the numbers of assessable patients, i.e., with sufficient reported data from the three 
months visit, are given in parentheses. For definitions of drug combinations, see text.  
 IFX overall IFX+MTX IFX+MTX+SSZ IFX+non-MTX 


















The ACR20 response rate at six months in the IFX+MTX group was 65% (42/65), and was 
in accordance with that of IFX standard dosage (3 mg/kg at weeks 0, 2, and 6, and 
thereafter every eight weeks) with concomitant MTX in the ATTRACT trial; 50% of the 
patients in the trial reached the primary endpoint of ACR20 response at 30 weeks (Maini et 
al., 1999). The per protocol analysis used in the current study may inflate the response rate 
relative to that obtained through intention-to-treat analysis. Assuming discontinuers to be 
ACR20 non-responders yields response rates closely approximating that of the ATTRACT 
trial. It is also possible that the open setting, where the patient and doctor are aware of the 
treatment given, affects the response rate. For example, greater responses in open settings, 
compared with RCTs, have also been found for ankylosing spondylitis (AS), e.g., when 
using the Assessment in Ankylosing Spondylitis Response Criteria (ASAS) which, similar 
to the ACR response criteria, include pain and global assessments as patient reported 
outcome measures (Breban et al., 2002; Temekonidis et al., 2003; Konttinen et al., 2007). 
Moreover, the routine care setting allows for individual treatment adjustments as needed, 
whereas rigid treatment protocols are applied in RCTs; however, decreases in GC and 
NSAID usage occurred more frequently than increases in the cohort patients, while 
cDMARD use remained relatively stable.  
 
The slightly better response rate in the observational cohort could also, perhaps, be 
explained by differences in the extent to which complete, but time consuming, joint counts 
are performed in the RCT and routine care settings. A separate register-based study of the 
SJCs of 86 RA patients treated with TNFi agents (mainly ETA and ADA) at the Helsinki 
University Surgical Hospital indicated that the metatarsophalangeal joints (MTPs) tended to 
improve to a greater extent than other joint areas (improvement after two to six months in 
96% of MTPs vs. 65% to 78% of metacarpophalangeal joints (MCPs), proximal 
interphalangeal joints (PIPs), wrists, elbows, and ankles, p<0.001; 88% of knees, p=0.09) 
(unpublished data). This could indicate thorough baseline, but more pragmatic follow-up 
assessments in which the thoroughness of the assessment of the MTPs partly depends on 
whether these joints pose a problem for the patient (Heikki Valleala, personal 
communication). Calculation of ACR response rates using 28 joint count indices might lead 




8.2.2 Adverse events of infliximab in RA patients treated with 
concomitant methotrexate and other conventional disease 
modifying antirheumatic drugs (I) 
 
The safety profiles appeared to be similar among groups of RA patients using IFX with 
various concomitant cDMARDs (assessed in the 436 patients who had received IFX at least 
once in the time period between May 1999 and September 2004 and whose data were 
extracted for Study I). Reported SAEs were, among 199 patients exposed to IFX+MTX, 
one each of infusion reaction, pancreatitis, an unspecified SAE, and a fatal myocardial 
infarction; among 68 patients exposed to IFX+MTX+SSZ, again one each, erysipelas and a 
life-threatening pneumonia; and among 142 patients exposed to IFX+non-MTX, five 
infections, two infusion reactions, and two eczemas. Four cancers were reported: one 
meningeoma in an IFX+MTX treated patient, and three breast cancers in IFX+non-MTX 
treated patients.  
 
8.2.3 Updated analysis of the cohort of RA patients treated with 
infliximab (V) 
 
An updated analysis of the original cohort of 364 IFX treated RA patients (hereafter 
denoted the original IFX cohort) was performed based on register data obtained in February 
2012. At that time, the mean follow-up time of IFX was 2.4 years (median 1.3 years, range 
0 to 11.2 years), and that of biological therapy was 5.4 years (median 6.0 years, range 0 to 
11.2 years). The patients had used a mean of two biological drugs (range one to six); 203 
(56%) of the patients had switched IFX to another biological drug, and 105 (29%) had used 
> 2 biological drugs.  
 
Of the 364 patients, 93 (26%) had discontinued IFX due to lack or loss of effectiveness 
(LOE), 53 (15%) due to AEs, four (1%) due to remission, and 100 (28%) due to other or 
unspecified reasons. 15 (4%) patients were still using IFX, but 99 (27%) had been lost to 
follow-up (defined here as no reports after 31.12.2010). At the last observation of 
biological therapy (IFX or other) most the patients had relatively low disease activity 
(Table 14). 113 of 254 assessable patients (45%) were in DAS28 remission (DAS28 score 
< 2.6). IFX and bDMARD survival, with any reason for discontinuation during up to five 






Figure 5. IFX and bDMARD survival in the cohort of IFX treated RA patients (n=364), 
with any reason for discontinuation during up to five years of treatment as the end-point. 
bDMARD refers to treatment with any biological agent, i.e., IFX or subsequent other drug. 
Black solid line: bDMARD survival, with patients lost to follow-up assumed to have 
continued treatment; gray solid line: bDMARD survival, with patients lost to follow-up 
assumed to have discontinued treatment; black dotted line: IFX survival, with patients lost 
to follow-up assumed to have continued treatment; gray dotted line: IFX survival, with 
patients lost to follow-up assumed to have discontinued treatment.  
 
 
The overall persistence of IFX treatment in the original cohort seems to be somewhat lower 
than that seen in other observational cohorts. Data from the British BSRBR revealed 
treatment persistence rates of the first TNFi therapy (IFX, ETA or ADA) of 71% at one 
year, 50% at two years, and 42% at five years (Soliman et al., 2011). Data from the Danish 
DANBIO register revealed the persistence rate of IFX at four years to be 41%, while that of 
ETA was 56% and that of ADA was 52% (Hetland et al., 2010). In that study, the lower 
persistence of IFX was mainly due to AEs (hazard ratio (HR) 2.7 compared with ETA, and 
1.8 compared with ADA), but also due to LOE (HR 1.7 compared with ETA, and 1.2 
compared with ADA). The discontinuation rates due to LOE and AEs in the original IFX 
cohort appear comparable with other observational cohorts (Curtis et al., 2010). In the 
study by Gómez-Reino et al. (2012), ca 7% discontinued their first TNFi agent during the 
first year of treatment due to LOE in 2000 to 2003, while in more recent years the 
percentage has increased to ca 12%. In the same study, the discontinuation rate due to AEs 
has remained stable at just under 10%. In the study by Soliman et al. (2011), with median 
follow-up time of two years, 22% of the patients had discontinued their first TNFi therapy 
due to LOE, and 21% due to AEs. It appears that other or unspecified reasons for 
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discontinuing IFX in the original cohort are comparatively large. The unspecified reasons 
may include nonmedical ones such as reimbursement or patient preference. Naturally, 
concomitant reasons for discontinuation may exist, whereby, e.g., better effectiveness is 
sought, despite, e.g., achievement of an ACR50 response and relatively low level of disease 
activity. 
 
The updated analysis of the original IFX cohort rendered ACR20, ACR50, and ACR70 
response rates at three months of 62% (n=148 of 237 assessable), 40% (n=95) and 17% 
(n=39), respectively. The rates were consistent with the “60-40-20” rule described in the 
review of the literature (Chi-square goodness-of-fit test, p=0.44, p=0.98, and p=0.17, 
respectively). Individual ACR core set measures at three months are shown in Table 14. 
The response achieved at 3 months was indicative of the subsequent probability of 
response, at least in those who responded to the treatment. For instance, an ACR50 
response achieved at three months was maintained up to two years in ca two-thirds of the 
patients. However, nearly half of the patients (48%) who were ACR50 non-responders at 
three months, but continued treatment with IFX, achieved this response at some time during 
the two year follow-up. These findings are consistent with those of pooled analyses of 
ROB-FIN data of biological therapies (mainly TNFi agents) (Virkki et al., 2010). 
Therefore, it appears that continuation of TNFi therapy may be beneficial even if a 
significant response is not achieved within the first few months. Findings from the TEMPO 
trial of ETA lend support for this notion (Kavanaugh et al., 2008). In that trial, up to half of 
the non- and partial responders at week 12 showed improved ACR responses at week 24 in 
all treatment arms (ETA, MTX, or ETA+MTX), while less than one-fourth showed a 
decreased response (≤10% in the ETA+MTX arm). The 24 week response was maintained 
in the majority of patients up to 52 weeks (>80% in the ETA+MTX arm). Importantly, in 
the ETA arms, a delayed response was not associated with increased radiographic 
progression at week 52 (radiological outcomes are not available in the ROB-FIN register). 
Based on several RCTs, clinical responses appear to level off after six months of treatment 
(Bathon et al., 2000; Keystone et al., 2004b; Klareskog et al., 2004; Emery et al., 2008). 
Therefore, three to six months may be an appropriate treatment trial duration, provided the 
patient tolerates the drug.   
 
The magnitude of baseline disease activity, assessed through SJC, CRP, and patient’s 
global assessment, correlated significantly with the magnitude of absolute improvement of 
the respective parameters (p<0.001). However, the relative degrees of improvement, as 
assessed by ACR20, ACR50, and ACR70 response rates at three months, were not 
dependent on the magnitude of baseline disease activity. Some observational studies have 
indicated that treatment responses, including ACR response rates, DAS28 improvement, 
EULAR response and remission rates, have improved, simultaneously with the trend 
toward starting TNFi treatment earlier in the disease course and in less severe disease 
(Hetland et al., 2008; Hyrich et al., 2011). The trend toward lower baseline disease activity 
implies a possibility of remission being achieved more frequently, if indeed the relative 
improvement remains at an unchanged level or is improved.  
 
Taken together, Study I and its updated results imply that IFX can be added to ongoing 
combination cDMARD therapy (e.g., FIN-RACo combination; Möttönen et al., 1999) or 
even cDMARDs other than MTX, e.g., in patients who do not tolerate MTX. The 
effectiveness of these combinations appears to be comparable. However, the possibly 
increased risk of developing SAEs and/or human anti-chimeric antibodies (HACAs) among 
patients not using concomitant MTX remains elusive and is difficult to assess in a non-
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randomized setting. Interestingly, data from the British Society for Rheumatology 
Biologics Register (BSRBR) indicated that, compared with patients using TNFi combined 
with MTX as the sole cDMARD, patients using TNFi in combination with MTX plus SSZ 
and/or HCQ were less likely to discontinue their first TNFi therapy due to inefficacy or 
AEs (Soliman et al., 2011). Conversely, patients using TNFi in combination with SSZ or 
LEF monotherapy, or not using concomitant cDMARDs, were more likely to discontinue 
their first TNFi therapy due to inefficacy or AEs. The reason for this remained speculative 
in that it may be affected by unmeasured confounders, such as a generally better drug 
tolerability of the patients using cDMARD combinations.  
 
8.2.4 Pooled analyses of ROB-FIN data of biological therapies 
 
Pooled analyses of ROB-FIN data on the effectiveness of biological therapies for the 
treatment of RA rendered ACR20, ACR50, and ACR70 response rates at three months of 
65% (n=440 of 673), 41% (n=277), and 20% (n=136), respectively (Virkki et al., 2010). No 
statistically significant differences in the rates were found among the biological agents 
assessed (IFX, ETA, ADA, anakinra, rituximab). The efficacy of the TNFi agents appears 
comparable also based on indirect comparisons and meta-analyses of RCTs (Hochberg et 
al., 2003; Gartlehner et al., 2006). However, observational data from the Danish DANBIO 
register indicate that differences between the agents may exist in practice (Hetland et al., 
2010). In that study, ADA had the highest treatment response rate and ETA had the longest 
treatment persistence rate, while IFX had the lowest rates. Of the three agents ETA was 
discontinued least frequently due to AEs. Our meta-analysis of RCTs also lends support to 
the notion that ETA perhaps is the safest alternative of the currently available TNFi agents 
(Aaltonen et al., 2012).  
 
The pooled ROB-FIN analyses yielded an improvement in the DAS28 score of an average 
of 1.8 at three months after commencement of bDMARD therapy. A clinically significant 
improvement of >1.2 was achieved by 69% of the patients (n=399 of 577 assessable). At 
baseline, 6% (n=36) of the patients had a low DAS28 score (<3.2), and 2% (n=12) were in 
DAS28 remission (<2.6); after three months, the corresponding proportions were 49% 
(n=285) and 33% (n=189), respectively. Within one, two and three years, DAS28 remission 
had been achieved by 42%, 50% and 55%, respectively.  
 
At the time of analysis, the mean follow-up time of the RA patients was 2.3 years (range 
0.0 to 8.8 years). During that time, the first bDMARD had been discontinued by 17% due 
to LOE and 10% due to AEs, usually within the first year. bDMARD switches were 
common, occurring in more than one-third for various reasons.   
 
8.3 Adverse events of anti-TNF therapy in a routine-care setting 
(II, V) 
 
At the time of the analyses performed for Study II (Konttinen et al., 2006), ROB-FIN 
encompassed 1 440 patients (61% with RA) who had received a biological drug at least 
once up to March 2005. During a period of five years 308 AE reports concerning 248 
patients had been filed, corresponding to 17% of all registered patients. This proportion was 
the same in an updated analysis on data obtained in April 2009, in which AEs had been 
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reported for 525 of the total of 3145 registered patients (hereafter denoted the total cohort). 
The mean follow-up time of the total cohort was 2.1 years (range 0.0 to 8.5 years). IFX had 
been used by 1127 patients, ETA by 1585, ADA by 1338, and anakinra by 98; other 
biological drugs had been used less frequently at the time of analysis. While all reported 
AEs for all biological agents have been included in the analyses, only the four mentioned 
have been statistically compared. Here, the focus will be mainly on the updates analyses, 
since the AEs reported by Konttinen et al. (2006) are included in these as well, and since 
the findings regarding, e.g., the most commonly reported AEs and those leading to 
treatment discontinuations remain the same. However, more information about rarer events 
(SAEs) has accrued, and the larger numbers of patients using various biological agents 
enable more statistical comparisons to be performed.   
 
Figure 6 shows the percentages of the reported AEs according to the updated analysis, 
classified according to type or site of the event. AEs led to discontinuation of the bDMARD 




Figure 6. Percentages of the reported adverse events (n=813), classified according to type 
or site of the event. These AEs concerned 525 of the total of 3145 ROB-FIN registered 





8.3.1 Most frequent adverse events (II, V) 
Infections (II, V) 
 
A total of 238 reports concerning various infections in 194 patients were reported; this 
corresponded to 6.2% of the total cohort. The mean time to the occurrence of the first 
infection was 11.5 months (median 8.3 months, range 0.1 to 59 months). Several 
observational studies and a meta-analysis of RCTs have indicated an increased risk of 
various (serious) infections during the first few months of TNFi therapy (Wallis et al., 
2004; Dixon et al., 2006; Dixon et al., 2007; Leombruno et al., 2009). This could be due to, 
e.g., use of oral GC as bridge therapy in the beginning of TNFi therapy, susceptible patients 
discontinuing the treatment, reactivation of latent infection (e.g., tuberculosis), and the fact 
that AEs occurring soon after starting a new treatment may be more likely to be reported. In 
contrast, Kroesen et al. (2003) did not find a time-dependency of infections.   
 
Infections were reported in approximately equal proportions of patients using various 
biological agents (IFX 4.8%, ETA 5.2%, ADA 4.3%, and anakinra 3.1%, p=0.64). The 
most frequently reported infections were upper airway infections (35 patients), pneumonia 
(23 patients), sinusitis (20 patients), urinary tract infection (18 patients), erysipelas (12 
patients), wound infection or infected eczema (12 patients), bronchitis (11 patients), and 
herpes zoster (11 patients). The serious infections are reviewed in the SAE section. 
Infections led to discontinuation of the biological agent in 55 patients (1.7% of the total 
cohort). 
 
Dermatological problems (II, V) 
 
Various eczemas were reported in 117 patients. This corresponded to 3.7% of the total 
cohort; drug-specific percentages were 4.2% for IFX, 2.4% for ETA, 2.5% for ADA, and 
3.1% for anakinra. The eczemas had various manifestations with regard to localization, 
description, and type; among these, urticaria occurred in 16 patients, and pustulosis 
palmoplantaris or psoriasis breakout or worsening in six. The mean time to occurrence of 
eczema was 8.0 months (median 3.8 months, range 0 to 53 months). Eczemas were among 
the most common sole or co-existing reasons for discontinuation of the biological agent 
(n=77, corresponding to 2.4% of the total cohort, with no statistically significant 
differences between the agents).  
 
Other skin or mucosal AEs included injection-site reactions in 26 patients, pruritus in 16, 
and xerosis in 12. Injection-site reactions led to discontinuation of the drug in only 18 
patients (0.6% of the total cohort), with drug-specific proportions of 0% for IFX, 0.4% for 
ETA, 0.7% for ADA, and 2.0% for anakinra (p<0.05).  
 
In a cross-sectional study, TNFi therapy was not associated with an increased prevalence of 
cutaneous infections, skin tumors, psoriasis, or atopic dermatitis, compared with 
conventionally treated patients (Davaine et al., 2008). However, the number of patients in 
the study was relatively small (59 of 187 patients received TNFi therapy), and the patients 
were not followed from the start of the treatment. It is therefore possible that they were 
mostly drug continuers with no dermatological problems attributable to the treatment. In the 
present study, the reported dermatological problems were clustered to the first months of 
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TNFi or anakinra treatment, which may point to a causal relationship between the drug and 
the event. However, it is also possible that events occurring early after the patient has 
started treatment with a new drug are reported more frequently. 
 
Infusion or allergic reactions (II, V) 
 
Infusion or allergic reactions were reported in 87 patients, which corresponded to 2.8% of 
the total cohort. The mean time to the occurrence of the infusion or allergic reaction was 
4.9 months (median 2.3 months, range 0 to 35 months). Infusion or allergic reactions 
occurred more frequently in patients using IFX (5.1%) than in patients using ETA (1.3%), 
ADA (0.7%) or anakinra (1.0%) (p<0.001). They were among the most common reasons 
for discontinuation of the biological agent (n=69, corresponding to 2.2% of the total cohort, 
with drug-specific proportions of 3.9% for IFX, 0.9% for ETA, 0.7% for ADA, and 1.0% 
for anakinra; p<0.001).  
 
Other frequently reported adverse events (II, V) 
 
Various general symptoms (e.g., headache, nausea, tiredness, vertigo, malaise) and elevated 
aminotransferases were also among the most commonly reported AEs. Aminotransferases 
were elevated above the upper limit of normal in 23 patients, of whom 19 used co-therapies 
which may have contributed. (The median alanine aminotransferase (ALT) value among 
the patients with elevated aminotransferases was 131 units/l; range 78 to 600 units/l). Other 
laboratory abnormalities included cytopenia in 13 patients and development of 
autoantibodies in seven.  
 
Comparisons of adverse event rates (V) 
 
The risk of infections appeared to be somewhat increased among RA patients, compared 
with other rheumatological diagnoses (Table 16). Higher age and longer treatment duration 
were also associated with an increased risk of infection. Notably, observational data 
indicate that, while increasing age may increase the risk of serious infection, TNFi therapy 











Table 16. Comparison of diagnosis (RA vs. other rheumatological diagnosis), sex, use of 
oral GC (at the time of the reported AE, or ever exposed during the follow-up), baseline 
age, and follow-up time in the register, in patients with or without reported infection, 
eczema, or infusion or allergic reaction. The total cohort of 3145 patients is included in the 
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Dg=diagnosis; OR=odds ratio 
 
 
Contrary to what would be expected, concomitant low-dose oral GC was not associated 
with an increased risk of infections in the present study; actually, the odds ratios indicated a 
decreased risk. GC usage was reported with 97% completeness in ROB-FIN. However, it is 
possible that the observation of a decreased risk is affected by selection bias. Low-dose oral 
GC is commonly used as a component in the treatment of RA in Finland (Pincus, 2013). 
Oral GC treatment may not have been started or may have been discontinued prior to 
biological treatment in patients susceptible to infections. Interestingly, Smitten et al. 
(2008), using the U.S. based PharMetrics integrated claims database, found oral GC use to 
increase the risk of hospitalized infection in a dose related manner (RR 1.3 with ≤5 mg/day, 
and up to RR 3.0 with >10 mg/day), while bDMARD use increased the risk only slightly 
(RR 1.2). Moreover, in that study, MTX and HCQ use were associated with a decreased 
risk of hospitalized infection (RR 0.8 and 0.7, respectively); this was thought to be due to a 
similar type of selection bias that may be relevant to the present observation as well. 
 
Eczemas were reported most frequently among RA patients, women, and patients with 
longer follow-up (Table 16). Oral GC use appeared to be associated with a decreased risk.     
 
Infusion and allergic reactions appeared to be more common among women than among 
men. Low-dose oral GC use, age, and follow-up time were not associated with the risk of 
infusion and allergic reactions in the present study. RA diagnosis was not a statistically 
significant predictor in the analysis adjusting for the other variables.  
 
The finding that women tended to be more susceptible to various AEs than men is in 
accordance with other studies of sex differences in AEs, which indicate that, in general, 
women experience more AEs than men, and that these events tend to be of a more serious 
nature (Soldin et al., 2011).  
 
The number of concomitant cDMARDs used was higher among RA patients than among 
patients with other rheumatological diagnoses in the whole cohort of registered patients 
(mean for the maximum number during the follow-up 1.7 vs. 1.4, respectively, p<0.001). 
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However, the number of concomitant cDMARDs did not yield statistically significant 
univariate nor adjusted odds ratios among patients with reported infection, eczema, or 
infusion or allergic reaction (data not shown).   
 
8.3.2 Serious adverse events (II, V) 
 
Serious, life-threatening, or fatal SAEs (excluding malignancies, which are reviewed 
separately) were reported in 98 patients, i.e., 3.1% of the total cohort. Compared with the 
ROB-FIN register, the Finnish Medicines Agency (Fimea) received more reports on SAEs 
(but not AEs in general) in rheumatologic patients using biological agents (Joensuu et al., 
2013). This may be due to the complete nationwide coverage of the Fimea database. The 
SAE may also be diagnosed and reported to Fimea by a non-rheumatologist physician, who 
may not even be aware of the ROB-FIN register. 
 
SAE infections were reported in 58 patients, corresponding to 1.8% of the total cohort. 
There were no statistically significant differences in the proportions among patients using 
various biological agents (IFX 1.7%, ETA 1.3%, ADA 1.3%, and anakinra 1.0%, p=0.82). 
These rates are similar or somewhat lower than those seen in RCTs or other observational 
studies, in which up to 6% of IFX, ETA or MTX treated patients had SAE infections during 
the first six to twelve months of treatment (Maini et al., 1999; Klareskog et al., 2004; 
Listing et al., 2005). This may be due to some underreporting of events to the ROB-FIN 
register, which, however, probably occurs more with mild/moderate AEs which may not 
have been reported to the attending rheumatologist (Gäwert et al., 2011). In accordance 
with the present study, results from several other observational studies indicate that the risk 
of serious infection is similar across the individual TNFi agents (IFX, ETA, ADA) (Listing 
et al., 2005; Dixon et al., 2006; Wolfe et al., 2006; Galloway et al., 2011).  
 
In the present study, 13 cases of septicaemia were reported: urosepsis in five, 
staphylococcal sepsis in three, and one each of Francisella tularensis, pneumococcal sepsis 
(pneumonia), streptococcal sepsis (erysipelas), empirical sepsis, and an unspecified 
septicaemia. Tuberculosis (TB) was reported in ten cases, of which six were pulmonary and 
six were extrapulmonary TB (in two patients simultaneously). SAE pneumonias were 
reported in seven patients (fatal in one patient with heart failure, life-threatening in one, and 
serious in five, in addition to the one that led to septicaemia). Unresolved infections 
requiring hospitalization were reported in five patients (one life-threatening and four 
serious). Three further life-threatening infections were reported: one endoprosthetic 
infection, one listeria meningitis, and one perforation peritonitis in a patient with stoma and 
diverticulitis. Further serious infections were four each of erysipelas (in addition to the one 
that led to septicaemia) and septic arthritis; three cases of endoprosthetic infection; two 
each of septic bursitis and wound infection; and one each of herpes zoster, peritoneal 
abscess, epiglottitis, an unspecified infection in the ankle, and pyelonephritis (in addition, 
two cases of pyelonephritis not classified as SAE were reported).   
 
Non-infection SAEs were reported in 40 patients (Table 17). The causal relationship 
between the bDMARD and the SAE is difficult to determine in this observational setting, as 
many patients used concomitant cDMARDs, GCs, or NSAIDs, or had comorbidities or 
medications thereof, that may have contributed. The main cluster of non-infection SAEs 





Table 17. Non-infection SAEs reported to the ROB-FIN register by April 2009. Forty-two 
non-infection SAEs were reported, concerning 40 of 3145 patients. (V)  
Adverse event Classification Biological drug Additional information 
Infusion / allergic reactions, 
n=13  
Serious n=11  IFX n=7, ETA n=3, 
ADA n=1 
 
Life-threatening n=2 IFX One anaphylaxis 
Myocardial infarction, n=5 Serious n=2 IFX, ETA  
Fatal n=3 
 
IFX One with concurrent pulmonary edema 




Pulmonary embolism, n=4 Serious n=2 IFX/ETA, ETA  
Life-threatening n=1 ADA  
Fatal n=1 IFX  
Vasculitis, n=3  Serious ETA n=1, ADA n=2 One Wegener’s granulomatosis 
Cerebral hemorrhage, n=3 Serious n=1 ADA  
Fatal n=2 IFX, ETA  
Hemiplegia n=2 Serious IFX  
Eczema n=1 Serious IFX  
Iritis n=1 Serious ETA  
Pancreatitis n=1 Serious IFX  
Multiple sclerosis n=1 Serious IFX  
Elevated aminotransferases 
(ALT) n=1  
Serious IFX Biopsy showed fatty liver and mild 
hepatitis 
Heart failure n=1 Serious IFX Required artificial pacemaker 
Unspecified SAE n=1 Serious IFX  
 
 
8.3.3 Cancer (II, V) 
 
Data obtained from the Finnish Cancer Registry (FCR) regarding RA patients registered in 
ROB-FIN by April 2009 (n=1691) revealed 110 cancer diagnoses during the years 1976 to 
2008; an additional ten were reported to ROB-FIN that occurred in non-RA patients or that 
were not verified by the data extraction from the FCR (Table 18). Of the 110 cancers, 59 
were diagnosed before treatment with biological drugs. The remaining 51 cancers were 





Table 18. Cancers diagnosed in RA patients up to the end of year 2008 in the combined 
data from ROB-FIN and the Finnish Cancer Registry. 
Total number of cancer diagnoses up to the end of 2008 in the combined data from ROB-FIN and the Finnish 
Cancer Registry: 120 
Cancer during or within 1 year after anti-TNF therapy: 37 Breast: 7 
Lymphoid and haematopoietic tissue: 5 
Melanoma of the skin: 5 
Lung: 3 
Brain, CNS: 3 
Thyroid gland: 2 
Prostate: 2 
Rectum, anus: 2 
Pharynx: 2 
Kidney: 1 




Ill-defined or unknown: 1 
Cancer diagnosed >1 year after last exposure to anti-TNF drug: 12 Breast: 3 
Digestive organs: 2 
Female genital organs: 2 
Lung: 2 
Lymphoid and haematopoietic tissue: 1 
Melanoma of the skin: 1 
Urinary organs: 1 
Cancer in patient on biological therapy but not exposed to anti-TNF 
drug: 2 
Digestive organs: 2 
Cancer in non-RA patient or not in Cancer Registry: 10 Brain, CNS: 3 
Prostate cancer: 2 
Breast: 1 
Melanoma of the skin: 1 
Urinary organs: 1 
Digestive organs: 1 
Ill-defined or unknown: 1 
Cancer before biological therapy was started: 59  
 
The median time to the cancer diagnosis in the 37 RA patients who were diagnosed during 
or within one year after TNFi therapy was 1.5 years (range 0.1 to 6.1 years) after 
commencement.  
 
For the cancer incidence analyses, 1621 RA patients treated with TNFi agents contributed 
5129 person-years under risk during the years 2002 through 2008. The overall incidence 
rate of cancer did not appear to be increased among RA patients treated with TNFi agents, 
compared with the Finnish adult population (SIR 1.1, 95% CI 0.8 to 1.5; p=0.67). Site-
specific SIR calculations indicated that the rates of skin melanoma and pharyngeal cancer 
were higher than expected among the RA patients treated with TNFi agents (Table 19). The 







Table 19. Standardized incidence rates (SIR) comparing cancer incidences during the years 
2002 through 2008 in RA patients diagnosed during or within one year after anti-TNF 
therapy, with those in the Finnish adult population. SIRs were calculated site-specifically 
for cancers that were diagnosed in >1 RA patient. Statistically significant SIRs are bolded.  
Cancer type 
 
SIR 95% CI 
Overall cancer  1.1 0.8 to 1.5 
Breast 0.7 0.3 to 1.5 
Lymphoid and haematopoietic tissue 2.2 0.7 to 5.2 
Melanoma of the skin 4.5 1.5 to 10.5 
Lung 1.3 0.3 to 3.7 
Brain, CNS 2.3 0.5 to 6.6 
Thyroid gland 3.3 0.4 to 11.9 
Prostate 0.6 0.1 to 2.1 
Rectum, anus 1.6 0.2 to 5.9 
Pharynx 14.9 1.8 to 53.5 
 
 
In the present study, the risk estimate for cancer in lymphoid and haematopoietic tissue was 
similar to the nearly three-fold incidence rate of lymphoma found in other studies 
comparing TNFi treated RA patients with the general population (Wolfe and Michaud, 
2004; Askling et al., 2009). Geborek et al. (2005), Setoguchi et al. (2006), and Askling et 
al. (2009) found a nonsignificantly increased risk of lymphoma (hematologic) malignancy 
among TNFi treated RA patients compared with those receiving conventional antirheumatic 
treatment (possibly affected by channeling bias). Whether TNFi agents as such increase the 
risk of lymphoma remains elusive.  
 
In a Swedish population-based observational study by Askling et al. (2005), the overall risk 
of solid cancers among TNFi treated RA patients appeared to be similar to that of the 
Swedish general population (SIR 0.9, 95% CI, 0.7 to 1.2). Also a meta-analysis assessing 
malignancy risk in association with TNFi treatment, based on registers and prospective 
observational studies, indicated comparable risks of overall cancer among exposed and 
non-exposed RA patients (risk estimate 1.0, 95% CI, 0.9 to 1.1) (Mariette et al., 2011). 
However, the risk of non-melanoma skin cancer appeared to be higher among the TNFi 
treated patients in the study by Askling et al. (2005) (SIR 3.6, 95% CI, 1.8 to 6.5), as well 
as in the meta-analysis by Mariette et al. (2011) (risk estimate 1.5, 95% CI, 1.2 to 1.8); in 
the meta-analysis, the risk estimate of melanoma was 1.8 (95% CI, 0.9 to 2.7).  
 
TNFi agents have not apparently been associated with pharyngeal cancer previously. In the 
present study, two cases were found, yielding a high SIR since this form of cancer is quite 
rare. The cases differed histologically; one was a squamous cell carcinoma, and the other 
was a lymphoma. Patient-specific information regarding known risk factors for this type of 
cancers (such as alcohol consumption and smoking) was not available.    
 
In summary, while the risk of overall cancer does not appear to be increased among RA 
patients within the first few years of TNFi therapy (compared with the general population), 
some signals of a possible increased risk of certain types of cancer exist. However, being 
uncommon or rare diseases among persons with a relatively rare exposure (TNFi therapy), 
these signals are based on modest numbers. Therefore, longer follow-up and larger 
collaborative studies would be required to obtain more precise estimates (Setoguchi et al., 
2006). Comparison to a relevant cDMARD treated cohort could allow a better isolation of 
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the eventual risk attributable to TNFi therapy. It is also important to note that the results are 
valid only in the setting from which they are derived. Changes in the selection of patients 
for TNFi therapy may influence the observed risks (Askling et al., 2005; Askling et al., 
2009).  
 
8.4 Cost-effectiveness of infliximab therapy (III) 
 
297 patients fulfilled the selection criteria of Study III (Virkki et al., 2008) at the time of 
data extraction in January 2007. Their baseline characteristics are presented in Table 20.  
 
 
Table 20. Baseline characteristics of the Study III cohort.  
Age (mean±SD) 51±11 years (range 18 to 78 years) 
Sex Women 69% 
Disease duration (median)* 10 years (range 0 to 47 years) 
HAQ score (median) 1.250 (range 0.0 to 3.0) 
Concomitant oral GC 87%  
At least one concomitant cDMARD 96%  
 methotrexate 66% 
 hydroxychloroquine 26% 
 sulfasalazine 18% 
 leflunomide 14% 
 azathioprine 8% 
 sodium aurothiomalate 8% 
 cyclosporine 7% 
 podophyllotoxin derivative 7% 
 
*) Calculated from the year of diagnosis 
 
 
Approximately half of the patients fulfilled the Current Care recommendations for 
commencement of TNFi therapy. In these patients, the median values of the clinical criteria 
were: SJC 14, TJC 16, ESR 50 mm/h, and CRP 5.2 mg/dl. In those who did not fulfill the 
recommendations, the corresponding values were: SJC 7, TJC 6, ESR 22 mm/h and CRP 
1.6 mg/dl. Due to the IFX package size of 100 mg/vial, the IFX dose was typically 200 mg 
(in two-thirds of the patients) or 300 mg (in one-fourth).   
 
At the time of analysis, the patients had been treated with IFX for an average of 21 months 
(range 1.5 to 78 months). A gain in quality-adjusted life years (QALY gain) occurred in 
76% of the patients (n=225); their utility scores improved during IFX treatment. Due to the 
varying follow-up times, the QALY change was divided by the number of years that the 
patient had received IFX therapy; each year of IFX therapy led to a mean QALY gain of 
0.179, equivalent to 65 days of perfect health (0.179×365). The median utility was 0.446 at 
baseline, and 0.704 at all subsequent control time-points up to five years.  
 
Around one-third (35%, n=79) of the patients with QALY gain had an incremental cost-
effectiveness ratio of ≤40,000 €/QALY gained. The cost per QALY gained (CQG) had a 
mean and median value of 153,121 € and 51,884 €, respectively. Obviously, some patients 
with a very high CQG had a major impact on the cost-utility. Their HAQ scores and/or 
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global VAS fluctuated during the course of the treatment, leading to only a small net gain in 
QALY (despite improvements in, e.g., joint counts).  
 
Subgroups with CQG ≤40,000 € (Group 1), CQG >40,000 € (Group 2), and no QALY 
benefit (Group 3) differed significantly with regard to baseline HAQ score and global VAS 
(p<0.001; Table 21). The highest values were seen in Group 1, indicating more severe 
functional limitation and higher disease activity in this group. Correspondingly, the baseline 
utility score was significantly lower in this group (p<0.001). The largest improvements in 
HAQ, global VAS and DAS28 score were seen in Group 1. Therefore, in the short- to 
medium-term, cost-utility was essentially affected by the potential for major improvement 
in functional ability due to amelioration of disease activity. The response to treatment 
according to the relative outcome measure ACR50 was also better in Group 1 than in the 
other subgroups. At three months after commencement of IFX therapy, the ACR50 
response rate was 64% in Group 1, 42% in Group 2, and 22% in Group 3 (p<0.05). 
However, the differences in DAS28 remission rates between the groups (46%, 35% and 
26%, respectively) were not statistically significant. The effect of prevention of functional 
decline (as measured by HAQ) due to progressive joint damage would require prolonged 
follow-up to become evident. 
 
 
Table 21. Comparison of baseline HAQ score, patient’s global assessment (mm VAS), and 
utility score in patients with CQG ≤40,000 €, CQG >40,000 €, and no QALY benefit (total 
n=297). Values are means.   
 CQG ≤40,000 € 
(Group 1, n=79) 
CQG >40,000 € 
(Group 2, n=146) 
No QALY benefit 
(Group 3, n=72) 
HAQ score  1.73 1.25 1.07 
Patient’s global (mm VAS) 74 61 48 
Utility score 0.38 0.51 0.59 
 
 
Group comparisons also revealed that Group 1 had the largest proportion of women (85% 
vs. 62% and 65% in the other subgroups, respectively, p<0.005). The women had higher 
baseline HAQ scores than the men (median 1.44 vs. 1.00; p<0.001); indeed, female sex has 
been found to be a predictor of disability in RA patients (Scott et al., 2000). The median 
IFX dose was 200 mg in all groups; however, a relatively small proportion of the patients in 
Group 1 used doses higher than 200 mg (13% vs. 35% and 29%, respectively; p<0.005). 
The dose of IFX may affect the cost-utility; treatment of a “light” patient may inherently be 
more cost-effective than treatment of a “heavy” patient, owing to the lower dose of IFX.  
 
A somewhat larger proportion of patients with QALYs gained used concomitant MTX 
(72% and 77% vs. 57% for Groups 1, 2, and 3, respectively; p<0.05). This indicates that the 
combination of IFX and MTX may be more cost-effective than treatment with IFX without 
concomitant MTX. Baseline joint counts, ESR, CRP, age, and disease duration did not 
differ significantly between the subgroups (SJC54, p=0.06; SJC28, p=0.28; TJC53, p=0.05; 
TJC28, p=0.11; ESR, p=0.65; CRP, p=0.60; age, p=0.27; disease duration, p=0.80). The 
Current Care recommendations for commencement of TNFi therapy were fulfilled in 
comparable proportions (54%, 46%, and 47%, respectively; p=0.54). This might indicate 
that the trend toward starting TNFi treatment earlier in the disease course and in less severe 
disease does not substantially affect the cost-effectiveness when only direct medical costs 
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of the treatment are considered. In fact, HAQ scores, global assessments, utility scores and 
CQG among patients diagnosed ≤3 years (n=30) vs. >3 years before commencement of IFX 
did not differ statistically significantly (HAQ, p=0.60; patient’s global, doctor’s global, and 
pain assessments, p=0.77, p=0.17, and p=0.44, respectively; utility score, p=0.91; CQG, 
p=1.00). However, the proportion of patients with a HAQ score ≥2, indicating severe 
functional limitation, was larger in the latter group throughout the follow-up. Some of the 
patients in the present cohort may have developed permanent joint damage due to 
longstanding progressive RA before the biological drugs became available. Joint damage 
has been estimated to account for up to 25% of disability in established RA (Scott et al., 
2000). Therefore, it could be supposed that the cost-effectiveness (including averted 
indirect costs) of TNFi agents is improved in cohorts of patients who have started their 
treatment when functional disability is more amenable to pharmacological intervention.   
 
In ACR50 responders at three months, the median DAS28 score was 2.3, and the DAS28 
remission rate was 65%; in ACR50 non-responders the corresponding values were 4.2 and 
13% (p<0.001 for ACR50 responders vs. non-responders). Among the ACR50 responders, 
the CQG was significantly lower compared with that of the non-responders (median 42,960 
€ vs. 62,141 €, respectively; p<0.05). Thus, ACR50 response at three months (the primary 
outcome measure of the 2003 Current Care recommendations for continuation of a 
bDMARD) was associated with a significantly higher DAS28 remission rate and a lower 
CQG than those seen in ACR50 non-responders.      
 
The CQG of TNFi therapy has ranged from <10,000 € to >150,000 € in published studies 
(Wong et al., 2002; Kobelt et al., 2003; Brennan et al., 2004; Kobelt et al., 2004; Welsing 
et al., 2004; Kobelt et al., 2005; Brennan et al., 2007). Thus, the costs cover the range from 
cost-effective to not cost-effective according to conventional thresholds (Wong et al., 2002; 
Rawlins and Culyer, 2004; Maetzel, 2005; Rawlins et al., 2010). The setting, methodology 
and assumptions across the studies are not uniform, and comparisons between them may be 
confounded by, e.g., the method of deriving utility scores and differing comparators, time 
horizons, discount rates, and attribution of direct and indirect costs. In the present study, 
which considered only direct drug and administration costs of IFX in an observational 
cohort, the CQG was similar or slightly higher compared with most of the earlier published 
cost-utility analyses (CUAs). Inherently, the result is affected by the prevailing treatment 
practices, including, e.g., the decisions to continue, discontinue or change the treatment. In 
view of the number of bDMARDs currently available and the common practice of 
switching between them, long-term studies may need to investigate goal-directed treatment 
strategies rather than individual drugs. Demonstration of the cost-effectiveness of biological 
agents in the context of modern treatment approaches and trends will be necessary, as they 
may have a significant impact on the use of bDMARDs and perhaps also on long-term 
outcomes (Gómez-Reino et al. 2012).  
 
8.5 Outcomes of switching anti-TNF agents (IV) 
 
Of the 1,688 registered patients receiving biological therapy for RA up to April 2009, with 
a mean follow-up time of 28 months (range, 0 to 105 months), 623 (37%) had switched 
biological drugs. 479 patients fulfilled the selection criteria of Study IV (Virkki et al., 
2011). Of these, 152 switched IFX to ETA; 98 switched IFX to ADA; 102 switched ADA 
to ETA; 104 switched ETA to ADA; 15 switched ETA to IFX; and eight switched ADA to 
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IFX. Switching to IFX was relatively scarce, presumably due to the reimbursement system. 
Therefore, sub-analyses focus on the switches to ETA and ADA.  
 
The characteristics of the cohort were: women 74% (n=355); median age at baseline 52 
years (range 18 to 83 years); and disease duration at baseline (calculated from the year of 
diagnosis) 9 years (range 0 to 48 years). At baseline, 91% used a concomitant cDMARD 
(56% used MTX), and 88% used oral GC. Values of the ACR core set measures and 
disease activity are given in Table 22. The mean follow-up time of the first TNFi agent in 
the present study is 12.9 months (median, 8.8 months; range, 0 to 73 months), and of the 
second agent, 17.4 months (median, 10.7 months; range, 0 to 63 months). 
 
 
Table 22. Baseline values of the ACR core set measures and disease activity (DAS28) in 
the cohort switching an initial TNFi agent to a second one. Values are median (range). A 
baseline report was available for 377 of the 479 patients included in the study.   
SJC 10 (0–44), n=367 
TJC 10 (0–53), n=355 
Patient’s global (mm VAS) 65 (0–100), n=344 
Pain (mm VAS) 65 (0–100), n=343 
ESR (mm/h) 32 (0–149), n=364 
CRP (mg/dl) 2.5 (0–18.9), n=362 
HAQ score 1.3 (0.0–3.0), n=341 
Doctor’s global (mm VAS*) 65 (14–100), n=314 
DAS28 score 5.3 (2.1–8.5), n=266 
 
*) Up to year 2004, register forms had a 5-grade Likert scale, which has been converted to 100 mm VAS according to the 
following: grade 1, 0 mm; grade 2, 25 mm; grade 3, 50 mm; grade 4, 75 mm; grade 5, 100 mm. 
 
 
Of the 479 switchers, 242 discontinued their first TNFi agent due to lack of effectiveness 
(LOE) (hereafter referred to as LOE switchers)5. Primary LOE (pLOE) was a more 
common switch reason than secondary LOE (sLOE) in the groups who started biological 
therapy with ADA or ETA, while primary LOE and secondary LOE was evenly divided 
within those who started biological therapy with IFX.  
 
Overall, compared to the baseline, the studied outcomes, i.e., SJC, CRP, and DAS28, were 
lower at the 3 months, best and last observations of both the first and second agents in 
patients who discontinued the first agent due to LOE (p<0.001). The outcomes of the 
second agent tended to be better than those of the first agent when comparing 
corresponding observations on the first and second agents, i.e., their 3 months, best and last 
observations, and, in addition, when comparing the last observation before the switch to the 
observations after the switch (p<0.05 for all comparisons except best SJC on the first agent 
vs. best SJC on the second, p=0.08).  
 
Outcomes at three months after the LOE switch are shown in Table 23. In comparing the 
drug-specific types of switches, the differences in proportions of patients with a clinically 
significant DAS28 improvement, or in those obtaining an ACR50 response, did not quite 
                                                 
5 IFX to ETA n=65 (median time to switch 15 months), IFX to ADA n=48 (median time to switch 14 
months), ADA to ETA n=54 (median time to switch 6 months), ETA to ADA n=61 (median time to switch 6 
months), ETA to IFX n=9, and ADA to IFX n=5 
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reach statistical significance (p=0.11 and 0.06, respectively). The type of LOE (primary or 
secondary) did not have a significant effect on the rate of clinically significant DAS28 
improvement (p=0.27). However, the type of LOE seemed to affect ACR50 response rates 
(p<0.001). The odds ratio of ACR50 response in sLOE was 5.5 (p<0.001). 
 
 
Table 23. Outcomes at three months after the LOE switch: proportions of patients with a 
clinically significant improvement of the DAS28 score (>1.2 points compared to the last 
observation before the switch); and ACR50 response rates (compared to the baseline). In 
the first column, the numbers of patients refer to each corresponding LOE switch subgroup. 
In the remaining columns, the numbers of patients refer to those with sufficient reported 
data from the three months visit after the switch. 









ACR50 response Odds ratio of 
ACR50 response 
IFX to ETA (n=65) 40% (n=10/25) 3.7 (p=0.06) 24% (n=8/33) 1.3 (p=0.69) 
IFX to ADA (n=48) 36% (n=8/22) 3.1 (p=0.10) 50% (n=10/20) 4.0 (p=0.03) 
ADA to ETA (n=54) 44% (n=15/34) 4.3 (p=0.02) 19% (n=6/31) 1.0 (p=0.95) 
ETA to ADA (n=61) 15% (n=4/26) Referent 20% (n=6/30) Referent 
Type of LOE     
Primary (n=122) 32% (n=23/71) Referent 15% (11/75) Referent 
Secondary (n=65) 44% (n=12/27) 1.7 (p=0.27) 49% (19/39) 5.5 (p<0.001) 
 
 
Disease activity parameters of patients with initial IFX had increased from lower on-
treatment values by the last observation prior to the switch, although SJC, CRP, and 
DAS28 (except DAS28 for IFX to ETA switchers) were still statistically significantly lower 
than at baseline. For these parameters, the switch to ETA or ADA restored the response 
initially achieved with IFX (Figure 7). As with patients with initial IFX, disease activity 
parameters of patients with initial ADA had also increased from lower on-treatment values 
by the last observation prior to the switch, so that CRP and DAS28 were not anymore 
statistically significantly different from baseline. The switch to ETA restored and even 
improved the responses in SJC, CRP, and DAS28 (Figure 7). The disease activity 
parameters (SJC, CRP, and DAS28) of patients with initial ETA fell significantly from 





Figure 7. SJC, CRP and DAS28 score of LOE switchers at baseline (BL) before 
commencement of anti-TNF therapy and at the 3 months, the best and the last observations 
before and after the switch. LOE switchers with reported BL and at least the 3 months 
controls of both the first and the second agent are included in the figure. The line 
transversing the X-axis marks the switch. Y-axes are scaled for each switch type separately. 
The horizontal line in the box represents the median. The box encloses the interquartile 
range. The whiskers extend to the minimum and maximum values, excluding outliers and 
extremes. Arrows indicate statistically significant differences (p<0.05) between paired 
observations (3 months controls, best observations, and last observations, respectively), and 
between the last observation vs. subsequent observations after the switch. The arrow head 
points to the more beneficial outcome. The number of included patients for IFX to ETA, 
IFX to ADA, ADA to ETA and ETA to ADA, respectively, are: SJC: 36, 24, 38 and 32; 
CRP: 36, 24, 34 and 29; DAS28: 11, 12, 24 and 14. The corresponding assessable outcomes 
of the excluded patients are similar to those of the included patients (data not shown). 
Outcomes of tender joint counts (TJCs) followed similar patterns as those of the SJCs, but 
were not as frequently statistically significant. Statistically significant (p<0.05) differences 
in TJCs were found in the following comparisons: in IFX to ETA, and IFX to ADA 
switchers, the last observation on IFX vs. all subsequent observations after the switch (i.e. 
the 3 months, best and last), and in ADA to ETA switchers, the last observation on ADA 
vs. the best observation after the switch. 
 
Of the total cohort of 242 LOE switchers, 28% (n=67) had discontinued also the second 
agent due to LOE after a mean follow-up time of 10 months (median 6 months, range 1 to 
50 months). Of the 237 patients who had discontinued their first agent due to other (non-
LOE) reasons, only 15% (n=35) had discontinued the second agent due to LOE after 
similar follow-up times (p<0.001). Survival rates up to 36 months with the end point being 
discontinuation of the second agent due to LOE are shown in Figure 8. The rates were 
lower for patients who had switched due to LOE, than for patients who had switched due to 
reasons other than LOE (hereafter denoted non-LOE switchers) (p<0.005). Notably, the 
rates were significantly higher for those who had switched due to sLOE than for those who 
had switched due to pLOE (p<0.05). The rates of the pLOE switchers were significantly 
lower compared with those of the non-LOE switchers (p<0.001), while the rates of sLOE 






Figure 8. Survival analysis with the end point being discontinuation of the second agent 
due to LOE. The compared groups are patients who switched their first TNFi agent to 
another one due to LOE (n=235 assessable out of 242), or due to other, non-LOE reasons 
(n=227 assessable out of 237). Also shown are the corresponding survival functions of 
primary LOE (n=115) and secondary LOE switchers (n=63), respectively.     
 
 
AEs leading to discontinuation of the initial TNFi agent and switch to a subsequent one 
were mostly infusion reactions, eczema, and local injection site reactions. AEs were the 
switch reason in 74 patients.6 Of these, 10% (n=7) discontinued also the second agent due 
to an AE, after a mean follow-up time of 6 months (median 3 months, range 0.1 to 23 
months). Survival analysis with the end point being discontinuation of the second agent due 
to an AE yielded survival rates at 6, 12, 24, and 36 months of 91%, 91%, 86%, and 86%, 
respectively, for the AE switchers. These rates did not differ statistically significantly from 
the corresponding ones of those who switched due to reasons other than AEs. The response 
achieved with the first agent, which caused AEs, as assessed by SJC, CRP, and DAS28, 
was maintained, or even improved, with the second agent after the switch. 
 
Other reasons than LOE or AE led to the switch in 163 patients.7 The reasons for these 
switches were mostly unspecified and may be diverse, e.g., due to reimbursement reasons 
(IFX to ETA or ADA), patient preference, and/or unacceptable residual disease activity 
despite ACR50 response. Overall, the response achieved with the first agent, as assessed by 
                                                 
6 IFX to ETA, n=25; IFX to ADA, n=10; ADA to ETA, n=23; ETA to ADA, n=13; ETA to IFX, n=2; and 
ADA to IFX, n=1 
7 IFX to ETA, n=62; IFX to ADA, n=40; ADA to ETA, n=25; ETA to ADA, n=30; ETA to IFX, n=4; and 
ADA to IFX, n=2 
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SJC, CRP, and DAS28, was maintained with the second agent after the switch. Subgroup 
analyses revealed a statistically significant (p<0.05) improvement only in the SJC of ETA 
to ADA switchers, at the 3 months and last observations (means 4.2 and 2.0, respectively, 
at 3 months; 3.4 and 0.7, respectively, at the last; n=11). Declination occurred in the SJC of 
IFX to ETA switchers, at the best and last observations (means 0.8 and 2.6, respectively, at 
the best; 1.9 and 3.5, respectively, at the last; n=27), and also in CRP at the best 
observations (means 1.3 mg/dl and 1.9 mg/dl, respectively; n=28). 
 
So far, most published studies on the outcomes of switching TNFi agents regard individual 
switch types, and some pooled data. Most studies lend support for a trial with another TNFi 
agent in case of LOE or AEs, although results regarding, e.g., outcomes in primary vs. 
secondary LOE and treatment survival and AE rates of the first vs. the second TNFi agent 
are not in complete agreement (Gomez-Reino and Carmona, 2006; Buch et al., 2007a; 
Hjardem et al., 2007; Hyrich et al., 2007; Conti et al., 2009). However, direct comparisons 
between studies may be challenging due to the different study contexts and studied 
outcomes. In the present study, switches were examined from the viewpoints of specific 
agents and reasons for switching. The results indicate that, for LOE switchers, switching a 
TNFi agent to another may be of most benefit in secondary LOE (defined as loss of ACR50 
response). AEs leading to discontinuation of the initial TNFi agent and subsequent switch 
to another consisted mostly of infusion or hypersensitivity reactions, and did not predict 
discontinuation of the second agent due to an AE. However, this result cannot be 
generalized, since patients may discontinue TNFi therapy altogether after, e.g., a TNFi 
class-specific and/or severe AE. In general, a similar degree of response achieved with the 
first agent was maintained with the second agent in patients who switched due to AEs or 
“other” (not LOE or AE) reasons. Responses could even improve in AE switchers, possibly 
as a result of better treatment compliance after the switch and resolved AE, although this 
could not be ascertained in the present study.  
 
The apparent efficaciousness of switching in secondary LOE led us to consider the possible 
impact of anti-drug antibodies (ADAbs). Up to nearly half of IFX treated patients may 
develop such Abs during the first year of therapy (Haraoui et al., 2004; Wolbink et al., 
2006). Coincidentally, approximately half of IFX treated patients demonstrate secondary 
LOE during the first year (Buch et al., 2007b). Development of anti-IFX Abs has indeed 
been associated with decreased serum trough levels of IFX (i.e., serum concentration of 
IFX just prior to a new infusion) and reduced response to treatment (Bendtzen et al., 2006; 
Wolbink et al., 2006; Radstake et al., 2009), but does not seem to affect adversely the 
effectiveness of other TNFi agents (van der Bijl et al., 2008).  
 
Anti-TNF drug switching seemed beneficial also in primary LOE of ADA. Abs against 
ADA do not seem to form as frequently as those against IFX, but may develop sooner 
(Wolbink et al., 2006; Bartelds et al., 2007). This may be due to differences in the dose 
schedules and usage of concomitant MTX. The loading dose regimen of IFX could, 
perhaps, prevent anti-IFX Ab formation in the beginning of the treatment, since the Ab 
formation has been found to be inversely related to the IFX dose (Rozin, 2004). Also, MTX 
may reduce both anti-IFX and anti-ADA Ab formation (Anderson, 2005; Krieckaert et al., 
2012). In the present study, MTX use was somewhat more common with IFX than with 
ADA (63% vs. 50%, respectively; p<0.05). Formation of neutralizing anti-ETA Abs is 
uncommon (Anderson, 2005). Switching from ETA to ADA maintained, but did not 
improve, the responses achieved before the switch. This may lend further support for the 
benefit of switching in cases where LOE is indeed due to development of neutralizing 
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ADAbs. However, this cannot be ascertained based on the present study, as data on the 
eventual presence of such Abs are lacking.  
 
Recently, it has been suggested that assessments of serum drug concentration and ADAb in 
TNFi non-responders might be useful both clinically and economically in therapeutic 
decision making (Bendtzen, 2012; Vincent et al., 2013; Bendtzen, 2013) (Table 24). 
Currently (at the time of study) methods to perform such assessments are not in routine 
clinical use, and therefore patients with an insufficient response to an initial TNFi agent 
must often rely on a process of trial and error with subsequent biological drugs based on 
clinical outcome alone. Immunopharmacological monitoring of individual patients may be 
justified in that an effective treatment alternative may be found sooner, whereby 
unnecessary direct and indirect expenses of ineffectual treatment trials may be avoided. Of 
note, algorithm-based treatment options (based on serum drug and ADAb levels) were 
shown to be more cost-effective than routine dose escalation of IFX in a randomized 
controlled trial involving patients with Crohn’s disease with secondary IFX treatment 
failure (Steenholdt et al., 2013).      
 
 
Table 24. Proposed algorithm to guide treatment decisions based on assessment of serum 
TNFi drug and ADAb levels in patients with insufficient clinical response to TNFi therapy 











 Anti-drug antibody 
Low High 
Low Intensify treatment with the same drug 
(increased dose or shortened dosing 
interval)1,2 
Switch to another TNFi agent1,2 
High Switch to other treatment (biologic with 
another mechanism of action)1,2 
Switch to another TNFi agent2;  
Test for neutralizing antibody using cell-
based assay / switch to other treatment 
(biologic with another mechanism of action)1 
 
 
A limitation of the present study is that the results may be affected to some extent by 
regression to the mean. In most cases, however, TNFi switching was not carried out 
immediately upon disease activation, as 83% of sLOE switchers had tried some form of 
optimization of their concomitant medication prior to the switch (e.g., increased dose of 
IFX, cDMARD, or GC, or addition of a cDMARD or GC). The results of the present study 
indicate that switching to a second TNFi agent may be beneficial in case of secondary LOE 




9 LIMITATIONS AND STRENGTHS OF THE STUDIES 
 
The limitations of Studies I to V are the same as those of observational studies in general. 
Firstly, the patient population is more heterogeneous than those seen in RCTs, since 
treatment decisions are not restricted by rigorous selection criteria to the same extent. 
Secondly, the patients are allocated to their respective treatments in a non-randomized 
fashion, whereby imbalances in factors affecting the outcomes of the treatment may exist. 
Thirdly, the effects of the intervention (TNFi therapy) cannot be isolated due to the lack of 
a comparable conventionally treated control group. Fourthly, the reliability of the results is 
to an extent limited by the incompleteness of the data. Therefore, the results of the studies 
should be regarded with due caution.  
 
On the other hand, the studies have a strong external validity, at least in the Finnish context, 
since they reflect the outcomes of TNFi therapy in a large, representative sample of Finnish 
RA patients using such agents. The studies complement RCT derived data by providing 
information on effectiveness and safety in a real-life setting. 
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10 MAIN FINDINGS 
10.1 Effectiveness of anti-TNF therapy in the treatment of RA (I, 
V) 
 
The patients in the study cohort had moderate to severe baseline disease activity and used 
various concomitant conventional disease modifying antirheumatic drugs (cDMARDs); 
most had long-standing disease. With roughly two-thirds of the patients achieving an 
ACR20 response within the first six months of infliximab therapy, the effectiveness was 
comparable to the efficacy seen in major randomized controlled clinical trials (RCTs) such 
as the ATTRACT trial (Maini et al., 1999). The ACR response rates among patients using 
various concomitant cDMARD therapies (methotrexate (MTX) with no other cDMARDs; 
MTX and sulfasalazine with or without other cDMARDs; or cDMARDs other than MTX) 
were comparable.  
 
Effectiveness (based on ACR response rates) of infliximab, etanercept, and adalimumab 
was comparable. During a mean follow-up time of 2.3 years, 17% of RA patients 
discontinued their first biological drug due to lack or loss of effectiveness, and 10% due to 
adverse events.  
 
10.2 Adverse events of biological drugs in a routine-care setting 
(II, V) 
 
Adverse events were reported in 17% of all ROB-FIN registered patients during a mean 
follow-up time of 2.1 years. The most frequent adverse events were various infections 
(reported in 6.2% of the patients), various dermatological problems (eczemas were reported 
in 3.7%), and infusion or allergic reactions (reported in 2.8%). Serious, life-threatening, or 
fatal adverse events (SAEs, excluding malignancies) were reported in 3.1% (fatal 0.2%) of 
the patients. The main cluster of SAEs was due to infections. Of the various non-infection 
SAEs the main cluster was due to infusion or allergic reactions.  
 
Data on cancers diagnosed in ROB-FIN registered RA patients was complemented with 
data from the Finnish Cancer Registry. Fifty-one cancers were diagnosed during or after 
biological therapy, corresponding to 3.0% of the RA patients. The overall incidence rate of 
cancer did not appear to be increased among RA patients treated with TNFi agents, 
compared with the Finnish adult population (SIR 1.1, 95% CI 0.8 to 1.5; p=0.67; the value 
pertains to RA patients diagnosed with cancer in 2002 through 2008, during or within one 
year after TNFi therapy). However, site-specific comparisons indicated that the rates of 
skin melanoma (similarly to other studies) and pharyngeal cancer were higher than 
expected among the RA patients treated with TNFi agents. However, the assessments are 







10.3 Cost-effectiveness of infliximab therapy (III) 
 
Health-related quality of life, as assessed through a combination of HAQ score and 
patient’s global assessment, improved in 76% of patients upon commencement of 
infliximab therapy. Of these, roughly one-third had an incremental cost-effectiveness ratio 
of ≤40,000 €/QALY gained, which can be regarded as cost-effective. This group of patients 
had higher baseline HAQ scores and global values than the groups with a higher cost per 
QALY gained, or with no QALY benefit. Therefore, in the short- to medium-term, cost-
effectiveness was essentially affected by the potential for major improvement in functional 
ability due to amelioration of disease activity. Other factors favoring cost-effectiveness 
included responding to a lower absolute dose of infliximab (e.g., 200 mg as opposed to 
higher doses), using concomitant MTX, and achieving an ACR50 response.  
 
10.4 Outcomes of switching anti-TNF agents (IV) 
 
Biological drug switches were common, occurring in more than one-third during a mean 
follow-up of roughly two years. The present study indicates that switching to a second 
TNFi agent may be beneficial in case of secondary lack of effectiveness (defined here as 
loss of ACR50 response) of the first TNFi agent or adverse events which do not require 
discontinuation of TNF blocking therapy altogether. The secondary lack of effectiveness 
may have been due to development of neutralizing anti-drug antibodies (ADAbs), although 





11 CONCLUSIONS AND FUTURE VISIONS 
 
This thesis work, based on Finnish nationwide observational data of RA patients treated 
with biological drugs, indicates that the effectiveness, in terms of relative degrees of 
improvement (ACR response rates), of TNFi agents in clinical practice is similar to the 
efficacy in RCTs, even when the biologic was used in combinations with cDMARDs not 
studied as concomitant therapy in the major RCTs, such as the FIN-RACo combination or 
even non-MTX cDMARDs. The trend of treating patients with moderate or high disease 
activity early in the disease course may contribute to the achievement of contemporary 
treatment aims, most notably remission. 
 
Immunization against chimeric or fully human TNFi agents and production of ADAbs may 
explain many of the cases of reduced drug response. Development of ADAbs may not be 
completely preventable, but it might be reduced with the use of sufficiently high doses of 
TNFi together with concomitant MTX, and possibly by avoiding intermittent treatments. 
This may require a special emphasis to be placed on adherence to the treatment. In TNFi 
non-responders, assessment of serum drug concentration and ADAb might be useful both 
clinically and economically in therapeutic decision making.    
 
Treatment of TNFi refractory RA remains a challenge. The novel biological agents (not 
targeting TNF) offer alternative treatment modalities, but finding the most effective 
treatment for individual patients relies to a considerable degree on a sawtooth-like treat-to-
target process of trial and error. In view of the high costs of ineffective treatments, both in 
terms of direct medical costs and possibly indirect costs, it would be important to continue 
the effort toward personalized medicine. TNFi treatment appears to be cost-effective if 
current treatment recommendations are followed, involving tight control and sufficient 
disease control for treatment continuation to be warranted. Nonetheless, in absolute terms, 
the direct medical costs of TNFi and other biological agents are high. The possible advent 
of biosimilars in the future might lower the direct costs. Personalized medicine might also 
bring about cost savings, in addition to individually optimized treatment. 
 
The most common and treatment-limiting AEs comprised of various infections, eczemas 
and skin reactions, infusion or allergic reactions, various general symptoms, and laboratory 
abnormalities. The main cluster of SAEs comprised of various infections. Of the non-
infection SAEs, the main cluster comprised of infusion or allergic reactions, mainly in 
patients using infliximab. Compared with the Finnish general population, the overall 
incidence of cancer did not appear to be increased within the studied cohort, at least not 
during the first few years of TNFi therapy. However, longer follow-up and larger 
collaborative studies are required in order to more reliably assess whether the risks of, e.g., 
lymphoma and skin cancers are increased among TNFi treated RA patients. TNFi therapy 
appears to be well-tolerated in most patients, but especially in view of the very diverse 
types of AEs and SAEs which may occur continued vigilance is required. It would be of 
interest and great practical importance to determine the extent to which information about 
SAEs reach the attending rheumatologist. In general, collaboration between the valuable 
clinical registers that exist in Finland would be a feasible way of overcoming some of the 
data limitations of individual databases, as well as learning more about the short- and long-
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